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Summary 
 
Protein Kinase C-related kinases (PRK) are members of the protein kinase C (PKC) 
superfamily of serine/threonine protein kinases. The structure of members of the PKC 
superfamily is highly conserved, with an N-terminal regulator domain linked to a C-
terminal catalytic domain via a linker segment. The catalytic core of all PKC 
superfamily members has 40-50% sequence identity. At the end of the catalytic 
domain, there is a C-terminal tail consisting of approximately 70 amino acid residues 
called the variable region 5 (V5) domain. This V5 domain is present in all 
PKC/PRKs, ranging from yeast to humans, but with a much lower sequence 
homology compared with that of the catalytic core.  
 
This project aims to determine the V5 domain as a determinant in isozyme-specific 
regulation in PRK1 and PRK2. The V5 region appears attractive for specific 
regulation due to its great variability in terms of amino acid length and sequence 
among the isozymes in the PKC family.  
 
Both PRK1 and PRK2 tolerated removal of up to seven amino acids from the C-
terminal (PRK1-Δ940 and PRK2-Δ978), where the hydrophobic motif was deleted, 
thus it appears that the hydrophobic motif is dispensable for PRK1 and PRK2 activity. 
However, PRK1 and PRK2 lacking the eight amino acids or more were catalytically 
inactive. Co-immunoprecipitation studies indicate that the absence of the hydrophobic 
motif in PRK1 and PRK2 did not affect PDK-1 binding. Thus, the general proposal 
that the hydrophobic motif functions as a substrate docking site for PDK-1 may not be 
accurate. The relation between PDK-1 binding and the consequent phosphorylation of 
the activation loop in PRK1 and PRK2 and kinase activity demonstrated that the 
     
  xv 
interaction of PDK-1 with PRK1 and PRK2, and the productive phosphorylations of 
the activation loop are separate biochemical events. Activation studies indicate this C-
terminus segment of residues is necessary for optimal activation.  
 
We propose that the importance of the very C-terminus in conferring the catalytic 
competence in PRK1 and PRK2 may be a common feature among several other PKC 
isozymes. This study has identified the extreme C-terminal of seven amino acids in 
PRK2 is critical for the function and regulation of the kinase. The data suggest that 
this segment of residues in the V5 domain in necessary to maintain critical interaction 
with the kinase domain to allow proper folding for catalysis.
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Chapter 1: Introduction 
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1.1  Signal Transduction 
Signal transduction at the cellular level refers to the process of converting one kind of 
signal or stimulus from the outside of the cell, to another signal inside the cell. In 
endocrine signaling, signaling molecules, called hormones, act on target cells distant 
from their site of synthesis (by cells of endocrine organs). By contrast, in autocrine 
signaling, cells respond to substances that they themselves release. Signal 
transduction involves a sequence of biochemical events inside the cell, which take 
place in a timeframe as fast as milliseconds to as long as days. In signal transduction 
processes, multiple enzymes and other molecules become engaged in the events that 
proceed from the initial stimulus. In such cases, the chain of steps is referred to as a 
“signaling cascade” or a “second messenger pathway” and enables a stimulus to elicit 
a large response. The eventual outcome is an alteration in cellular activity and 
changes in gene expression in the responding cells.  
 
1.1.1 Signal Receptors  
A cell will only react to a signal if it has a receptor that recognizes that specific signal. 
Receptors usually have high specificity for a specific signal. This specificity is 
directly related to the molecular contours of the receptor and the signal, so that they fit 
each other at the molecular level. Once bound, the receptor will transmit the signal 
into the cell. It is noteworthy that signal receptors may be localized in different 
compartments in cells, and even the same receptors within the same cell may have 
different biological functions when situated in different locations. 
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1.1.1.1 Cell surface receptors 
Fat-soluble signals, such as hormones and some vitamins, are thought to simply 
diffuse across the membrane. Their receptor proteins are usually found within the cell. 
In contrast, most chemical signals are water-soluble and thus unable to cross the lipid 
bilayer of the cell membrane. Their receptor proteins must therefore span the 
membrane. Although cell-surface receptors differ in the way that they transmit 
information into the interior of the cell, in mammalian cells most can be generalized 
into three distinct and large families based on the mechanism they use to accomplish 
this transmission: ion-channel-linked receptors, G-protein-linked receptors, and 
enzyme-linked receptors [1]. 
 
1.1.1.2 Ion-channel-linked receptors 
These are fast acting receptors, exemplified by the nervous system that allows sub-
millisecond transmission times across synapses. The receptors for some transmitters 
themselves are ion channels. Alternatively, the receptors can link with ion channels. 
Chemical signals in the form of neurotransmitters are transduced by ion-channel-
linked receptors directly into an electrical signal in the form of a voltage difference 
across the plasma membrane. This occurs when a neurotransmitter binds to this type 
of receptor, altering its conformation to open or close a channel (often through or near 
the receptor) to the flow of Na+, K+, Ca2+, or Cl- ions across the membrane. With the 
change of flow of ions, the potential of target cells subsequently changes, thus signals 




     
  3 
1.1.1.3 G-protein-linked receptors 
Many hormones, neurotransmitters and sensory stimuli elicit cellular responses 
through the targeted activation of cell surface receptors coupled to Gq family G 
proteins. The Gq family members, Gq, G11, G14, and G15/16, like all heterotrimeric 
G proteins, are composed of three subunits, Gα, Gβ and Gγ, that cycle between 
inactive and active signaling states in response to guanine nucleotides [3, 4]. These 
membrane-bound proteins are engaged and activated by G protein-coupled receptors 
(GPCRs) for the GTP-dependent transduction of extracellular signals into cellular 
responses. The receptor-bound conformation of the G protein favors the displacement 
of GDP by GTP on the Gα subunit and induces dissociation of the heterotrimer 
subunits from the receptor and from each other. Gα-GTP and the Gβγ dimer then 
transmit the receptor-generated signals to downstream effector molecules and protein 
binding partners until the intrinsic GTPase activity of Gα hydrolyzes GTP to GDP and 
the inactive subunits reassociate.  
The canonical effector molecules of activated, GTP-bound Gq family Gα subunits are 
the β-isoforms of phospholipase C (PLC-β). Gqα, G11α, G14α, and G15/16α 
(mouse/human orthologues, respectively) bind and stimulate PLC-β enzymes to 
initiate inositol lipid signaling. PLC-β enzymes catalyze the hydrolysis of the minor 
membrane phospholipid phosphatidylinositol bisphosphate, PIP2, to release inositol 
trisphosphate (IP3) and diacylglycerol (DAG) [5]. These second messengers serve to 
propagate and amplify the Gα-mediated signal with calcium mobilization following 
release from IP3-regulated intracellular stores and DAG-mediated stimulation of 
protein kinase C (PKC) [6, 7]. Inositol lipids, DAG, PKC and calcium each 
participate in multiple signaling networks and in this way link Gqα family members to 
a host of different cellular events [8]. 
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There also are many reports of signaling pathways and global cellular responses 
activated by Gqα family proteins in which the mediating Gα-effector protein(s) are 
unknown. Signaling downstream of these Gα involves diverse and complex kinase 
cascades that ultimately lead to regulated gene transcription and changes in cell 
physiology. Each Gqα family member has been implicated in regulating one or more 
of the mitogen-activated protein kinase (MAPK) pathways in cultured cells, although 
the precise mechanisms of signal transfer are not well understood [9-15]. In some 
instances, PKC is the critical component linking Gqα signaling to activation of 
MAPK pathways [16].  
 
1.1.1.4 Enzyme-linked receptors 
There are at least five classes of enzyme-linked receptors;  
(1) receptor tyrosine kinases,  
(2) tyrosine kinase-associated receptors,  
(3) receptor serine/threonine kinases,  
(4) transmembrane guanylyl cyclases, and  
(5) histidine-kinase-associated receptors.  
The first two classes are the most abundant in cells. Enzyme-linked receptors are 
single-pass transmembrane proteins with an extracellular ligand-binding domain and 
an intracellular catalytic or enzyme-binding domain. The great majorities of receptors 
are protein kinases or are associated with kinases. Binding of agonists to receptors 
induces a conformational change of the receptors. Such conformational changes lead 
to the activation of kinases that are either intrinsic to the receptor or associated with 
the receptor. Thus the signals are transduced from the extracellular to the intracellular 
environment [17, 18]. 
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Besides the five groups of cell surface receptors, there are some other cell surface 
receptors that do not fit into these classes. There is one group of cell surface receptors 
that activate the signaling pathways depending on proteolysis. For example, the 
receptor protein Notch is activated by cleavage. In vertebrates, most Notch protein is 
targeted to the cell surface after processing by a furin-like convertase (FLC) at 
cleavage site 1 [19, 20]. The S1 cleavage divides Notch into two polypeptides: one 
contains almost the entire extracellular domain and the other contains a short 
ectodomain and a long cytoplasmic tail. After ligand binding, a change occurs that 
renders the region just proximal to the membrane susceptible to cleavage by 
metalloproteases of the ADAM family (a disintegrin and metalloprotease), especially 
at a position 12 amino acids from the membrane. This site is referred to as the S2 site. 
After ligand-induced ectodomain shedding, Notch undergoes cleavage at a third site 
(S3) located within the transmembrane domain by the enzyme γ-secretase. The freed 
intracellular domain enters the nucleus, where it switches a DNA-bound corepressor 
complex into an activating complex, leading to activation of selected target genes [21, 
22]. 
 
1.1.1.5 Nuclear receptors 
The nuclear receptors are localized in the cytosol and/or nucleus. Many of the natural 
ligands of nuclear receptors are lipophilic hormones that enter the cell in a passive 
manner or by active transport mechanisms. These agonists include steroid hormones, 
thyroid hormones, retinoids, and vitamin D. The ligand binding activates the 
transcriptional regulation function of the receptor by binding to specific DNA 
sequences adjacent to the target genes. The receptors are structurally related and are 
part of the nuclear receptor family. Some receptors that are activated by intracellular 
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metabolites are also included in this family. Some nuclear receptors, such as those for 
cortisol, are located in the cytoplasm, and translocate to the nucleus after ligand 
binding, while other nuclear receptors, such as those for thyroid hormone and 
retinoids, are bound to DNA in the absence of ligands. The cognate receptors are quite 
promiscuous with respect to the nature of the ligand. The binding of hormones to the 
receptors allows the inhibitory protein complexes which are bound to the inactive 
receptors to dissociate while the binding of coactivator protein to the receptors 
induces gene transcription [23]. 
 
1.1.1.6 Intracellular enzymes as receptors 
Nitric oxide (NO) and carbon monoxide (CO) can rapidly diffuse across the 
membrane and bind to iron in the active site of guanylyl cyclase, thereby stimulating 
this enzyme to produce the small intracellular mediator cyclic GMP. The cyclic GMP 
can induce responses in target cells, for example, keeping blood vessels relaxed [24]. 
 
1.1.2 Intracellular signaling molecules 
After extracellular signaling molecules bind to the receptors, the signals are relayed 
into the cell interior by a combination of small and large intracellular signaling 
molecules. The former is second messengers; the latter are called intracellular 
signaling proteins and includes G proteins, small GTPase and protein kinases [25-27]. 
 
1.2 Signal transduction by phosphorylation 
A central tool for signal transduction in a cell is phosphorylation. Protein 
phosphorylation is a ubiquitous regulatory mechanism in both eukaryotes and 
prokaryotes. Intracellular phosphorylation by protein kinases, triggered in response to 
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extracellular signals, provides a mechanism for the cell to switch on or off many 
diverse processes. These processes include metabolic pathways, kinase cascade 
activation, membrane transport and gene transcription. The reverse reaction of 
dephosphorylation is catalysed by protein phosphatases that are controlled by 
response to either the same or different stimuli so that phosphorylation and 
dephosphorylation are delicately controlled to achieve optimal state of 
phosphorylation at a given time. In eukaryotes, the protein kinase domains 
responsible for phosphorylation on serine, threonine, or tyrosine residues are the first, 
second and third most common domains in the genome sequences of yeast (S. 
cerevisiae), the worm (C. elegans), and the fly (D. melanogaster), respectively, 
indicating the importance of phosphorylation signaling in higher organisms [28]. The 
human genome contains 575 eukaryotic protein kinase domains which represents 2% 
of the total genome [29]. In prokaryotes, signaling by phosphorylation is equally 
important. In E. coli, there are 62 genes that encode proteins involve in dual 
histidine/response regulator systems, representing approximately 1.5% of the entire 
genome.  
 
1.2.1 History and definition 
The first protein kinase obtained in a purified form was the Ser/Thr-specific 
phosphorylase kinase of muscle in 1959 [30]. With the discovery of the Tyr-specific 
protein kinases [31], the Ser/Thr-specific protein kinases were joined by another 
extensive class of protein kinases of regulatory importance, to which a central 
function in growth and differentiation processes was soon attributed. At present, 
several hundred different protein kinases are known in mammals, most of which are 
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Ser/Thr or Tyr-specific. In addition, there are some protein kinases that phosphorylate 
other amino acids.  
 
Based on the nature of the acceptor amino acids, four classes of protein kinases can be 
distinguished [32]: 
• Ser/Thr-specific protein kinases esterify a phosphate residue with the alcohol 
group of Ser or Thr residues. 
• Tyr-specific protein kinases create a phosphate ester with the phenolic OH 
group of Tyr residues. 
• Histidine-specific protein kinases form a phosphorous amide with the 1 or 3 
position of His. The members of this enzyme family also phosphorylate Lys 
and Arg residues.  
• Aspartate- or glutamate-specific protein kinases create a mixed phosphate-
carboxylate anhydride.  
 
Reversible phosphorylation of proteins on Ser/Thr and Tyr residues functions as a 
switch in signaling pathways. The phosphate esters formed on proteins by the action 
of protein kinases are stable modifications that cause profound changes in the activity 
of cellular proteins. Because of the stability of the phosphate esters, protein 
phosphatases are required for their removal. The concerted and highly regulated 
action of both protein kinases and protein phosphatases is used by the cell to create a 
temporally and spatially restricted signal influencing the activity state of proteins in a 
highly specific way.  
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1.2.2 Classification of superfamily of protein kinase 
Protein kinases are classified according to the scheme proposed by Hanks and Hunter 
[32] based on similarity in catalytic domain amino acid sequence. Using this 
classification has the advantage of revealing other features held in common by the 
different members of a family. Therefore kinases having catalytic domains with high 
homology are likely to:  
1) be similar in overall structural topology,  
2) have similar modes of regulation, and  
3) have similar substrate specificities.  
 
The subgroups are: 
1. AGC Group  
1. AGC Group I 
Cyclic nucleotide regulated protein kinase (PKA & PKG) family  
2. AGC Group II 
Diacylglycerol-activated/phospholipid-dependent protein kinase C 
(PKC) family  
3. AGC Group III 
Related to PKA and PKC (RAC/Akt) protein kinase family 
4. AGC Group IV 
Kinases that phoshorylate G protein-coupled receptors family  
5. AGC Group V 
Budding yeast AGC-related protein kinase family  
6. AGC group VI 
Kinases that phosphorylate ribosomal protein S6 family  
7. AGC Group VII 
Budding yeast DBF2/20 family  
8. AGC Group VIII 
Flowering plant PVPK1 protein kinase homolog family  
9. AGC Group Other 
Other AGC related kinase families  
2. CaMK Group  
1. CaMK Group I 
Kinases regulated by Ca2+/CaM and close relatives family  
2. CaMK Group II 
KIN1/SNF1/Nim1 family  
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3. CaMK Other 
Other CaMK related kinase families  
3. CMGC Group  
1. CMGC Group I 
Cyclin-dependent kinases (CDKs) and close relatives family  
2. CMGC Group II 
ERK (MAP) kinase family  
3. CMGC Group III 
Glycogen synthase kinase 3 (GSK3) family  
4. CMGC Group IV 
Casein kinase II family  
5. CMGC Group V 
Clk family  
6. CMGC Group Other  
4. PTK Group - `Conventional' protein-tyrosine kinases 
Group I-IX Non-membrane spanning protein-tyrosine kinases 
Group IX-XXI membrane spanning protein-tyrosine kinases  
1. PTK group I 
Src family 
2. PTK Group II 
Tec/Atk family  
3. PTK Group III 
Csk family  
4. PTK Group IV 
Fes (Fps) family  
5. PTK Group V 
Abl family  
6. PTK Group VI 
Syk/ZAP70 family  
7. PTK Group VII 
Tyk2/Jak1 family  
8. PTK Group VIII 
Ack family  
9. PTK Group IX 
Focal adhesion kinase (Fak) family  
10. PTK Group X 
Epidermal growth factor receptor family  
11. PTK Group XI 
Eph/Elk/Eck receptor family  
12. PTK Group XII 
Axl family  
13. PTK Group XIII 
Tie/Tek family  
14. PTK Group XIV 
Platelet-derived growth factor receptor family  
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15. PTK Group XV 
Fibroblast growth factor receptor family  
16. PTK Group XVI 
Insulin receptor family  
17. PTK Group XVII 
LTK/ALK family  
18. PTK Group XVIII 
Ros/Sevenless family  
19. PTK Group XIX 
Trk/Ror family  
20. PTK Group XX 
DDR/TKT family  
21. PTK Group XXI 
Hepatocyte growth factor receptor family  
22. PTK Group XXII 
Nematode Kin15/16 family  
23. PTK Other membrane spanning kinases 
Other PTK kinase families  
5. OPK Group - Other protein kinases (not falling in major groups)  
1. OPK Group I 
Polo family  
2. OPK Group II 
MEK/STE7 family  
3. OPK Group III 
PAK/STE20 family  
4. OPK Group IV 
MEKK/STE11 family  
5. OPK Group V 
NimA family  
6. OPK Group VI 
wee1/mik1 family  
7. OPK Group VII 
Kinases involved in transcriptional control family  
8. OPK Group VIII 
Raf family  
9. OPK Group IX 
Activin/TGFb receptor family  
10. OPK Group X 
Flowering plant putative receptor kinases and close relatives family  
11. OPK Group XI 
PSK/PTK "mixed lineage" leucine zipper domain family  
12. OPK Group XII 
Casein kinase I family  
13. OPK Group XIII 
PKN prokaryotic protein kinase family  
14. OPK Other  
Other protein kinase families (each with no close relatives)  
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1.2.3 Protein Kinase C superfamily 
The family of protein kinase C enzymes includes 11 isozymes of Ser/Thr-specific 
protein kinases, which were first identified by the requirement of cofactors of 
diacylglycerol, Ca2+ and phospholipids for activation. The grouping of PKC isotypes 
based on both their structures and requirement of cofactors is useful for comparing the 
association of these enzymes at the protein level. PKC isotypes are categorized into 
five subgroups based on sequence alignment (Fig. 1.1) and this grouping is similar to 
the enzymatic grouping, with the only difference being the bisection of the nPKCs 
into two pairs of proximately associated kinases, namely, δ and θ, ε and η. 
 
 
Fig. 1.1. Dendogram of the PKC superfamily 
 
The first PKCs to be identified and cloned were the α, β and γ isotypes, which were 
initially isolated from rat brain cDNA libraries [34, 35]. Three additional PKCs, the δ, 
ε and ζ isotype were found via low-stringency screening of brain cDNA libraries with 
probes derived from the α, β and γ isotypes [36]. Subsequently, screens of other tissue 
cDNA libraries isolated  PKCη [37], PKCθ [38] and PKCι (of which PKCλ is the 
mouse homolog). The PKC-related kinases (PRKs) cDNA was first identified as 
protease-activated serine/threonine kinases via conventional protein chemistry and 
were originally named protease-activated kinases (PAK). Later, PRK1 was isolated 
from rat liver and was shown to be able to phosphorylate S6 peptide and its analogue 
[39-41]. Subsequently, PRK1 and PRK2 were isolated from a human hippocampal 
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cDNA library by a low stringency plaque hybridization using the cDNA for the 
catalytic domain of PKCβII as a probe [42], or by PCR [43], and PRK protein was 
purified to homogeneity from rat testes using a specific antibody raised against 
recombinant PRK [44].  
 
The mammalian PKC isotypes have been categorized into subclasses on the basis of 
the domain composition of the regulatory moiety, which in turn specify the cofactor 
dependence of the isozymes (Fig. 1.2).  
 
Fig. 1.2. Domain structures of the PKC subfamilies. PKC isotypes are made up of a 
regulatory and a catalytic domain, separated by a hinge region. The regulatory domain 
consists of conserved regions of C1 domain which binds phosphatidylserine and C2 
domain which binds Ca2+, while the catalytic domain is made up of the C3 which 
binds ATP and C4 domain which contains the substrate binding site. The C-terminal 
of all PKCs has a variable region (V5) which is highly variable in sequence and 
length. The requirements for cofactors for the different subclasses are shown on the 
right. PS, pseudosubstrate. AA, arachidonic acid. (adapted from [45]).   
 
The most studied and understood of these groups is the conventional PKCs (cPKCs), 
which comprise the α, βI, βII and γ isotypes (the PKCβ gene is alternatively spliced to 
generate two distinct proteins which vary only in their C-terminal [46]). These cPKC 
isotypes are activated by phosphatidylserine (PS) in a Ca2+-dependent fashion; they 
also interact with diacylglycerol, which both increase the specificity of the enzyme for 
phosphatidylserine and also lowers the affinity for Ca2+ into the physiological range 
[47]. The cPKCs are activated by the tumour-promoting phorbol ester PMA, which 
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stimulates these enzymes by removing the need for diacylglycerol and lowering the 
threshold of Ca2+ needed for activation [48].  
 
The novel PKCs (nPKCs) consist of the ε, η, δ and θ isotypes. These kinases are Ca2+ 
-insensitive, but are still regulated by diacylglycerol and/or phorbol esters in the 
presence of phoshatidylserine. The atypical PKCs (aPKCs), ι and ζ, constitute a third 
category. Similar to the novel PKCs, these protein kinases are Ca2+-insensitive, nor do 
they respond to PMA/DAG. Instead they are activated by lipids, such as 
phosphatidylinositols and phosphatidylserine, and/or via interaction with Cdc42-GTP-
Par6 complex [8, 49, 50].  
 
Finally, the recently discovered PRKs constitute a fourth group with at least three 
members, PRKs 1-3. Resembling the aPKCs, all PRKs are insensitive to Ca2+, DAG 
and phorbol esters [51, 52]. Instead, PRK 1,2 and 3 are activated by phospholipids 
and unsaturated fatty acids, notably by cardiolipin and arachidonic acid [44, 52-54]. 
At the same time, these kinases have been shown to be regulated by small G-proteins 
of the Rho class, through interactions at the N-terminal homologous region domains 
[55, 56]. It has been reported that Rho binding leads to increased activity (up to four 
fold) in vitro [57, 58].  
 
1.2.3.1 Domain Structure  
Each PKC isozyme consists of a single polypeptide chain having two structurally 
distinct domains: the amino-terminal regulatory moiety and the carboxyl-terminal 
catalytic core (app. 45 kDa). Each domain is further composed of specific modules. 
The regulatory moiety contains two key functions: an autoinhibitory sequence 
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(pseudosubstrate) and one or two membrane-targeting modules (C1 and C2 domains) 
that combine to regulate PKC activity and localization. The carboxyl-terminal region 
is the kinase domain and comprises two regions:  the ATP binding lobe (C3) and the 
substrate binding lobe (C4). Separating the regulatory and catalytic domain is a hinge 
region which is susceptible to proteolytic cleavage by cellular proteases. Interspersed 
between the highly conserved regions (C1-C4) are divergent sequences known as 
variable regions (regions V1 to V5).  
 
1.2.3.2 Pseudosubstrate 
All PKCs have an N-terminal pseudosubstrate domain which confers auto-inhibition 
in the native enzyme. This module closely resembles the optimal substrate recognition 
motif of the PKC except that the serine/threonine is replaced by an alanine. In an 
inactive kinase, the pseudosubstrate domain binds to the substrate-binding pocket in 
the catalytic domain, thus achieving auto-inhibition [59]. Peptides based upon this 
sequence are competitive inhibitors of PKC, while peptide with a serine at the 
putative phosphor-acceptor position served as good substrates. Antibody developed 
against the pseudosubstrate sequence can activate PKC without cofactors, probably by 
retracting the pseudosubstrate from the active site.  
 
In vivo studies provided evidence that indeed, regardless of PKC mode of activation, 
either via binding to its cofactors or by atypical processes such as binding cofactor-
independent substrates, removal of the pseudosubstrate is a pre-requisite [60]. Further 
evidence comes from studies using proteases as conformational probes. Explicitly; the 
pseudosubstrate of PKC is resistant to cleavage in an inactivated kinase but when the 
kinase is activated, specific arginine residue in the pseudosubstrate sequence become 
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liable to cleavage [61]. Cleavage at the hinge removes the steric hindrance established 
by the autoinhibitory region such that, freed from the restraint; the catalytic domain 
becomes constitutively active. Energetics studies demonstrate that the energy required 
to liberate the pseudosubstrate region from the catalytic domain may be from the 
engagement of the membrane-targeting modules onto the membrane [62]. Thus to 
activate the kinase, the pseudosubstrate must be removed. 
 
1.2.3.3 Membrane targeting modules 
PKCs epitomize the use of two membrane-targeting modules (C1 and C2) to provide 
sensitive, specific, and reversible regulation of protein function. PKCs have provided 
insights that the collaborative engagement of both the membrane-targeting modules is 
a fundamental mechanism to reversibly regulate cellular location. The role of these 
modules is not limited to just regulating the membrane binding and removal of the 
inhibitory region from the kinase domain, thus mediating substrate specificity and 
biological function of the kinase [63, 64].  
 
1.2.3.3.1 C1 domain 
All PKC isozymes contain one (C1) or two (C1A and C1B) globular C1 domains, 
which are Cys-rich regions of approximately 50 residues. The module has two 
structural variants: the typical C1 domain which binds phorbol esters/diacylglycerol 
found in conventional and novel PKCs and the atypical C1 domain, which does not 
bind these ligands, in atypical PKCs [65].  
 
Structural data from crystal [66] and NMR [67] analysis suggest that the binding site 
of the C1B domain is formed with two separated beta pockets (Fig. 1.3) to form a 
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globular domain. Conventional PKCs co-ordinate four Zn2+ atoms, two per C1 
domain. The two ion binding sites play a key role in maintaining the folds of the C1 
domain by bringing together residues that are far removed in the primary sequence. 
One metal binding site is near the bottom of the globular domain consisting of 
residues at the N and C termini of the domain, and the second site is in the middle of 
the molecule. In atypical C1 domains, the consensus sequences present in typical C1 
domain are not present, thus compromising the structure in the binding site and the 
binding of phorbol esters or diacylglycerol [68] 
 
Through a combination of structural analysis and site-directed mutagenesis, the 
molecular basis of phorbol ester binding has been established [66, 67, 69]. Ligand 
binding does not induce significant changes in the conformation of the cysteine-rich 
domain, but rather ‘caps’ a hydrophilic site at the top of the structure, forming a 
contiguous hydrophobic region that promotes insertion of the domain into the lipid 
bilayer. Specifically, in the absence of phorbol binding, the top half of the C1 domain 
is relatively hydrophilic because of the water-lined groove formed by the separated 
beta sheets. Once PMA binds to this groove, the domain is “capped” so that the top 
third provides a contiguous hydrophobic exterior. Thus, membrane targeting is 
elegantly achieved by ligands changing the surface properties of the module.  
 
1.2.3.3.2 C2 domain 
Although first described for the cPKCs, the C2 domain had been recognized as a 
widespread domain among numerous proteins (E.g. synaptotagmins, phospholipase C 
isozymes, phospholipase A2, rabphilin-3A, Unc-13), with most of them related to 
signal transduction mechanisms or membrane trafficking [70]. As with the C1 
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domain, there is a second messenger-regulated and a second messenger-independent 
variant of the C2 domain. In conventional PKCs, this 12 kDa domain binds anionic 
phospholipids in Ca2+ dependent manner. Novel C2 domains lack key residues 
involved in Ca2+ binding and, as a consequence, novel C2 domains do not bind Ca2+ 
and phospholipids.  
 
The C2 domain has two topological folds that differ only in that the first strand of one 
topology corresponds to the eighth strand of the second topology as a result of 
different positions for the amino and carboxyl termini: the type I topology exists for 
domains that follow the C1 domain (i.e. conventional isozymes) and the type II 
topology exists for domains that precede the C1 domain (i.e. novel isozymes) [70]. 
Despite a marked variation in primary sequence, structural analysis has revealed that 
all C2 domains fold similarly into a structure consisting of two four-stranded anti-
parallel β-sheets connected by variable loops at the end of each strand to form a 
pocket, with the Ca2+ binding site located at one end of the domain [71, 72]. In Ca2+ 
responsive C2 domains, this pocket is lined by multiple aspartic acid residues that 
coordinate 2-3 Ca2+ ions. In novel C2 domains, key aspartic acid residues are missing 
and the domain does not bind Ca2+ [73].  
 
The C2 domain binds membranes via residues that are on, or near, the loops that 
comprise the Ca2+ site [72]. Whether Ca2+ serves as a bridge in the lipid interaction is 
unknown. However, it is worthwhile to note that novel PKCs do not require Ca2+ for 
membrane binding and, since their C2 domain is missing critical aspartates in the Ca2+ 
binding groove of the C2 domain, the lipid interaction is not mediated by a Ca2+ 
bridge for these PKCs [73].  
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A number of functions in addition to membrane interaction have been ascribed to C2 
domains, with many of the determinants mediating these other functions localized to 
the basic sheet behind the Ca2+ site. For example, peptides based on sequences in the 
basic sheet of PKC βII’s C2 domain compete with binding to the PKC anchoring 
protein, RACK 1 [74]. Consistent with this, cloned putative IP4 receptor contains two 
C2 domains [75], and peptides derived from the basic face of the C2B domain 
effectively bind IP4 [76]. Recently, a study provided evidence that the C2 domain of 
PKCδ directly binds to phosphotyrosine peptides in a sequence specific manner, thus 
directly linking tyrosine phosphorylation with serine/threonine phosphorylation [77]. 
Thus the C2 domain may form a multi-functional module, with membrane targeting 
functions localized to the Ca2+ binding loops, and additional functions arising from 
the basic face or other regions of the domain.  
 
1.2.3.4 HR1 domain  
The homologous region 1 (HR1) domain was first identified in the regulatory region 
of PRK1, based upon sequence conservation with PRK2. This domain is composed of 
three repeats of an approximately 55-amino acid motif [43]. The first of these repeats, 
HR1a, is now known to incorporate the inhibitory pseudo-substrate site [78]. 
 
Protein alignments between PRK1 and PRK2 show that each motif seems to consist 
of two blocks of sequence with a short intervening linking sequence (Fig. 1.3). The 
first repeat is made up of basic amino acids which have a predicted α-helical structure. 
A short, partially conserved sequence of Gly-Ala-Glu-Asn acts as an intervening 
sequence. The second portion of the motif shows high homology to a leucine zipper in 
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terms of primary sequence.  However, this does not lead to the folding of leucine 
zipper in vivo due to presence of helix breaker residues of glycine and proline. 
Fig. 1.3. Sequence conservation in HR1 motif. The HR1 domain is made up of three 
repeats: 1a, 1b and 1c. Sequence alignment among these three repeats in both PRK1 
and PRK2 shows conservation of key residues. “*” means that the key residues in the 
column are identical in all sequences in the alignment. “.” means that semi-conserved 
substitutions. “:” means conserved substitutions.  
 
The involvement of small G proteins as binding partners for PRK1/2 was first defined 
when the HR1 motif was found to be a recurring sequence in two other RhoA-binding 
proteins, rhophilin [58] and rhotekin [79]. The minimal region required for Rho 
binding was found to be residues 33-111 in PRK1, which contain the first repeat, 
HR1a and the pseudo-substrate site [55]. Rho was subsequently found to bind to both 
isolated HR1a and HR1b domains but to HR1a in a more GTP-dependent manner, 
whereas no interaction was detected for HR1c [56]. G protein-interacting proteins are 
classically defined as effectors if they bind selectively to the GTP-bound (active) form 
of the G protein. These suggest that the HR1a repeat is the important Rho-binding site 
as it provided discriminated binding in favour of GTP-bound RhoA. The HR1c repeat 
does not bind Rho [56], and currently, its function is unknown. A possible role for 
HR1c may be to provide tighter binding to Rho through the combined contacts of 
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HR1a, b and c, since small protein motifs are often stacked together to form more 
stable domains [80]. 
Both PRK1 and -2 have been demonstrated to be targets not only for Rho but also for 
Rac [81, 82] and RhoB [83]. While PRK1 is targeted to the endosomal compartment 
by RhoA, localization studies have shown that the wild-type RhoB (of which only a 
fraction is in the GTP-bound state) is as efficient at targeting PRK1 to endosomes as a 
constitutively GTP-bound mutant RhoB [83]. This suggests that a weak interaction 
between PRK1 HR1b and RhoB is sufficient to confer binding in vivo and that the 
HR1 domain can act as localization signal as well as function in controlling kinase 
activation.  
 
In this respect it is important to note that the published binding studies have been 
performed with recombinant RhoA which lacks the C-terminal prenylation 
modification found in the authentic molecule. It is possible that further contact points 
are made with the modified Rho that may require the complete HR1abc domain (or 
indeed other PKC domain). Alternatively, the HR1c motif may confer binding to 
some other proteins, perhaps another member of the Rho GTPase family.  
 
1.2.3.5 Catalytic Domain 
1.2.3.5.1 Kinase Core  
The kinase domains of PKC have significant similarity to that of the archetypal 
kinase, PKA and PKB/Akt, with slightly more than 40% overall sequence identify. 
The architecture of the kinase domain was elucidated with the crystallization of PKA 
in 1991 [84] and PKB/Akt in 2002 [85]. There is a common structural fold of the 
kinase domain which consists of a bilobal structure with an N-terminal lobe that is 
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primarily composed of β sheet, and a C-terminal lobe that is primarily α helix [28, 
86]. The ATP- and substrate-binding site is tucked in a groove between the two lobes. 
However, the kinase domain of PKC remained refractory to crystallization until 
recently when the structures of the catalytic domain of a member of the novel PKC 
subfamily, PKCθ [87] and a member of the atypical PKC subfamily, PKCι were 
solved [88]. The overall tertiary structure of the kinase domain of both PKCθ and 
PKCι displays the conserved fold of all other protein kinase structures solved so far: a 
bilobal kinase fold, with a small N-lobe, a large C-lobe and a hinge-linker.  
 
The N-lobe of PKCθ is based on a five-stranded β-sheet (β1-β5) and two α-helices 
(αB and αC), and the C-lobe is mostly helical consisting of eight α-helices (αD-αK). 
The ATP-binding site, with the adjacent peptide-substrate binding site open to 
solvent, constitute the active site cleft at the interface of the two lobes. Although there 
is no observable electron density for regions corresponding to the turn motif and C-
terminal to hydrophobic motif, superposition of PKCθ structure with PKA reveal 
similarity in overall structure.  
 
For PKCι, the N-lobe consists of a five stranded anti-parallel β-sheet, two α-helices 
(αB and αC) and two short 310-helices. The C-lobe is mainly α-helical, with eight α-
helices (αD-αJ, α-helix in turn motif) and three 310-helices. The C-terminal tail 
consisting of 72 residues (516-587) is wrapped around the surface of both lobes (Fig. 
1.4). The first 14 residues (residues 517-530), are firmly attached to the C-lobe, while 
the latter residues (552-587) interact with the N-lobe.  As with PKCθ, the aligned 
structures of PKCι with PKA display good agreement in overall conformation.  
 
     









Fig. 1.4. Ribbon plot of the catalytic domain structure of PKCθ (A) and PKCι 
(B). The N-lobe is cyan and the C-lobe is blue. The activation loop, turn motif and the 
hydrophobic motif segment are displayed in red (from [88] and [87]). 
 
1.2.4 Phosphorylation in the kinase core 
Considerable information concerning phosphorylation sites on various kinases and 
their role in regulation of the enzyme now exists. The ABC kinases share three 
conserved phosphorylation motifs that must be processed sequentially for the enzyme 
to gain catalytic competence and correct intracellular localization [89, 90]. Thus, these 
sites act as phosphorylation-regulated switches to control intra and intermolecular 
interactions and to prime the kinase to be catalytically competent.    
 
1.2.4.1 Activation loop site 
Phosphorylation at a segment near the entrance to the active site provides an 
important regulatory mechanism throughout the protein kinase superfamily [28, 86]. 
The initial, rate-limiting step is the phosphorylation of the activation loop, on a 
threonine residue. Phosphorylation of this site is required for protein kinase activity. 
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Phosphate at this conserved segment not only precisely positions key arginine 
residues for catalysis, it also uncovers the access to the substrate binding site [84, 86, 
91]. Kinetic studies showed a dramatic increase in phosphoryl transfer rate following 
activation loop phosphorylation [92]. Mutation of the critical threonine residue to a 
neutral, non-phosphorylatable residue inhibits the activity of the kinases, whereas 
mutation to an aspartate residue in the case of PKA and PKB/Akt, or to a glutamate 
residue in the case of PKC, results in the formation of a catalytically competent kinase 
[93-96]. In PKA, this site can be modified by autophosphorylation [93]. In the case of 
PKC, this reaction depends on an upstream kinase: PDK-1 [97-100], however, in 
PKCθ, there is evidence to suggest that the activation loop phosphorylation may be 
autophosphorylated [87]. 
 
1.2.4.2 Turn motif  
Subsequent to the activation loop phosphorylation, phosphorylation of a motif in a 
Pro-rich domain follows. Unlike the activation loop, this site is modified by 
autophosphorylation [101, 102] and it corresponds to Ser338 in PKA which is 
positioned at the apex of a turn on the upper lobe of the kinase domain. This 
phosphorylated residue anchors the C-terminal tail to the top of the kinase lobe, with 
the phosphorylated residue located at the crest of a sharp turn, hence the name ‘turn 
motif’. The crystal structures of PKCθ and PKCι provided evidence that this site 
occupies a similar position in PKCs. The structural studies imply that the 
phosphorylation at the turn motif is critical in stabilizing the kinase domain by fixing 
the C terminus at the top of the upper lobe of the kinase core [87, 88]. Negative 
charge at the turn motif is essential and adequate for kinase activity. Kinases with 
dephosphorylated activation loop and hydrophobic motif are still catalytically 
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competent [89]. However, mutation of the turn motif to alanine does not completely 
abolish activity due to other adjacent serine/threonine sites that can undergo 
compensating phosphorylation [103, 104]. In addition, the sequence encompassing 
this motif corresponds to a 14-3-3 binding site, thus suggesting a possible protein-
protein interaction site [105].  
 
1.2.4.3 Hydrophobic motif 
The third phosphorylation site contains a serine or threonine residue flanked by 
hydrophobic residues, which is autophosphorylated following phosphorylation of the 
turn motif. This hydrophobic phosphoryation site is the least conserved of the three 
processing sites, with atypical PKCs having a glutamic acid (as phosphate mimic), at 
the phosphor-acceptor position. The sequence of PKA ends at the hydrophobic 
residue (phenylalanine) immediately preceding the phosphor-acceptor site. The 
crystal structure of PKA reveals that this terminal phenylalanine residue is tucked into 
a hydrophobic pocket on the back of the active site [106]; thus the back side of the 
kinase core has a binding pocket for the hydrophobic core. Structural studies of PKCθ 
and PKCι suggest a model in which the negative charge at the phosphor-acceptor site 
of the hydrophobic motif triggers an intramolecular ‘clamp’ with the upper lobe of the 
kinase domain. This not only serves to align residues more favorably, but also allows 
stabilizing contact with the activation loop [85, 87, 88, 107], which together promote 
catalysis.  
 
In addition to stabilizing the kinase for activity, the hydrophobic motif is proposed to 
provide a docking site for PDK-1. Studies by Alessi [108] provided evidence that 
PDK-1 interacts with high affinity with sequences corresponding to the hydrophobic 
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phosphorylation motif, by identifying the C-terminus of PRK2 in a yeast two-hybrid 
screen for PDK-1 binding partners. Subsequently, it has been shown that the 
hydrophobic motif is the docking site of PDK-1 for a variety of substrates, including 
PKC and p70S6 kinase [109, 110]. In a study of PKCβII, it was suggested that in the 
unphosphorylated form, the hydrophobic site is exposed for PDK-1 binding but once 
phosphorylated, this site is hidden in an inactive kinase conformation [110].  
 
1.2.4.4  V5 domain 
The V5 domain, despite containing several highly conserved residues, has the lowest 
overall amino acid sequence identity among PKC. PKC are part of the AGC family of 
serine/threonine protein kinases [86]. Biochemically and structurally, PKA is perhaps 
the best studied protein kinase [111].  As Fig. 1.5 shows, the sequence of PKA 
terminates at Phe350, which corresponds to the invariable phenylalanine residue NH2-
terminal to the phosphor-acceptor residue at the hydrophobic motif found in many 
AGC kinases [112]. 
 
 
Fig. 1.5. Alignment of amino acid sequences of V5 domains of representative 
isozymes in the PKC superfamily with that of PKA. V5 domains from 
representative isozymes from cPKC (bovine PKCα) [35], nPKC (mouse PKCε [113], 
aPKC (rat PKCζ) [49] and PRKs (rat PRK1 [114]) and human PRK2 [43]) were 
aligned with that of human PKA [115].  Amino acid residue numbers are shown to the 
left of the sequences. 
 
Although too short (approximately 50 amino acids) to be considered a protein 
domain, the V5 domain of PKC and PRK plays an important regulatory role in kinase 
function. The initial identification of the V5 region was based upon the decrease in 
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sequence homology among PKC α, β and γ at the extreme C-terminus of the kinase 
domain [34]. Primarily, interest in the V5 region stems from PKC βI and II,  which 
are differential spliced products of the same gene and differ only in the V5 region 
[116, 117]. PKC βI and βII are shown to be localized differentially both in their active 
and inactive state [116, 117] and translocate to different intracellular compartments 
following PMA treatment [118]. The isolated V5 domain of PKC βI suppresses 
proliferation of neuroblastoma cells more than that from PKC βII [119]. Chimeras 
generated between various regions of PKC α and βII demonstrated that the COOH-
terminal 13 amino acids from PKC βII are sufficient to confer the nuclear 
translocation and lamin B phosphorylation characteristic of PKC βII [120, 121]. 
Further studies showed a selective interaction between this region and the nuclear 
membrane lipid, phosphatidylglycerol, which may account for the specific nuclear 
function of PKC βII [120]. In addition, the V5 region in PKC βII is shown to bind to 
the selective anchoring protein, RACK1, and the inhibition of this interaction by 
peptides derived from the βII region abolished PKC βII mediated cardiac myocyte 
hypertrophy [122].  
 
The PDZ (PSD-95, Dlg and Zo-1) domain is found in a variety of scaffolding proteins 
that mediate the organization of signaling networks [123]. Thus far, three PKC 
binding proteins that contain PDZ domains have been identified, namely, PICK1, 
INAD and ASIP, which interact with the V5 domain of PKC isozymes. PICK1 was 
isolated in a yeast two-hybrid screening, using the catalytic domain of PKCα as bait 
[124]. PICK1 localizes PKCα to a perinuclear region [124, 125]. The Drosophila 
scaffolding protein INAD contains five PDZ domains, two of which interact directly 
with Drosophila eye PKC [126, 127]. The PKC binding site for INAD had been 
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mapped to the carboxyl-terminal region of PKC, although sites outside the V5 region 
may also be involved [127]. Finally, the third PDZ-containing protein ASIP, which 
was recently identified by Ohno and co-workers [128], is a novel atypical PKC-
specific interacting protein. This protein contains three PDZ domains. ASIP localizes 
atypical PKCs to tight junctions and may play a role in the maintenance of epithelial 
cell polarity.  
 
In addition, the V5 regions of PKCs are critical in phosphorylation. This region 
incorporates two key phosphorylation sites (the turn and the hydrophobic motif), both 
of which are critical in priming the kinase. Phosphorylation of these sites controls the 
accumulation of phosphate at other sites in PKCα, as well as contributing to the 
maintenance of the phosphatase-resistant conformation [129], which affect the rate of 
dephosphorylation in PKC α and β [103, 129, 130]. The basis for these effects seems 
to be in part due to the interaction of the phosphorylated V5 region with the kinase 
domain itself, inducing a closed, stable conformation.  
 
The elucidation of the three dimensional structure of PKCθ and PKCι provides 
structural prototypes for the entire protein kinase family [87, 88]. Studies on the 
conformations of active PKCs show that the V5 domain of the kinases contributes to 
substrate recognition and substrate-enzyme complex stability by helping to secure the 
kinase core, especially the ATP-binding site, in a functional conformation. This is 
done by wrapping back the C-terminal tail around the lower and upper lobes of the 
kinase domain. Indirect evidence that this region of PKC α is important for 
stablility/activity derives from a deletion analysis of the mammalian protein expressed 
in Saccharomyces cerevisiae, where removal of just the C-terminal 26 amino acids 
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destroys activity [131]. It is noteworthy that the most C-terminal phosphorylation site 
in the V5 regions of PKCs (the so-called ‘FSY’ site) is replaced by a glutamic acid 
residue or an aspartic acid residue in the aPKCs and PRKs, respectively. In PKC α the 
equivalent mutation (S657D) partially retains wild-type PKC α properties [129]. Thus 
it appears that for aPKCs and PRKs, the requirement for a phosphate residue on this 
hydrophobic site is by-passed.  
 
1.3 Activation 
1.3.1 PKC activation in vivo by membrane translocation 
PKC is readily recovered as a soluble protein from resting cells homogenized in the 
presence of EDTA [132]. Upon treatment of cells with agonists leading to the 
stimulation of phosphatidylinositol-specific phospholipase C activity, a redistribution 
of PKC from cytosol to the plasma membrane is observed. Treatment of parietal yolk 
sac cells with phorbol ester elicits a rapid decrease in cytosolic PKC that is 
accompanied by a significant increase in the level of plasma membrane-associated 
enzyme [133]. A rise in either internal Ca2+ or DAG can cause cytosol-membrane 
translocation of PKC [134, 135]. These results established a temporal correlation 
between the intracellular distribution of PKC and its putative activation state. Phorbol 
esters are potent activators of PKCs. They can mimic the effects of the natural 
activator of PKCs, diacylglycerol [136]. It is widely recognized that phorbol esters are 
promoters of skin tumors, with pleiotropic and often tissue specific cellular responses 
such as proliferation [137], differentiation [138], apoptosis [139] and gene expression 
[140]. PKC has been identified as the high-affinity intracellular receptor of phorbol 
esters. Phorbol ester activates PKC in vitro and can substitute for DAG in platelet 
activation [141]. DAG can inhibit phorbol ester binding to PKC competitively, 
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indicating that the sites of interaction for these activators are similar if not identical 
[142]. Since phorbol esters have more than 1000-fold higher affinity than DAG for 
PKC in the presence of lipid [143], they have been used extensively in many PKC 
assays.  
 
1.3.2 Lipid-induced PKC activation 
Pseudosubstrate sequences within the intramolecular regulatory domain have been 
identified in PKCs. These sequences provide a means of autoinhibitory activity of 
proteins by interacting with the catalytic domain [144, 145]. The interaction between 
specific lipids or other activators and the regulatory domain of the PKCs leads to 
conformational changes that release autoinhibitory restraints imposed by the 
pseudosubstrate domain and induce PKC activation [60]. Some lipid activators of 
PKC are illustrated in the following segments, including diacylglycerol, phosphatidyl-
L-serine, and fatty acids. 
 
1.3.2.1 Diacylglycerol (DAG) 
cPKCs and nPKCs are activated by DAG and phorbol esters in the presence of 
phosphatidylserine (PS) [49, 146]. Activation of PKC by DAG analogues is very 
stereospecific: the sn-1,2-DAGs, but not the 1,3- or 2,3-DAGs are effective in assays 
using either lipid vesicles or mixed micelles [147, 148]. Both the oxygen esters (1, 2-
position) and the primary hydroxyl group (3-position) are essential for DAG function. 
The acyl chain composition does not appear to be critical although a preference for 
unsaturated side chains has been reported [149-151]. The major requirement with 
respect to acyl chains appears to be their length. In vitro studies showed that DAG 
with both acyl chains containing six or more carbon atoms induces maximal kinase 
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activity, indicating that DAGs must be sufficiently hydrophobic to associate with 
membranes or micelles [152-154]. Activation of PKC by DAGs is believed to result 
from two effects. Firstly, the affinity of PKC for PS increases in the presence of DAG 
and strengthens PKC association with the membrane [155, 156]. Secondly, DAG 
together with PS induces the conformational changes that expose the pseudosubstrate 
domain [61]. 
 
1.3.3.2 Phosphatidyl-L-Serine (PS) 
It has been almost 20 years since Nishizuka and coworkers reported that the pro-
enzyme of the protease-activated kinase (PKC) is activated by PS [157]. PS is the 
phospholipid which is best able to activate PKC [158, 159] and is thought to represent 
the principal  physiological phospholipid cofactor. The high affinity of PKC for PS in 
mixed micelles requires DAG. DAG can increase the affinity of PKC for PS [155]. 
Similarly, Ca2+ increases the affinity of PKC for PS [155]. The activation response 
curve of PKC by PS is sigmoidal. PS concentrations of 15 mol % of total lipid in the 
plasma membrane are sufficient to totally activate PKC in the presence of saturating 
amounts of Ca2+ and DAG. PKC interacts with multiple phosphatidylserine 
molecules. The actual number of PS molecules that interact with one PKC molecule 
has recently been calculated to be on the order of eight.  Thus, PKC interaction with 
PS can cause extensive segregation of acidic phospholipids [160]. 
 
1.3.3.3 Other phospholipids 
Several other negatively charged phospholipids such as phosphatidylinositol (PI), 
phosphatidic acid (PA), phosphatidylglycerol (PG) and cardiolipin (CL) are capable 
of supporting PKC activity although they are less effective than PS [154, 161]. In 
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contrast to the highly specific interaction between PKC and PS in the presence of 
DAG, the interaction between PKC and other phospholipid effectors appears to be 
due to less specific electrostatic effects, reflecting the capacity of acidic lipids in 
general to bind to PKCs [162]. Various PKC isozymes have distinguishable responses 
to these phospholipids in some instances. For example, cardiolipin is a strong 
activator of PKCγ and PKCε [163, 164]. The precursors of DAG, 
phosphatidylinositol-4,5-biphosphate (PIP2), phosphatidylinositol-3,4,5-triphosphate 
(PIP3) and phosphatidylinositol-3, 4-biphosphate have been reported to be potent and 
selective activators of PKCδ, ε, η [165, 166]. PIP3 was also implicated in the 
activation of PKCζ [167]. Recent evidence demonstrates that PKCζ can be activated 
by ceramide, which is produced by stimulation of sphingomyelin hydrolysis catalyzed 
by sphingomyelinase, both in vitro and in vivo [168]. These data suggest that 
individual PKC isozymes can be regulated by more than one lipid and they may have 
separate and unique functions in the cell. 
 
1.3.3.4 Fatty acids 
In the absence of PS and Ca2+, cis-unsaturated fatty acids such as arachidonic, 
linoleic, linolenic and oleic acid can activate PKC to varying degrees depending on 
the isozyme [159, 169-171]. Furthermore, fatty acids have been shown to activate 
PKC synergistically with DAG in the presence of PS and to produce nearly fully 
active PKC at basal cytosolic Ca2+ concentrations [172-175]. PKC activation by fatty 
acids is thought to be physiologically relevant but the mechanism of activation is 
distinct from that of DAG. Fatty acids do not interact with PKC at the phorbol 
ester/DAG-binding site [172, 173]. Fatty acids are usually produced by phospholipase 
A2, while DAG is produced by phospholipase C-catalyzed hydrolysis of 
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phosphatidylinositol and phosphatidylcholine or via prior formation of phosphatidic 
acid through phospholipase D-catalyzed hydrolysis [176, 177]. Three major groups of 
phospholipase C, PLCβ, PLCγ, and PLCδ, have been identified in mammalian tissues, 
and each group consists of more than one isoform. The enzymes are activated upon 
cell stimulation and cleave inositol phospholipids to produce inositol phosphates and 
DAG needed for PKC activation. At a later phase of the cellular response, 
phospholipase D plays a major role in the production of DAG from PC to prolong 
PKC activation [178]. Lysophosphatidylcholine (lysoPC) is the product of PC 
hydrolysis by PLA2. LysoPC together with DAG can significantly strengthen 
subsequent cellular responses [8]. DAG produced from PI hydrolysis is rapidly 
converted to phosphatidic acid (PA) by the action of DAG kinase, and further to PI, 
PIP, and PIP2. PA produced from PC is converted to DAG by the action of 
phosphomonoesterase [177, 179, 180]. On the other hand, the DAG produced from 
PC hydrolysis is a poor substrate for DAG kinase, and is slowly degraded by DAG 
lipase [181]. 
 
In summary, PKC activation is a convergent point for various signal-induced 
pathways, such as membrane phospholipid hydrolysis products formed by the 
activation of phospholipases A2, C and D [182]. These phospholipases may be 
activated by different stimuli at different locations in cells. In specialized cases, 
activation of PKC may also be regulated by sphingolipid metabolites [8, 183] or even 
ultraviolet B (UVB) [184, 185]. A recent study by Shen and colleagues demonstrated 
that although both pro-apoptotic PKC (PKCδ) and pro-survival PKC (PKCζ) were 
activated by UVB, specific and opposing regulation on both isoforms was achieved 
with a sesquiterpene lactone [185].    
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1.4 Post-translational processing and maturation 
All known PKC isozymes can autophosphorylate [37, 38, 102, 146, 186-190]. 
Detailed studies of the role of autophosphorylation have mostly been carried out with 
cPKC isozymes and have revealed that the autophosphorylation is an intramolecular 
reaction at both serine and threonine residues on both regulatory and catalytic 
domains [191-193]. Autophosphorylation of PKC has a Km value for ATP about 10-
fold lower than that for substrate phosphorylation [191], similar to that observed for 
phosphorylation of exogenous substrates [194, 195]. At the same time, there appears 
to be a dependence on PS and DAG [4, 196]. The final step for PKC maturation is the 
autophosphorylation of serine/threonine residues in the turn motif and hydrophobic 
motif. After this, the PKCs become catalytically competent upon activation by 
cofactors such as DAG [45]. The competence of members of the PKC family to 
respond to lipid second messengers depends on a series of ordered phosphorylation 
events [197, 198]. The kinase domain of PKCs contains three conserved 
phosphorylation sites: the activation loop (XTXTFCG) which is phosphorylated by 
phosphoinositide-dependent kinase (PDK1) [97, 100], and two carboxyl-terminal 
sites, the turn motif and hydrophobic FXXFS/TF/Y motif which are regulated by 
autophosphorylation [101]. Phosphate at the activation loop unmasks the substrate 
binding cavity and structures the enzyme for catalysis, with phosphates at the two 
carboxyl-terminal positions then locking the enzyme in this catalytically competent 
conformation. Newly synthesized PKCs are in a conformation that promotes binding 
of PDK-1 to its carboxyl terminus and in which the activation loop is exposed for 
phosphorylation. Thus, the primary regulation of this phosphorylation event is the 
direct interaction of PKC with PDK1. Although phosphorylation at the activation loop 
is required for the maturation of PKC, once the enzyme is phosphorylated at the C-
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terminal sites, the activation loop phosphate is dispensable [89]. The fully 
phosphorylated species of PKC is the mature form that is competent to respond to 
lipid second messengers. 
 
It has been reported that protamine can stimulate autophosphorylation of PKC [199, 
200], which is consistent with the role of protamine as an unconventional activator of 
PKC [201]. Protamine is thought to induce a conformational change that releases the 
pseudosubstrate domain from the active site, thereby leading to PKC activation [60]. 
Protamine sulfate induced phosphorylation occurs in the absence of 
phosphatidylserine, diacylglycerol, and calcium [157]. Protamine sulfate alters the 
structure of PKC in the same way as lipid activators, thus effecting the same change 
in function: activation. Protamine sulfate can expose Arg19 of PKCβII’s 
pseudosubstrate domain to proteolysis [199].  
 
The active species of PKC is highly sensitive to dephosphorylation: biochemical 
studies have shown that membrane-bound PKC is two order of magnitude more 
sensitive to dephosphorylation than is soluble PKC [197]. In fact, prolonged 
activation by treatment of cells with phorbol esters results in dephosphorylation and 
down-regulation of PKC [202]. The dephosphorylated species localizes to the 
detergent-insoluble fraction of cells, where it eventually proteolysed. Studies with 
PKCα suggest the involvement of caveolin-dependent targeting to endosomes [203]. 
Limited evidence suggests that proteolysis may be through an ubiquitin-mediated 
pathway [204, 205]. Treatment with phorbol esters is frequently used to ‘down-
regulate’ PKC in experiments aimed at addressing the involvement of PKC in cell 
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signaling [206]. Atypical PKCs are resistant to this phorbol-ester mediated down-
regulation.  
 
Although the phosphorylation of conventional PKCs is constitutive, their 
dephosphorylation may be under agonist control [202]. Both phorbol esters and 
ligands such as tumour necrosis factor α (TNFα) result in PKC inactivation and 
dephosphorylation [207-209]. Furthermore, serum selectively promotes the 
dephosphorylation of the activation loop segment in conventional PKCs, thus 
uncoupling the phosphorylation of the activation loop from that of the C-terminal sites 
[210]. The hydrophobic site of PKCε has also been reported to be selectively 
dephosphorylated by a rapamycin-sensitive phosphatase [211]. Recent studies have 
shown that the dephosphorylated turn motif provides a specific binding site for the 
molecular chaperone, Hsp70 [212]. This dephosphorylated-dependent binding of 
Hsp70 stabilizes PKC and allows it to become rephosphorylated and cycle back into 
the pool of functional PKC. Disruption of the interaction of Hsp70 with PKC results 
in accumulation of dephosphorylated PKC in the detergent-insoluble fraction of cells, 
which are subsequently targeted for degradation.  
 
1.5 Isozyme specific regulation 
The existence of PKC heterogeneity poses the question as to why so many isotypes 
exist and what the functional relevance of each of them could be. The high degree of 
conservation of the individual PKC isotypes over various mammalian species 
indicates that maintaining heterogeneity is useful and suggests specific roles for each 
isotype. Currently, isozyme specific regulation is proposed to be mediated by 
substrate specificity, localization and cofactor dependence. 
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1.5.1 Substrate specificity 
A large number of proteins have been shown to be phosphorylated either in vitro or in 
vivo by PKC [213]. Based on these data as well as studies using synthetic peptides, a 
basic consensus PKC phosphorylation motif was originally determined: 
RXXS/TXTX, where X indicates any amino acid. These studies underscored the 
importance of basic residues N- and C-terminal to the phosphor-acceptor residue. 
Similarly, a large number of ‘artificial’ substrates of PKC are also known and used for 
activity measurements, such as myelin basic protein, various histones, protamine and 
protamine sulfate. Recently, an oriented peptide library approach was used to 
determine the optimal substrate selectivity of nine PKC family members [214]. The 
results confirmed the requirement for basic residues surrounding the Thr or Ser, and 
indicated that although the optimal phosphorylation for each PKC is similar, there are 
some subtle differences between family members, particularly between conventional, 
novel and atypical PKCs. All PKCs prefer basic residues at positions -6, -4 and -2 to 
the Ser/Thr. cPKCs also prefer basic residues at +2, +3 and +4, whereas nPKC and 
aPKC prefer hydrophobic residues at these positions. The only deviation to this 
selectivity was PKCμ, which had a strikingly distinct optimal motif from all other 
PKCs, with a strong selectivity for Leu at the -5 position [214]. This approach has 
provided an explanation for the substrate selectivity of certain PKCs over other family 
members. For example, the MARKCS protein (myristoylated alanine-rich C-kinase 
substrate), a ubiquitous PKC substrate in all cells, is phosphorylated by all PKCs 
except PKCζ [215]. Similarly, plectstrin (platelet and leukocyte C-kinase substrate 
protein), a PKC substrate found in cells of hematopoietic origin, appears to be 
phosphorylated by all PKCs [216]. Conversely, Sheu and colleagues [217] 
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demonstrated that although all members of cPKCs efficiently phosphorylate GAP-43 
(growth-associated protein of 43 kDa, also known as neuromodulin), neuromodulin 
was a better substrate for PKCα and PKCβ than PKCγ. The human telomerase-
associated protein 1 (hTEP1) and the telomerase catalytic subunit (human telomerase 
reverse transcriptase hTERT) were found to be selectively phosphorylated by PKCα 
[218] while the heterogeneous ribonucleo-protein A1 (hnRNP A1) was efficiently 
phosphorylated by PKCζ but not other PKCs [219], whereas elongation factor eEF-1α 
was a good PKCδ substrate [220]. In addition, Sheu et al [221] demonstrated that 
oxidized neurogranin was a poorer substrate for PKC; both the reduced and oxidized 
forms had similar Km values, but the Vmax of the oxidized form was about one-fourth 
that of the reduced form. Thus oxidation/reduction mechanisms may function as an 
additional level of specificity.  
 
Despite these subtle differences, it is clear that all PKCs generally prefer to 
phosphorylate similar sequences, suggesting that other mechanisms must exist to 
discriminate which particular PKC isoform participates in signaling mechanisms.  
 
1.5.2 Specific cellular localization  
Since the early 1990s it has become clear that in addition to binding to lipids, PKC 
can also interact with proteins via protein-protein interactions. These interactions play 
an important role in the localization and function of PKC isozymes. PKC binding 
proteins are defined as proteins (which may or may not be PKC substrates) that bind 
PKC directly via a nonsubstrate binding site. These proteins may be grouped together 
on the basis of the conformation of the PKC required for binding, cofactor 
requirement, and whether or not the proteins are PKC substrates. PKC in an active 
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conformation will bind to receptor for activated C-kinase (RACKs) [222, 223] or 
substrates that interact with C kinase (STICKs) [224, 225], whereas inactive PKCs 
will interact with A kinase anchoring protein (AKAPs) [226] and 14-3-3 [227, 228]. 
PKC binding proteins may or may not be PKC substrates (e.g STICKs and RACKs, 
respectively) and may require cofactors for binding to PKC (STICKs require 
phosphatidylserine [224]; GAP-43 requires Ca2+ [229]). Such proteins serve many 
functions, which include localizing inactive (AKAPs) or active (RACKs) PKC 
isozymes to specific intracellular sites or serving as substrates (STICKs), shuttling 
proteins (RACK1) [223], PKC activator (syndecan-4) [230], or PKC inhibitors (14-3-
3, Nef) [231, 232]. 
 
1.5.2.1 RACKs 
RACKs were originally identified by Mochly-Rosen and co-workers, who in the early 
1990s proposed that the intracellular localization of PKC isozymes upon activation is 
mediated via interaction with isozyme-specific anchoring proteins [233, 234]. RACKs 
were first characterized as Triton-X 100 insoluble proteins that bind PKC isozymes 
only in the presence of PKC activators [233, 234]. The PKC-RACK interaction is 
mediated, at least in part, by the C2 region in cPKCs and the C2-like region (within 
the V1 domain) in nPKCs [222, 235-237]. Two RACKs have been identified to date 
by using overlay assays: RACK1, which specifically interacts with PKC βII [74, 223], 
and RACK2 (β’-COP), which specifically interacts with PKCε [222]. Both RACKs 
bind PKC in its active conformation. Despite the differences in sequence between 
RACK1 and RACK2, the two proteins share common features. Although RACK1 and 
RAKC2 are not PKC substrates, both increase PKC phosphorylation of substrates 
[222, 223]. RACKs contain ‘WD-40 repeats’, a motif known to mediate protein-
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protein interaction. It was observed that RACK1 translocates to the same site as 
activated PKCβII and specifically associates with this isozyme upon activation. These 
findings suggest a potential role for RACK1 as a shuttling protein [237].  
 
1.5.2.2 STICKs 
STICKs are an important group of PKC binding proteins that were discovered by 
Jaken and co-workers [238]. STICKs require phosphatidylserine for interaction and 
are PKC substrates. Phosphorylation of STICKs regulates their association to PKC. 
The identified STICKs include MARCKs, MacMARCKs, α-adducin, β-adducin, γ-
adducin and clone 72 (SseCKs) [224, 238-240]. STICKs are involved in a variety of 
functions. For example, adducins are cytoskeletal proteins involved in the interaction 
between actin and spectrin. Expression, localization, and phosphorylated states of α-
adducin and γ-adducin have been correlated with renal tumor progression [238-240]. 
Clone 72, a major PKC binding protein in REF52 fibroblasts, is involved in 
cytoskeleton modeling and cell growth [241]. Another STICK is the serum 
deprivation response protein (Sdr) that binds and localizes PKCα within the 
microdomain of caveolae [224].  
 
1.5.2.3 Scaffolding proteins 
Scaffolding proteins cluster signaling proteins, thus allowing a tight control of cellular 
pathways as well as cross-talk between different cascades. Scaffolding proteins such 
as caveolin, AKAPs and 14-3-3 cluster PKC to specific intracellular sites. PKC 
scaffolding proteins that have been identified to date bind to PKC in its active 
conformation.  
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1.5.2.3.1  Caveolin 
Caveolin targets a variety of signaling proteins such as the α-subunit of G-proteins, 
Src and EGF receptors to the caveolae [242-244]. PKCα localizes to the microdomain 
of the caveolae [224, 244]. PKCα, in addition to PKCζ also associates with caveolin, 
whereas PKCε was not found to associate with this protein [244]. Caveolin interaction 
with PKC results in the inhibition of PKC activity. Moreover, a short peptide derived 
from caveolin interacts directly with PKC and inhibits its kinase activity [244]. 
 
1.5.2.3.2 AKAPs 
Two members of the AKAP family of proteins that target PKA to a specific 
intracellular site are also scaffolding proteins for PKC. Elegant work by Scott and co-
workers has demonstrated that AKAP79 assembles PKC, phosphatase 2B, and PKC at 
postsynaptic dendritic fractions [226, 245, 246]. AKAP79 inhibits PKC activity [226]. 
Ca2+- calmodulin as well as DAG release PKC from AKAP79 [246]. In HEK-293 
cells, AKAP79 is phosphorylated after PMA stimulation [247]. Phosphorylation of 
AKAP79 by PKC regulates its subcellular compartmentalization [247]. Thus, there is 
a reciprocal regulation of AKAP79 and PKC with regard to subcellular localization. 
Another AKAP identified by Scott and co-workers , AKAP250 (Gravin), assembles 
both PKA and PKC to the filopodia in human erythroleukemia cells [248]. 
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1.5.2.3.3 14-3-3 
14-3-3 is a family of highly homologous proteins that are ubiquitously expressed. The 
role of 14-3-3 proteins in PKC signal transduction remains controversial. 14-3-3 
isozymes may either inhibit [227, 249] or enhance PKC activity [228, 250]. The 
dimeric structure of 14-3-3 enables the protein to serve as an adaptor or scaffold for a 
variety of signaling proteins, including PKC [251]. Meller et al [231] have reported a 
specific interaction between a PKC isozyme (PKCθ), which may help keep this PKC 
isozyme in its inactive conformation. 14-3-3τ may represent an example of RICK (a 
receptor for inactive C kinase), which binds to PKC and targets the inactive isozyme 
to specific intracellular sites.  
 
1.5.2.4 Direct interaction of PKC isozymes with cytoskeletal proteins 
PKC isozymes associate with cytoskeletal proteins and this interaction between PKC 
and cytoskeletal proteins is at least in part isozyme-selective. An example of this 
isozyme specificity is PKCζ, which associates with tubulin via the pseudosubstrate 
region [252]. Terrain and co-workers have demonstrated that PKCε specifically binds 
F-actin via an actin binding site within the C1 region [253, 254]. F-actin activates 
PKCε in the absence of phospholipids [253]. PKC βII (but not PKC βI) also interacts 
with F-actin via its V5 domain and tranlocates to the actin cytoskeleton upon 
activation [255]. PKC βII selectively phosphorylates actin, although actin is a poor 
substrate. The interaction of PKC βII with actin results in a significant enhancement 
in autophosphorylation and in an alteration in substrate specificity [255]. Furthermore, 
the interaction between PKC βII and actin protects PKC from degradation and down-
regulation [255]. The interaction between PKC and F-actin was also observed in 
Aplysia [256] 
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1.6 Protein Kinase C Related Kinase (PRK) 
1.6.1 History and structure of PRK 
Protein kinase C-related kinases (PRKs) were first identified as protease-activated 
serine/threonine kinases via conventional protein chemistry and were originally 
named protease-activated kinases (PAK). They were isolated from rat liver and were 
shown to be able to phosphorylate S6 peptide and its analogue [39-41]. Later, PRK 
cDNAs were isolated from a human hippocampal cDNA library by low stringency 
plaque hybridization using a cDNA fragment for the catalytic domain of PKCβII as a 
probe [42] or by PCR [43] ,or with specific oligonucleotide primers [114]. PRKs have 
50 % sequence similarity in the catalytic domain to protein kinase  C [43, 257]. PRK 
but not PKN is adopted as the preferred nomenclature because before Mukai and Ono 
used PKN to describe this kinase, another serine/threonine protein kinase which is a 
basic 45-47 kDa kinase activated by NGF and several other factors in PC12 cells and 
other cell types had already been named PKN [258]. Secondly, to reflect the 
homology to PKCs and to prevent confusion, PKC-Related Kinase (PRK) may be a 
more suitable nomenclature than PKN. The structures of the isoforms of PRK are 
shown schematically in Fig 1.6.  
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Fig 1.6.  Primary structure of PRKs (adapted from Mukai [259]). 
 
1.6.2 Distribution of PRK 
PRK1 mRNA is expressed ubiquitously in human and rat tissue [42, 260]. Mouse 
PRK2 mRNA was detected ubiquitously in tissues by Northern blotting [261] and 
whole body situ hybridization while human PRK2 mRNA was reported to express 
specifically in a DX3 lymphoid lineage by Northern blotting and RT-PCR 
experiments [43]. In contrast, PRK3 mRNA was almost undectable in normal human 
tissues. Levels were especially abundant in chronic myelogenous leukemia K-562, 
colorectal adenocarcinoma WE480, and HeLa cells [262]. PRK1 level in the rat brain 
was found to be approximately 0.01% of total protein and biochemical fractionation 
revealed that the half of the total PRK1 is distributed in the soluble cytosolic fraction, 
and one-third of it is in a post-nuclear membrane fraction [44]. PRK1 was found to be 
especially abundant in the neurons of human brains, with a concentration in the 
endoplasmic reticulum (ER) and ER-derived vesicles localized to the apical 
compartment of the apical compartment of the juxtanuclear cytoplasm, late 
endosomes, multivesicular bodies, Golgi bodies, secretory vesicles and cell nuclei 
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[263]. On the other hand, PRK3 was detected in the cell nucleus and the perinuclear 
region, but not in the cytoplasmic region [262]. 
 
1.6.3 Regulation of activity 
Activators of PKC such as calcium, phosphatidylserine/diolein do not enhance PRK 
activity [44, 54]. On the other hand, unsaturated fatty acids such as arachidonic and 
linoleic acids were identified as potential activators of PRK [52], albeit PRK2 is 
significantly less sensitive to arachidonic acid than PRK1 [262, 264]. Cardiolipins, 
phospholipids such as phosphatidylinositol 4,5-biphosphate (PI4,5-P2) and 
phosphatidylinositol 3,4,5-triphosphate (PI3,4,5P3), and lysophospholipids such as 
lysophosphatidic acid (LPA) and lysophosphatidylinositol can also stimulate the 
kinase activity of PRK1 and 2.  
 
It has been reported that the GTPase RhoA bind to PRK1 in a GTP-dependent manner 
and the activity of purified bovine brain PRK1 is stimulated in the presence of a 
GTPγS bound form of RhoA [55-58]. PRK1 has been reported to interact with Rac 
but interaction is weak with negligible activation [56-58, 82]. As for PRK2 binding 
with Rho family GTPase, there exist different schools of thought, with one reporting 
that the binding is GTP-dependent [261] and the other reporting the binding to be 
nucleotide-independent [82].  
 
The N-terminal region of PRK is thought to act as an inhibitory region to the kinase 
activity, of which the binding of activators causes the inhibition to be lifted [52, 78, 
114, 265]. The prevailing model by RhoA activation proposes the binding of RhoA to 
the ACC finger domain removes the pseudosubstrate region from the catalytic domain 
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and thus presents an active kinase domain [266]. However, an N-terminal deleted 
mutant without the three anti-parallel coiled coil (ACC) fingers has a basal activity 
similar to wild type kinase [267]. The exact mechanism by which PRK is activated by 
RhoA to produce conformational changes is still unknown. Recently, Parekh et al. 
[198] proposed a model of Rho dependent PRK activation via PDK1 based on the 
data reported in [268]. Activated Rho binds to PRK, to disrupt the autoinhibitory 
effect mediated by the pseudosubstrate domain, and induces a conformational change 
that is permissive for PDK docking to PRK. PDK subsequently phosphorylates the 
activation loop to render the kinase competent.   
 
1.6.4 Biological functions 
The micro-injection of kinase inactive form of PRK2 into NIH3T3 fibroblasts results 
in the disruption of actin stress fibers [82], while the kinase negative form of PRK1 
prevented insulin-induced actin stress fiber breakdown and membrane ruffling [269], 
suggesting a role for PRK1 and 2 in regulating actin cytoskeletal reorganization.  One 
of the cytoskeletal functions of PRK was elucidated from loss of function studies in 
the Drosophila PRK homologue (Prk). In the late stages of Drosophila development, 
dorsal closure takes place whereby cells of the lateral epidermis elongate along the 
dorsal-ventral axis. However, Prk loss of function mutants display a dorsal closure 
defect [81]. This dorsal closure defect appears to be highly similar to the phenotype of 
loss of function of Rho1 gene and several components of the Rac-mediated JNK 
cascade.  
 
In in vitro experiments, PRK1 was shown to directly phosphorylate myosin and CPI-
17 [50, 270]. Furthermore, PRK1 has been shown to interact with a number of 
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cytoskeletal proteins and thus may be involved in the modulation of cytoskeletal 
dynamics. PRK1 has been found to bind to the third spectrin-like repeats of the actin 
cross linking protein α-actinin [271]. PRK1 also directly binds to and efficiently 
phosphorylates the head-rod region of the intermediate filament proteins [272]. On the 
other hand, PRK2  has been reported to bind to tyrosine phosphatase-basophil like 
protein (PTP-BL), a large non-transmembrane protein tyrosine phosphatase 
implicated in the modulation of the cytoskeleton [273]. The binding and 
phosphorylation of a major cytoskeletal component by PRK1 and the strong 
colocalization of endogenous PTP-BL and PRK2 in lamellipodia-like structures, 
regions of extensive actin turnover, suggest the close correlation of PRK1 and 2 in the 
regulation of the actin-cytoskeleton.   
 
Further biological roles of PRK may include vesicle and glucose transport. The 
overexpression of RhoA retards EGF receptor movements from early to late 
endosomal compartments after stimulation by EGF, and a catalytically inactive form 
of PRK1 mutant completely blocks this effect [274]. Thus PRK1 may regulate the 
kinetics of EGF receptor trafficking. In 3T3/L1 cells, expression of both Rho and 
PRK1 activates glucose transport, and replacement of dominant negative-form of Rho 
and PRK1 inhibits this. [275]. In rat adipocytes, transient expression of wild type 
PRK1 provokes an increase in the translocation of glucose transporter Glut4 to the 
plasma membrane.  It remains to be determined whether PRK1 is involved in the 
transport of glucose under physiological conditions. 
 
In addition, PRK2 may be involved in the regulation of apoptosis. PRK2 cleaved in 
the early stages of apoptosis binds to and prevents phosphorylation of PKB in vivo at 
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Ser 473 and Thr 308 [276]. Since phosphorylation of PKB is necessary for its full 
activation, PRK2 may inhibit PKB downstream signaling and abrogate its anti-
apoptotic effects. In contrast, a recent study proposed a new function of PKC in cell 
death by demonstrating that PKC activation stabilizes X-linked inhibitor of apoptosis 
protein (XIAP) and thus suppresses tumour necrosis factor-related apoptosis-inducing 
ligand (TRAIL) induced apoptosis [277]. PRK1 can be cleaved at specific sites in 
some apoptotic cells [278]. This cleavage seems to be catalyzed by caspase-3 or a 
related protease. The major proteolysis takes place between the N-terminal regulatory 
domain and the C-terminal catalytic domain, and generates a constitutively active 
kinase fragment which may contribute to signal transduction, eventually leading to 
apoptosis. Finally PRK1 may play some roles in the development of cancers, because 
PRK1 can interact with the E6 oncoprotein and phosphorylate E6 [279]. 
 
1.7 Approaches used to elucidate isozyme-specific functions of PKC 
The discovery of staurosporine, an antifungal agent, as an inhibitor of PKC effective 
at nanomolar concentrations [280] led to development of many derivatives. Two such 
compounds, Ro31-8220 and Go6850 were subsequently used in cell-based assays to 
determine specific roles for PKCs. However, these were later shown to lack 
specificity and to inhibit several other protein kinases in vitro [281, 282]. One 
derivative of staurosporine, LY333531, which inhibits PKC-β more potently than 
other PKC isoforms, is reported to normalize the elevated levels of PKC activity in 
the retina and kidneys of diabetic rats [283]. It is in Phase III clinical trials for the 
treatment of diabetic microvascular disease.  
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In terms of basic science, kinase inhibitors are useful in elucidating downstream 
targets and signaling networks. Each kinase can have several substrates and be itself a 
substrate for other kinases. To delineate the complex network of kinase signaling 
pathways, matching of every kinase in a cell to specific phosphorylation sites on 
target proteins is necessary. Not every kinase will work in an in vitro assay and a 
peptide that is phosphorylated by a kinase in vitro does not necessarily reflect that 
kinase's physiological target. The holy grail of kinome analysis is to determine the 
physiological substrates of all kinases to begin to map out signaling pathways. In the 
absence of isotype-specific PKC inhibitors, it is difficult to assess the exact 
consequences of the activation of a certain isotype in terms of substrate 
phosphorylation and biological effect. This presents a major challenge at the moment, 
and several interesting models have been developed to address these issues.  
 
For instance, a variety of stable cell lines have been generated that overexpress PKC 
isotypes [284, 285], allowing the examination of their effects on biological processes 
or specific proteins of interest. Although this approach is potentially fruitful, it has the 
drawback that effects of the overexpressed PKCs on protein phosphorylation may not 
be direct and may not be physiological.  
The use of dominant negative mutants of PKC isotypes provides another way of 
assessing their functional involvement in signal transduction processes. These mutants 
are generated by modifying the ATP-binding site, thus abolishing the kinase activity 
of the enzyme. Overexpression of such kinase-negative mutants might lead to a 
disruption of the signaling pathways in which the kinase is normally active, by 
interacting with endogenous activators, activating kinases or binding proteins and so 
competing with endogenous wild-type protein. However, in this dominant negative 
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approach, it is unclear to what extent the kinase negative mutants affect signaling by 
other PKC isotypes. Thus it is difficult to assess the specificity.  
 
1.7.1 PKC knock-out mice  
A more direct approach for the study of isozyme-specific function of PKC isozymes 
is targeted gene inactivation (gene knock-out) in mice. Neural, immunologic and 
endocrine phenotypes have been reported.  
 
Recently, the role of PKCα in primary T cell activation and tumor suppression was 
identified. Loss of PKCα had no apparent effect on T cell development and selection 
in the thymus. Instead, PKCα was required for the activation and in vivo function of 
mature CD3+ T cells, such as recall antigen-induced T cell growth, IFN-γ production, 
and the support for class switching to IgG2a and IgG2b after OVA antigen challenge 
in vivo. The study indicated that, in addition to PKCθ, PKCα is part of a signaling 
pathway that is necessary for full antigen receptor-mediated T cell activation and T 
lymphocyte immunity [286]. While PKCα has been proposed to act both as a tumor 
promoter and a tumor suppressor in intestinal cancer via multiple signaling pathways 
[287], Oster and colleagues provided evidence that PKCα function as a tumor 
suppressor in intestinal cancer. Deletion of PKCα but not of PKCζ was found to 
promote polyp formation in wild-type mice and in the ApcMin/+ tumor model [288]. 
Although PKCα appears to be one of the predominant isoenzymes in the kidney [289-
291], studies by Yao et al showed that PKC-α appeared not to play a major role in 
renal sodium reabsorption but, consistent with its expression in the medullary 
collecting duct, contributed to urinary concentration in mice. Thus PKCα–/– mice 
showed approximately 50% greater urine flow rate and lower urinary osmolality 
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compared to PKCα +/+ mice and exhibited a modestly greater urinary flow rate and 
modestly lower urinary osmolality under basal conditions [292]. In addition, the hearts 
of Prkca-deficient mice were hypercontractile, whereas those of transgenic mice 
overexpressing Prkca were hypocontractile. Hence PKCα has been proposed to be a 
fundamental regulator of cardiac contractility and Ca2+ handling in myocytes. [293].   
 
PKCβ mice were initially found to demonstrate deficiencies in B-cell function and 
impaired humoral immune responses [294]. Another study documented deficits in 
mast cell degranulation and interleukin-6 production [295]. It is not yet certain if both 
these changes were due to developmental effects of the null mutation or loss of 
enzyme in adult tissues. PKCβ-null mice have been found to show modest increases 
in insulin-stimulated translocation of GLUT-4 glucose transporters and in glucose 
transport in some tissues [296]. This can be rescued in part by transgenic expression 
of PKCβI, suggesting that it is due to the loss of that enzyme. Recent work had 
demonstrated PKCβ’s contribution to the regulation of arterial blood pressure and its 
requirement for normal acid-base balance [292]. 
 
The T lymphocyte-restricted PKCθ is unique among other PKC members because it 
colocalizes with the T cell receptor in the T cell immunological synapse [297, 298]. 
The physiological functions of PKCθ for T cell receptor signaling were subsequently 
demonstrated by two independent studies with PKCθ-deficient mice [299, 300]. 
Peripheral T cells of PKCθ–/– mice show reduced proliferation and IL-2 production 
and significant impairment in AP-1 and NF-κB activation [299, 300] as well as NFAT 
[300] activation in response to TCR/CD28 stimulation. Although studies have 
implicated the IκBα kinase IKK complex in linking PKCθ to NF-κB activation [301-
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303], the pathway responsible for coupling PKCθ to AP-1 appears to be JNK 
independent [299]. However, another set of studies showed that at least in the immune 
response to murine gamma-herpesvirus 68 (MHV-68), PKCθ is not essential for the 
T-cell activation events leading to viral clearance [304]. This disparity in PKCθ 
function, where PKCθ is dispensable for certain T-cell functions during a viral 
infection in vivo but is required for T-cell activation in vitro, is currently unclear.  
 
Studies have shown that local accumulation of fat metabolites inside skeletal muscle 
may activate a serine kinase cascade, involving serine phosphorylation of insulin 
receptor substrate–1 (IRS-1), leading to defects in insulin-mediated IRS-1–associated 
PI3K and glucose transport in skeletal muscle [305, 306]. Skeletal muscle insulin 
resistance is associated with increases in intramuscular fat metabolites (i.e., fatty acyl-
CoA, diacylglycerol) and PKC-θ activity, suggesting an important role for PKC-θ in 
mediating fat-induced insulin resistance in skeletal muscle [307]. From PKC-θ null 
mice, it was demonstrated that PKCθ functions as a crucial component mediating fat-
induced insulin resistance in skeletal muscle [308].  
Studies from PKCλ knockout ES cells indicate that PKCλ is required for insulin-
stimulated glucose transport. Insulin activated PKC-λ and stimulated glucose transport 
in wild-type (WT) PKC-λ+/+, but not in knockout PKC-λ-/-, ES cells. However, 
insulin-stimulated glucose transport was rescued by expression of WT PKC-λ in PKC-
λ-/- ES cells [309]. 
 
Although PKCε null mice display normal responses to noxious thermal and 
mechanical stimuli, they show decreased nociceptor  sensitization after local injection 
of epinephrine [310]. Similar findings were obtained in rats injected locally with a 
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peptide inhibitor of PKCε, confirming that responses observed in null mice are due to 
loss of PKCε function in mature neurons. In a different set of studies by the same 
laboratory, PKCε null mice were found to be supersensitive to the sedative effects of 
ethanol, barbiturates, and benzodiazepines and this correlates with enhanced 
sensitivity of γ-aminobutyric acidA receptors to the agonist properties of these drugs in 
vitro [311]. This supports other findings in rats and humans, indicating an inverse 
correlation between alcohol consumption and sensitivity to acute alcohol intoxication. 
These studies suggest that inhibition of PKCε may reduce alcohol consumption and 
prove useful in the treatment of alcoholism.  
 
Recent work by Stawowy has demonstrated an essential role of PKCε for activation of 
β1-integrins by angiotensin II (AII) in fibroblasts [312]. AII induces fibronectin, 
laminin and TGF-β1 mRNA via its angiotensin type 1-receptor (AT1) in cardiac 
fibroblasts [313, 314]. In PKCε (−/−) cells basal adhesion was not significantly 
disturbed, but AII treatment did not induce a significant increase of adhesion, in 
contrast to PKCε (+/+) cells where AII treatment induced a significant increase in 
adhesion to collagen I [312].  
 
A brief period of ischemia-reperfusion protects myocardial tissue from a subsequent 
prolonged ischemia by delaying cardiomyocyte death, a phenomenon called ischemic 
preconditioning. Whereas the protective role of PKC-ε in preconditioning is well 
established, controversial results exist concerning the cardioprotective effects of PKC-
δ [315, 316]. For instance, Wang et al. [317] demonstrated that mitochondrial 
translocation of PKC-δ is related to cardioprotection induced by ischemic 
preconditioning, whereas Fryer et al. [318] reported that PKC-δ plays an important 
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role in pharmacological-induced preconditioning but not in ischemic preconditioning. 
Yet another study, using metabolic and proteomic analysis, demostrated that 
preconditioning exaggerated ischemia-reperfusion injury in PKC-δ–/– mice [319].  
 
PKCγ null mice were first generated by Abeliovich et al [320]. Because this isozyme 
is exclusively expressed in the central nervous system, all phenotypes involved central 
nervous system function. The first one described was deficient in spatial learning, as 
observed during a Morris water maze probe test [320]. The deficit was mild and could 
be overcome by intensive training. It was associated with impaired contextual fear 
conditioning. Both findings suggest hippocampal dysfunction associated with 
impaired long-term potentiation in CA1 hippocampal pyramidal neurons after high-
frequency stimulation of CA3 axons. A subsequent study by the same laboratory 
disclosed a second phenotype of gait ataxia associated with persistent multiple 
climbing fiber synapses on cerebellar Purkinje cells due to impaired synapse 
elimination during development [321]. Other laboratories have identified additional 
phenotypes in PKCγ mice. Malmberg et al found that these mice showed normal pain 
responses but decreased hyperalgesia after mechanical or inflammatory peripheral 
nerve injury [322]. Furthermore, nerve injury increases the levels of neuropeptide Y 
and neurokinin-1 receptor immunoreactivity and decreases substance P receptor 
immunoreactivity in the dorsal horn of the spinal cord, but these responses are 
diminished in PKCγ null mice. This findings suggest that PKCγ is important in the 
neural plasticity within the spinal cord after nerve injury that contributes to 
neuropathic pain [323].   
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It is interesting to note that while PKCs demonstrate relatively broad in vitro substrate 
specificity, the published PKC isozyme knockout studies underscore the specific roles 
played by each isozyme, indicating distinct in vivo functions. It is possible that the 
reason for the fairly benign phenotypes of the single PKC knockouts in mice is that 
other members of the same PKC subfamilies are able to substitute partially for the 
deleted gene. In this case, the crossing of single knockout mice to remove an entire 
PKC subfamily may give more definitive results.  
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Aim 
 This study seeks to determine the V5 domain as a determinant in isozyme-specific 
regulation. It aims to elucidate the contribution of the V5 domain to specific kinase 
function in PKCs, using PRK1 and PRK2 as a models. It is hoped that such studies 
lay the foundation for the design of isozyme-specific kinase inhibitor targeting the V5 
domain. The diverse and distinct roles of individual PKC are, at least in part, 
attributed to differences in their structural features. The V5 region appears attractive 
for specific regulation due to its great variability in terms of amino acid length and 
sequence among the isozymes in the PKC family. While previous studies focused on 
the turn and hydrophobic motifs, this study concentrates on the function of the 
additional residues C-terminal to the absolutely conserved phenylalanine residue 
corresponding to the last residue in PKA (Phe350 in PKA, Phe939 in PRK1 and Phe977 
in PRK2) in the regulation and in the establishment of isozyme-specificity of the PKC 
superfamily of kinases in vivo.  
 
A further objective is to unravel the molecular instruction of the C-terminus of PKCs 
for PDK-1 interaction and subsequent priming reaction of the activation loop. In 
addition, the potential role of V5 in response to lipid activation, leading to the 
production of kinases with differential catalytic activity was examined. A final 
objective is to explain the functional difference of V5 deleted kinases by investigation 
of computer modeling of the three-dimensional structure of the catalytic domain of 
PRK1 and PRK2. 
 
Consequently, this thesis aims to investigate and compare the role of the V5 domain 
in the regulation of two PKC superfamily isoforms, PRK1 and PRK2, by defining: 
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1) the structural elements within the V5 domain of PRK1 and PRK2 that are 
required for the catalytic competence of the kinases;  
2) the necessity of the hydrophobic motif for PDK-1 interaction and activation; 
3) the function of the C-terminal extension of PRK beyond the conserved 
phenylalanine (corresponding to Phe350 in PKA and Phe939 in PRK1 and 
Phe978) in the response of the kinases to lipid activators; 
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2.1 MOLECULAR BIOLOGY 
Table 2.1.1 Frequently Used Buffers and Media 
TE 10 mM Tris/HCL pH 7.5 or pH 8.0, 1 mM EDTA (autoclaved) 
50 X TAE 2 M Tris/Acetate, 0.1 M EDTA. The solution was adjusted to pH 
7.7 with 0.2 M acetic acid. 
10 X loading dye 0.1% bromophenol blue, 0.1% xylene cyanol, 40% glycerol 
LB medium 1% bactotryptone, 0.5% yeast extract, 1 % NaCl (autoclaved) 
2 X TY medium 1.6% bactotryptone, 2% yeast extract, 0.5% NaCl, pH 7.0 with 
NaOH (autoclaved) 
Bacterial plates 1.5% bacto agar suspended in LB, or TY 




20 mg/ml (2%) in dimethylformamide (DMF) stock (500X) 
Isopropylthio-β-D-
galactoside (IPTG) 
1 M stock in water (2000X) 
Ethidium bromide 10 mg/ml stock (20,000X) 
Lysozyme 5 mg/ml stock 
SOC LB containing 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 
mM glucose 
RF1 12g/L RbCl, 10g/L MnCl2, 30 mM  potassium acetate (pH 7.5),  
1.5 g/L CaCl2.2H2O, 15% (v/v) glycerol. The solution was adjusted 
to pH 5.8 with 0.2 M acetic acid and filter sterilized.  
RF2 1g/L RbCl, 10 mM MOPS (pH 6.8), 11g/L CaCl2.2H2O, 15% (v/v) 
glycerol. The solution was adjusted to pH 6.8 with 0.1 M NaOH 
and filter sterilized.  
Pfu DNA polymerase 
10 x reaction buffer 
200 mM Tris-HCl (pH 8.8), 100 mM KCl, 100 mM (NH4)2SO4 
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2.1.2 Vectors 
Vectors used in this study are listed in Appendix A. pcDNA3 (Invitrogen) was used as 
an expression vector in mammalian cells. pGEX-kg (GE Healthcare, formerly 
Amersham Bioscience) was used for GST fusion protein expression in E. coli. 
Vectors were stored at -20oC in TE buffer.  
 
2.1.3 Plasmids 
2.1.3.1 Escherichia coli (E. coli) strains 
The E. coli strains and genotype used in the recombinant DNA experiments are as 
follows: 
DH5α supE44placU169(ΦlacZpM115) hsdR115 recA1 endA1 gyrA96 thi-1 
relA1 
JM109 recA1 supE44 endA1 hsdR17 gyrA96 relA1 thiρ(lac-proAB) F’[traD36 
proAB+ lacIq laclq lacZρM15] 
 
2.1.3.2 Gift plasmids 
N terminally Myc-epitope-tagged rat PRK1 cDNA cloned into a pcDNA3 vector was 
a kind gift from R. E. H. Wettenhall (University of Melbourne). Human Myc-PRK2, 
Myc-RhoA-Q63L and C3 plasmids were a kind gift from P. J.Parker (Cancer 
Research UK, London). Human RhoA-T19N DNA and glutathione-S-transferase 
(GST)-tagged human wild-type RhoA DNA in a pGEX4T-3 vector were kind gifts 
from Silvio Gutkind (NIH) and R. M. Evans (Salk Institute), A. O. Brinkmann 
(University Medical Center Rotterdam, The Netherlands) respectively.  
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2.1.4 Polymerase chain reaction (PCR) 
The PCR reaction was performed using a PTC-100 TM Programmable Thermal 
Controller, (MJ Research, Inc. Watertown, MA, USA). A PCR reaction mixture 
consisted of 100 ng of template DNA, 200 ng of each of the primers, 2 mM MgCl2, 
200 μM dNTPs, 1 x Pfu DNA polymerase reaction buffer and 2.5 U of Pfu DNA 
polymerase in a volume of 100 μl. The reaction was carried out for 30 cycles of 45 
sec at 95 oC (denaturing), 30 sec at 55 oC (annealing), and 2 min/kb at 72 oC 
(extension) with one final cycle for 20 min at 72 oC. 
 
2.1.5  Site directed mutagenesis using PCR 
Circular plasmid DNA of about 8 kb in length was used a template. A pair of 
complementary primers was designed with the desired mutation in the middle of the 
primer sequence. Primer sequences used in this study to generate point and deletion 
mutants are listed in Appendix B. The reaction was carried out using Pfu Turbo for 16 
cycles of 30 seconds at 95oC, 30 seconds at 55 oC and 16 minutes at 68 oC. After the 
PCR, 5 μl of 3 M sodium acetate (pH 4.6) was added to the PCR mixture, followed by 
100 μl of 100% ethanol and the DNA was precipitated at -70 oC overnight. The DNA 
was recovered at 14000 x g at 4 oC, washed with 70% ethanol and air-dried. The DNA 
pellet was dissolved in sterile water and digested with Dpn I at 37 oC for 5 h. Ethanol 
precipitation was then performed. The DNA pellet was dissolved in 10 μl of TE and 
transformed into E. coli. The mixture was plated onto LB-Ampillicin plates and the 
plates were incubated at 37 oC overnight. Single colonies were picked and grew in 5 
ml of 2 X TY at 37 oC overnight. The DNA was extracted with the Wizard SV DNA 
purification system and the mutation was confirmed by sequencing with appropriate 
primers. These primers sequences are listed in Appendix C.  
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2.1.6 Precipitation of DNA 
DNA was precipitated at -20 oC or -70 oC by addition of two volumes of absolute 
ethanol and sodium acetate (pH 5.2) to a final concentration of 0.3 M. The 
precipitated DNA was then pelleted by centrifugation at 14,000 × g for 30 minutes at 
4 oC. The pellet was washed with 70 % ethanol (pre-cooled at -20 oC) and air-dried for 
20 minutes. For the precipitation of DNA at low concentration (below 20 μg/ml), 
glycogen was added to a final concentration of 1 mg/ml as a carrier to facilitate 
efficient precipitation.  
 
2.1.7 Transformation of E. coli 
2.1.7.1 Preparation of competent cells for transformation by heat shock 
1 litre of LB was inoculated with 10 ml of an overnight culture of DH5α (F’) and 
grown at 37 oC in a culture shaker until in log phase, OD600 approximately 0.5-0.6. 
The flask was chilled on ice for 15-30 minutes and the cells pelleted by centrifugation 
in a chilled rotor for 5 min at 2,000 x g. After all of the supernatant was discarded, the 
bacterial pellet was washed twice by resuspension and then pelleted in 1L of cold 
deionised water in a chilled rotor for 5 min at 2,000 x g. After pelleting the washed 
bacteria the supernatant was removed and the cells resuspended in 30 ml of cold 50 
mM CaCl2, 10 mM NaCl, 10 mM MgCl2. the cells were repelleted by centrifugation at 
3,020 x g. The supernatant was removed and the cells then resuspended in 2-3 ml of 
50 mM CaCl2, 10 mM NaCl, 10 mM MgCl2 and 10% glycerol, snap-frozen in liquid 
nitrogen at 100 μl aliquots in Eppendorf tubes and stored at -80 oC.  
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2.1.7.2 Heat shock transformation of E. coli 
Competent cells were thawed on ice, and 5-10 μl of a ligation mix was added. After a 
gentle mix the DNA-cells mixture was incubated on ice for 30 min and then heat 
shocked in a 42 oC water bath for 5 min. The cells were then transferred back to ice 
and allowed to recover for 20 min. Subsequently, 1 ml of LB media was added and 
the cells allowed to express their antibiotic resistance for 1 h at 37 oC in an orbital 
shaker set at 150 rpm. After this incubation, the cells were pelleted by centrifugation 
and resuspended in 200 μl of LB media for plating on selective media.  
 
2.1.8 Plasmid DNA preparation 
2.1.8.1 DNA Minipreps using the boiling method. 
An overnight culture (1.5 ml) was pelleted in a microfuge tube and the supernatant 
discarded. The bacterial pellet was then resuspended by vortexing in 300 μl of STET 
buffer before adding lysozyme solution to a final concentration of 30 μg/ml in each 
tube. The samples were then boiled for 10 min in a heating block after which they 
were centrifuged at 12,000 x g in a benchtop centrifuge for 10 min to pellet the debris. 
The white gelatinous pellet of bacterial debris was removed from each tube with 
either a sterile toothpick or a sterile pipette tip. An equal volume of isopropanol was 
added to the supernatant to precipitate the DNA and the tubes mixed by gently 
inverting several times. The precipitated DNA was then pelleted by centrifuging at 
12,000 x g for 10 min after which the pellet was resuspend in 50 μl of TE with 
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2.1.8.2  High Quality Minipreps 
Small-scale preparation of plasmid DNA, or minipreps, for small volumes of bacterial 
cultures (1-3ml) were carried out using the Hybaid Spin prep system as described in 
the manufacturer’s handbook. This method is based on alkaline lysis of the bacterial 
cells and precipitation of debris, followed by a purification of plasmid DNA using a 
silica resin based on differential binding of the DNA to the silica at different pH/ionic 
strengths.  
 
2.1.8.3  Qiagen maxi-preps 
Large-scale preparations of plasmid DNA, or maxipreps, of large culture volumes 
(0.5-1.5 L) were performed with the Qiagen Plasmid Maxi Kit using Qiagen-tip 500 
resin columns according to the manufacturer’s protocol. This plasmid DNA 
purification technique is also based on an alkaline lysis procedure and subsequent 
purification of DNA using an ion exchange resin.  
 
2.1.9   Agarose gel electrophoresis of DNA 
Analysis of plasmid and DNA fragments from 0.2 to 8 kb in size was carried out by 
electrophoresis on horizontal agarose gels. Gels contain 0.8 to 1.5% (w/v) 
electrophoresis grade agarose in TAE or TBE buffer and GelStar® Nucleic Acid Gel 
Stain (Cambrex Bio Science Rockland, Inc #50535, stock supplied at 10,000 X 
concentration). Molten agarose was cooled to 55 oC and poured into a sealed 
horizontal gel casting tray with a comb positioned. The polymerized gel was 
subsequently submerged in an electrophoresis tank containing TAE buffer.  
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DNA samples were mixed with 6 X DNA loading dye before loading into the wells. 
Electrophoresis was performed at a constant voltage of 9 V/cm. The migration of 
DNA was monitored by the migration of the bromophenol blue dye in the loading 
buffer and DNA bands were visualized under UV light and image captured using the 
LAS imager.  
 
2.1.9.1  Isolation of DNA fragments from agarose gels 
Linearised DNA fragments that had been separated on the basis of size were 
visualized by staining with GelStar®. Desired bands of the appropriate size were 
excised from agarose gels using a clean scalpel and placed into clean 1.5 ml 
Eppendorf tubes. DNA was extracted from the agarose slice using the QIAquick-
Agarose Gel Extraction  kit from Qiagen which is based on solubilisation of the 
agarose with a chaotropic agent and mild heat and binding of DNA to a silica based 
resin. DNA isolation was carried out according to the manufacturer’s guidelines.  
 
2.1.10  DNA Sequencing using the BigDye Terminator cycle sequencing system 
DNA sequencing was carried out with BigDye Terminator Cycle Sequencing system 
(Perkin-Elmer, ABI Prism377). This method is based on the dideoxy chain-
termination protocol originally described in Sanger et al. [324], but uses dye-labeled 
terminators for a rapid DNA sequence determination. Fluorescent dye terminators 
attached to a dideoxynucleotide via a linker allow single-tube reaction set-up, longer 
reads, reduced pipetting and liquid handling, as well as increased sample throughput. 
Such methods routinely generate 600-800 bp of sequence. 
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Both the ABI PrismTM dRhodamine and BigDyeTM Terminator cycle sequencing 
system (Perkin-Elmer) use these principles of fluorescent automated DNA 
sequencing. The dichlororhodamine dyes (ABI Prism dRhodamines) are an 
improvement over conventional rhodamine dyes. dRhodamines are better spectrally 
resolved and their sequencing products show reduced background noise. This results 
in cleaner signal and greater base calling accuracy at longer readlengths. The BigDye 
Terminator is a further improvement over the dRhodamine dyes. BigDye terminators 
contain a fluorescein energy donor linked to a dRhodamine acceptor dye by a highly 
efficient energy transfer linker. This allows for very efficient energy transfer in a 
single dye molecule. Hence, brighter and cleaner signals are obtained.  
 
In the BigDye Terminator cycle sequencing systems, the dye terminators, dNTPs, 
AmpliTaq® DNA polymerase FS sequencing enzyme and reaction buffer are 
premixed in a single tube (Terminator Ready Reaction Mix). The reaction was 
performed using 4 μl of the Terminator Ready Reaction Mix, DNA template (250 ng 
double-stranded DNA), and 1.6 pmole primer in a 10 μl total volume. The thermal 
cycle profile of the 30 cycles reaction consist of denaturation at 96 oC for 10 s, 
annealing at 50 oC for 5 s and extension at 60 oC for 4 min. After the reaction, the 
products was precipitated with 10 μl of deionized water, 2 μl of 3 M sodium acetate 
(pH 4.6) and 50 μl of 95 % ethanol, to remove excess dye terminators. The DNA was 
pelleted by centrifugation at 14,000 x g for 30 min at 4 oC. The pellet was then rinsed 
twice with 70 % ethanol and vacuum dried. Prior to loading of sample, the pellet was 
resuspended in 4 μl of loading buffer (5 volumes of deionized formamide and 1 
volume of 25 mM EDTA, pH 8.0, with 50 mg/ml blue dextran). The samples were 
denatured at 95 oC for 2 min and loaded onto a vertical gel system. The samples were 
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electrophoresed on the ABI PRISM® 377 DNA Sequencer (Perkin-Elmer) which is 
linked to a computer for automatic analysis of the multiple fluorescent dyes labeled 
DNA molecules. 
 
 2.2 Protein Analysis 
Table 2.2.1 Buffers for protein analysis 
2 X SDS gel-loading buffer 100 mM Tris HCl pH 6.8, 200 mM dithiothreitol 
(DTT), 4% SDS, bromophenol blue, 20% 
glycerol.  
10 X Tris-glycine electrophoresis 
(PAGE) buffer, pH 8.3 
30.2 g Tris, 188 g glycine, 50 ml 20% SDS, add 
distilled water to 1000 ml 
Resolving gels for Tris-glycine 
SDS-Polyacrylamide Gel 
Electrophoresis (PAGE) 
10% (w/v) acrylamide, 0.37 M Tris (pH 8.8), 
0.1% (w/v) SDS, 0.4% (w/v) ammonium 
persulfate (APS), 0.04% (w/v) TEMED.  
5 % stacking gels for PAGE 5% (w/v) acrylamide, 62.5 mM Tris (pH 6.8), 
0.1% (w/v) SDS, 0.05% (w/v) APS, 0.1% (w/v) 
TEMED. 
Western blot transfer buffer, pH 
8.3 
25 mM Tris, 192 mM glycine, 20% (v/v) 
methanol (do not adjust the pH).  
TBST buffer 100 mM Tris, 1.5M NaCl, 0.1% Tween-20 (v/v) 
Cell lysis buffer (Buffer A) 20 mM Tris pH 7.5, 150 mM NaCl, 10 mM 
EDTA, 1% (v/v) NP-40, 20 mM sodium 
fluoride, 5 mM sodium pyrophosphate, 1 mM 
sodium vanadate, 10% (v/v) glycerol. Add 
Protease Inhibitor cocktail just before use (from 
Roche Molecular Biochemicals/Boehringer, 
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2.2.2 Sample preparation 
Cells were washed with ice-cold PBS and lysed in the wells by adding 200 μl of ice-
cold Buffer A. The plate was incubated in 4oC for 15 min. The lysate was collected 
and centrifuged at 12000 x g for 30 min at 4oC. The clarified supernatant was 
separated from the pellet. SDS loading buffer was added to the remaining pellet and 
the mixture was subjected to one cycle of boiling and chilling on ice for 3 min each to 
denature the DNA. SDS loading buffer was also added to the supernatant and both 
pellet and supernatant fractions were boiled for 5 min. The samples were further 
clarified by centrifugation at 12,000 x g for 15-30 min at room temperature before 
undergoing SDS-PAGE.  
 
2.2.3 Preparation of sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) 
A standard discontinuous SDS-PAGE gel is made up of two layers: a stacking gel on 
the top and a resolving gel at the bottom of the gel. The composition of the stacking 
gel is 4 % (w/v) acrylamide-bisacrylamide, 0.1 % (w/v) SDS, 0.05 % (w/v) 
ammonium persulfate, 0.1 % (w/v) TEMED, 125 mM Tris-HCl, pH 6.8. 
 
In this study, 7.5 %, 10 % and 12.5 % resolving gels were used to resolve proteins of 
various molecular weights. Ten percent gels were used in most experiments. The 
composition of the 10 % resolving gel was 10 % (w/v) acrylamide-bisacrylamide, 0.1 
% (w/v) SDS, 0.4 % (w/v) ammonium persulfate, 0.04 % (w/v) TEMED, 375 mM 
Tris-HCl, pH 8.8. 
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The Bio-Rad Protean-III gel apparatus was set up to cast the SDS-PAGE gel. The 
resolving gel was poured first and a layer of butanol was added on top to erase the 
bubble and make the liquid interface horizontal. After the resolving gel was set (this 
normally took 40 min at room temperature), butanol was removed. The stacking gel 
solution was pipetted onto the top of the resolving gel and the wells were prepared by 
inserting the comb into the stacking gel. After the gel was set, the whole gel set was 
submerged into the electrode buffer (25 mM Tris-base, 250 mM glycine, 0.1 % (w/v) 
SDS). The wells were flushed using the electrode buffer. Samples were loaded and 
the electrophoresis was carried out at a constant voltage of 100 V for 15 min to ensure 
that the dye front reached the interface of the stacking gel and the resolving gel. 
Electrophoresis was continued at 180 V until the dye front reached the edge of the gel. 
 
2.2.4 Gel staining (Coomassie blue staining of the SDS-PAGE gel) 
After electrophoresis, the gel was peeled off from the plate and soaked in staining 
solution (0.25 g Coomassie brilliant blue R250, 45 ml methanol, 45 ml H2O, and 10 
ml glacial acetic acid) at room temperature with gentle agitation for 1 hour. The 
staining solution was removed and destaining solution (40 % methanol and 10 % 
acetic acid) was added. According to the visibility of the protein bands, the destaining 
procedure lasted from a few hours to overnight.  
 
2.2.5 Western Blotting 
Protein samples were electrophoresed on SDS-PAGE gel. Nitrocellulose membrane 
(PROTRAN, #10401196 from Schleicher & Schuell) was cut to cover the gel. Two 
sheets of 3 mm paper were also prepared and soaked in cold transfer buffer (25 mM 
Tris-base, 192 mM glycine, 20 % (v/v) methanol). The whole set was assembled on 
the blotting panel in the following order: Scotchbrite, 3 mm paper, gel, nitrocellulose 
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membrane, 3 mm paper and Scotchbrite. When nitrocellulose membrane was placed 
on the gel, air bubbles were rolled out. The blotting assembly was then secured in the 
blotting apparatus that was filled with pre-cooled (4 oC) transfer buffer and 
electrotransfer carried out at 100 V for 1 h. 
 
At the end of blotting, the apparatus was dis-assembled and the nitrocellulose sheet 
placed in TBST buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1 % (v/v) Tween-
20). The membrane was blocked with 10 ml of blocking solution (TBST with 5 % 
skim milk) for 60 min. The membrane was incubated in the primary antibody for 1 h 
with gentle agitation at room temperature. The membrane was washed three times 
with TBST for 5 min each. The secondary antibody was diluted 50,000 fold in a 
volume of 25 ml and the membrane incubated in this for 1 h. The membrane was 
washed 3 times with TBST, for 5 minutes each. Chemiluminescence solution 
(SuperSignal West Dura chemiluminescence, PIERCE, #34075) was added (200 μl/ 
each membrane for a mini gel) to the membrane and the chemiluminescence was 
detected using a LAS-1000 plus Chemiluminescence and Fluorescence Imaging 
System (Fuji Film) or Kodak BioMax MR films. 
 
2.2.5.1 Sources of antibodies  
Sigma-Aldrich  
Anti-PKC-ζ, #P0713, rabbit polyclonal; anti-PDK1, #P3110, rabbit polyclonal; anti-
FLAG M2, # F3165, mouse monoclonal; anti-β-actin, #A5441, mouse monoclonal. 
Cell Signaling 
Anti-Phosphor-(Thr) PDK1 Substrate Antibodies, #2291, rabbit polyclonal; anti-
PKD/PKCμ, #2052, rabbit polyclonal; anti-PDK1, #3062, rabbit polyclonal; anti-
Phosphor-PRK1 (Thr778)/PRK2 (Thr816), #2611, rabbit polyclonal. 
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Santa Cruz Biotechnology 
Anti-RhoA (26C4), sc-418, rabbit polyclonal. 
Roche Applied Science 
Anti-Myc, clone 9E10, #1667203, mouse monoclonal. 
Secondary antibodies (from Pierce Biotechnology) 
ImmunoPure Goat anti-Mouse IgG, (H+L), peroxidase conjugated, #31430; 
ImmunoPure Goat anti-Rabbit IgG, (H+L), peroxidase conjugated, #31210. 
 
2.2.6 Immunoprecipitation (IP) 
2.2.6.1 Magnetic beads coating 
For one million cells lysed by Buffer A (20 mM  Tris-HCl, pH 7.5, 150 mM NaCl, 10 
mM EDTA, 1 % NP-40, 20 mM sodium fluoride, 5 mM sodium pyrophosphate, 1 
mM sodium vanadate, 10 % glycerol, supplemented with protease inhibitor cocktail 
and 1 μM okadaic acid), 8 μl of paramagnetic Dynabeads were used to pull down the 
proteins for IP.  The beads coated with antibodies against mouse IgG1 (DYNAL, 
#110.12) or rabbit IgG (DYNAL, #112.04) were washed by vortexing in washing 
buffer (5 % serum in PBS (phosphate-buffered saline, 140 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4·2H2O, 1.8 mM KH2PO4, adjusted to pH 7.4)) at 4 oC.  The beads 
were collected by a magnetic bar and blocked with COS1 cell homogenate 
supplemented with 20% serum for 1 h by gentle rotation at 4 oC. The primary 
antibody (0.5 μg/ 8 μl beads) was added in 500 μl washing buffer containing the beads 
followed by incubation overnight at 4 oC with gentle rocking. Before 
immunoprecipitation, the beads were washed 3 times for 5 min each using PBS 
containing 5 % calf serum at 4 oC with gentle rocking. Finally, the antibody-coated 
beads were resuspended in PBS containing 5 % calf serum. 
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2.2.6.2 Immunoprecipitation  
Cultured cells were lysed in Buffer A. The clarified cell lysates were incubated with 
paramagnetic Dynabeads that had been coated with relevant primary antibodies 
overnight at 4 oC. The immunoprecipitated complexes were washed twice with 1 ml 
buffer B (1 % NP-40 in 1 XPBS, 1 mM PMSF (phenylmethylsufonyl fluoride) added 
before use) for 30 min, twice with buffer C (10 mM Tris-HCl, pH 7.5, 0.5 M LiCl) for 
30 min with gentle rotation. For kinase assay, the immunoprecipitates were subjected 
to two more washes in buffer D (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 50 mM 
NaCl).  For co-immunoprecipitation, the complexes were washed twice with 1 ml 
buffer B and twice with buffer F (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 300 mM 
NaCl).  
 
2.2.7 Preparation of GST-RhoA and GST-Tau1 
GST-RhoA and GST-Tau1 plasmids were transformed separately into E. coli strain 
BL21-CodonPlus (Stratagene, La Jolla, CA).  A single colony was picked and 
cultured in 10 ml of LB medium (10 g bacto-trypton, 5 g yeast extract, 10 g NaCl in 1 
liter, pH 7.0) with 100 µg/ml ampicillin and 20 µg/ml chloramphenicol overnight at 
37 oC.  The E. coli culture was then added to 100 ml LB medium and incubated for 
another 16-18 h.  The total of 100 ml of medium with the cells was transferred to 
fresh 900 ml pre-warmed LB medium and incubated at 37 oC with shaking for 1 h.  
IPTG (isopropylthio-β-D-galactoside) was added to the bacterial culture upon 
reaching an OD600 nm of 0.6~0.7 to a final concentration of 0.1 mM to induce the 
expression of GST-RhoA. Three hours later, E. coli cells were pelleted by 
centrifugation at 1935 × g (Beckman J2-MC centrifuge, JA-20 rotor) for 10 min at 4 
oC and resuspended in 3 ml of cold lysis buffer (50 mM Tris-HCl, pH 7.6,  50  mM 
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NaCl, 25 mM MgCl2, 1 mM DTT, 1 mM PMSF, 1 % Triton X-100) on ice.  The 
bacteria were sonicated to release intracellular proteins. The sonicate was cleared by 
centrifugation at 17,300 × g for 10 min at 4 oC. The supernatant was removed for 
column purification of GST-tagged proteins with a 20 μl aliquot of the supernatant set 
aside for Western blot analysis. The commercial glutathione-agarose beads (Sigma, 
#G4510) were washed once with distilled water and followed by 3 volumes of lysis 
buffer to remove ethanol (used as a preservative for the column). The washed beads 
were resuspended in lysis buffer as a 1:1 suspension (v/v). One ml of the suspension 
was added to the supernatant of the E. coli sonicate. The mixture was incubated at 4 
oC for 1.5 hour with gentle rotation. The agarose beads were pelleted by 
centrifugation in a benchtop centrifuge at 1000 × g for 1 min and washed with 5 ml 
cold lysis buffer (without DTT and PMSF) 5 times.  GST-tagged proteins was eluted 
with 0.5 ml of freshly prepared elution buffer with 5 mM reduced glutathione (pH 
7.5) (Sigma, #G4251) with gentle rotation for 20 minutes at 4 oC.  The beads were 
regenerated and aliquots of GST-RhoA and other fractions were subjected to gel 
staining to verify the purity of the eluted GST-RhoA. 
 
2.2.8 GTP-γ-S loading of RhoA 
Purified GST-RhoA (7.8 μM in 27 μl) was loaded with 30 μM GTP-γ-S (Sigma, # 
G8634) at 30 oC for 20 minutes in loading buffer (0.05 M Tris-HCl, pH7.5, 1 mM 
EDTA, 5 mM MgCl2, 0.06 % CHAPS).  Immediately after loading, the entire mixture 
of GTP-γ-S-loaded RhoA was mixed with immunoprecipitated WT-PRK1 (wild type) 
and various truncation mutants and incubated at 4 oC for 1 h with rocking. The 
immune-complex was then washed twice with buffer A for 30 min. Half of the 
complex was subjected to Western blot analysis; while the other half of the beads was 
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subjected to kinase assay.  Autophosphorylation was performed for WT-PRK1 and 
various mutants followed by phosphorimaging and Western blotting.  
 
2.3 Cell Culture and Transfection 
2.3.1 Cell lines 
COS1, African green monkey kidney fibroblast, ATCC #CRL-1650; 
HEK293, human fetus kidney epithelial, ATCC #CRL-1573; 
NIH3T3, mouse embryo fibroblast, ATCC #CRL-1658; 
N1E-115, mouse neuroblastoma C-1300, Passage No.#17,  ATCC, #CRL-2263. 
2.3.2 Cell culture medium 
Routine cell culture was carried out in a medium of 90 % high glucose (4.5 g/L) 
version of DMEM (Invitrogen, #12100-046) supplemented with 10 % fetal calf serum 
and 2 mM L-alanyl-L-glutamine (Invitrogen, #35050-061).  
 
2.3.3 Transfection by liposomal method 
2.3.3.1 Transfection of mammalian cells using LIPOFECTAMINE Reagent 
Cells were seeded at 3 ×105 per well in a 6-well plate one day prior to transfection. 
Cells of 60-80 % confluency were transfected. One hundred μl of OPTI-MEM 
(Invitrogen, #22600-050) was mixed with 6 μl LIPOFECTAMINE Reagent 
(Invitrogen, #18324-012).  At the same time, 100 μl of OPTI-MEM was mixed with 1 
μg of plasmid. These two mixtures were combined and incubated at room temperature 
for 45 min. Eight hundred μl of serum–free medium was added to the mixture and the 
mixture was transferred to cells in the wells which were pre-washed with PBS. The 
cells were incubated at 37 oC in a humidified atmosphere with 5 % CO2 and 95% air. 
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Six hours later the transfection mixture was removed and replaced with the complete 
medium containing 10 % fetal bovine serum. 
 
2.3.3.2 Transfection of mammalian cells with PolyFect Reagent 
HEK 293 cells or CHO-K1 cells were cultured in 60-mm plates with 4 ml of DMEM 
supplemented with 10 % FCS (Fetal calf Serum). Sixteen hours prior to transfection, 
cells were seeded at a density of 8×105 cells per plate. One hundred and fifty μl of 
OPTIMUM medium containing 2.5 μg of DNA for CHO-K1 cells (4 μg for HEK293 
cells) was mixed with 15 μl of PolyFect Transfection reagent (QIAGEN, # 301107) 
for CHO-K1 cells or 40 μl reagents for HEK293 cells for 10 min at room temperature 
to allow the formation of transfection complex. Three ml of the full growth for CHO-
K1 cells or low-serum medium (DMEM with 0.5 % FCS) for HEK 293 cells was 
added to the cells and 1 ml of the same medium was added to the tube containing the 
transfection complex. The mixture was transferred to plates with cells and the cells 
were incubated with the complexes for at least 24 h prior to other assays. 
 
2.4 Assays 
2.4.1 In vitro kinase assay (immune-complex kinase assay) 
2.4.1.1 Autophosphorylation  
Immunoprecipitates were used in immune-complex kinase assays carried out in 30 µl 
of reaction mixture containing buffer (20 mM Tris-HCl, pH 7.6, 5 mM MgCl2, 40 mM 
KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT) and 1 μl of protease inhibitor cocktail 
(Roche Diagnostics, Protease Inhibitor Cocktail Tablets, #1697498) and 200 μM γ-
[32P]-ATP (GE Healtcare #AA0018, specific activity 360 cpm/pmol) at 30 oC for 7 
min. The solution was mixed by tapping every 2 min and, after 7 min, SDS loading 
dye (50 mM Tris-HCl, pH 6.8, 14.4 mM mercaptoethanol, 2 % (w/v) SDS, 0.05 % 
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(w/v) bromophenol blue, 10 % (w/v) glycerol) was added to the mixture to stop the 
reaction. The phosphorylated proteins were separated by 10 % SDS-PAGE and 
analyzed using a BAS-2500 phosphorimager (Fuji Photo Film) and Image Gauge 4.0 
software. The kinase activity of each sample was corrected for background 
phosphorimaging densitometric units from negative controls of vector transfected 
cells. The amount of kinase in each sample was determined by chemiluminescence-
based Western blotting using a LAS-1000plus Imaging System equipped with a CCD 
camera that does not register radiation from 32P.  The relative intensity of the kinase in 
question was then used to normalize the phosphorimaging densitometric units to 
derive the specific activity of the kinase.   
 
2.4.1.2 Transphosphorylation  
After immunoprecipitation and washing, 30 µl of kinase buffer (20 mM Tris-HCl, pH 
7.6, 5 mM MgCl2, 40 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT) including 
110 µM S6 peptide, which is based on human ribosomal protein S6 residues 229-239 
(AKRRRLSSLRA-NH2), 1 μl of protease inhibitor cocktail and 200 μM γ-[32P]-ATP 
(specific activity 360 cpm/pmol) were added to the immunoprecipitates.  The 
transphosphorylation reaction was carried out for 7 minutes at 30 oC and terminated 
by adding 3.3 μl stop solution (200 mM ATP, 500 mM EDTA, pH 8.0). The kinase 
bound to Dynabeads was retained at the bottom of the tube by a magnet. The 
supernatant containing the peptide substrate was transferred onto P81 
phosphocellulose paper (Whatman, #3698021). The paper was washed three times 
with 75 mM phosphoric acid and once with 95% ethanol and 5% H2O and dried. The 
incorporated radioactivity was determined by scintillation counting. The kinase 
activity of each sample was corrected for background counts from negative controls 
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of vector transfected cells. The amount of kinase in each sample was determined by 
chemiluminescence-based Western blotting using a LAS-1000plus Imaging System 
equipped with a CCD camera that does not register radiation from 32P.  The relative 
intensity of the kinase was then used to normalize the counts to derive the specific 
activity of PRK1.   
 
2.4.2  Protein half-life assay 
Twenty hours post-transfection, the medium for COS-1 cells was replaced with a 
fresh medium containing a final concentration of 200 μg/ml cycloheximide. In these 
experiments, the cycloheximide used was from a stock solution of cycloheximide that 
was dissolved in tissue culture grade dimethyl sulphoxide (Sigma, catalogue numbers 
C7698).  At the time points indicated, cells were lysed with buffer A and the lysate 
was centrifuged at 14,000 x g for 30 min to obtain a clarified lysate and a pellet which 
corresponds to the detergent soluble and –insoluble fractions of the lysate. The zero 
point of the time course was defined as 4 h after the addition of cycloheximide. 
During the course of experimentation, the culture medium was replaced every 8 h 
with freshly prepared medium containing cycloheximide.  The amounts of exogenous 
kinase in each sample were normalised by that of endogenous β-actin in Western 
blotting. 
 
2.4.3 N1E-115 neurite retraction assay 
N1E-115 neuroblastoma cells were cultured in DMEM supplemented with 10 % FCS. 
One day prior to transfection, cells were seeded in 24-well plates at a density of 5 × 
104 cells /well.  Cells were transfected with WT-PRK1, empty vector (pcDNA3), 
PRK1-S377A, RhoA-T19N, WT-RhoA, WT-PRK1 plus RhoA-N19, WT-RhoA plus 
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RhoA-T19N, C3 (exoenzyme, ADP-ribosyltransferase) and C3 plus WT-PRK1 using 
LIPOFECTAMINE reagent and incubated in serum-free medium for 30 h to induce 
neurite outgrowth. Cells were treated with 3 μM LPA for 3 min and photographed 
immediately using an Axiovert-25 inverted phase contrast microscope (Carl Zeiss) 
equipped with a Coolpix 990 CCD camera (Nikon).  At least one hundred cells for 
each well were counted. The morphology of cells was classified as round: rounded 
cells without neurites; flat: flattened cells without neurites or extensions shorter than 
the soma diameter; and neurites: flattened cells with at least one process greater than 
the soma diameter. 
 
2.5 Homology modeling  
A structural alignment of human PKCθ at 2.0Å (PDB code 1XJD [87]), human PKBβ 
at 1.6Å (PDB code 1O6L [85]), the catalytic subunit of PRK1 at 2.04Å and the 
turn/hydrophobic motif from the recently solved structure of human PKCι at 3.0Å 
[325] was generated by superposing the 3-D coordinates according to a CLUSTALW 
[87] alignment of their sequences, followed by manual manipulation using QUANTA 
(Accelrys, San Diego, CA, USA). To this alignment, the sequence for the catalytic 
domains of PRK1 (residues 612-946) was added and aligned. Insertions and deletions 
relative to the known structures were positioned in the loop regions, keeping the 
secondary structure elements intact. The program MODELLER [326] was then used 
to generate 20 initial homology models of bovine PRK1612-946 based on this 
alignment. The model with the lowest objective function was chosen as the 
representative model for further study. To provide some structural basis for the 
positioning of the final nine residues, the PRK1 sequence was also used to search the 
PDB using LOOPP [327] and BLAST [328].  The models were then further optimized 
     
  79 
using CHARMM [329] to add hydrogen atoms to the protein, and phosphate atoms to 
the known phosphorylated residues, followed by a restrained energy minimization to 
remove any remaining steric clashes.  
 
2.5.1 Molecular dynamics simulation of PRK1 model  
To probe the possibility of structural changes in the native and mutant models, the 
models structures were subjected to a 10 ns molecular dynamics simulation using 
NAMD software with the CHARMM22 force field.  
     
 The model structures were solvated to a distance of eight Å from all protein atoms in 
a rectangular box of water.  Fifteen sodium cations were added to each box to 
neutralize the overall negative charge of the structures. Molecular dynamics 
simulations were performed with a 2 fs time step at a constant temperature of 300 K 
and a constant pressure of one atmosphere under periodic boundary conditions. The 
Particle Mesh Ewald method was used for electrostatics, and a 12 Å cut-off was used 
for van der Waals interactions. The TIP3P water model was used to model the 
solvent. 
 
The ensemble was minimized for 1500 steps using the conjugate gradient method. 
This was followed by a heating protocol where the ensemble temperature was 
increased from 0 K to 300 K over 5 ps. Afterwards, the backbone atoms of the 
structure were fixed, while the side chains and solvent were allowed to move 
unrestrained for a further 30 ps, followed by totally unrestrained equilibration for 10 
ps. The production run was then performed for 10 ns, with the SHAKE algorithm 
implemented to restrain all hydrogen motions.  Coordinates were saved every 1 ps.  
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Appendix B: Primer sequences 
  
Rat PRK Δ946 
 
DWS 240 (sense) 
5’- GTG GCA GGA GGC TAA TAG CCC TAA GC -3’ 
 
DWS 241 (antisense) 
5'- GC TTA GGG CTA TTA GCC TCC TGC CAC -3' 
 
Rat PRK Δ944 
 
DWS 238 (sense) 
5’- GAC TTT GTG GCA TGA GGC TAT TAG C -3’ 
 
DWS 239 (antisense) 
5’- G CTA ATA GCC TCA TGC CAC AAA GTC -3’ 
 
Rat PRK Δ942 
 
DWS 236 (sense) 
5’- GAT TTC GAC TTT TAG GCA GGA GGC -3’ 
 
DWS 237 (antisense) 
5’- GCC TCC TGC CTA AAA GTC GAA ATC -3’ 
 
Rat PRK Δ941 
 
DWS 1095 (sense) 
5’- CGG GAT TTC GAC TAA GTG GCA GGA GGC TAT TAG -3’ 
                                           
DWS 1096 (antisense) 
5’- CTA ATA GCC TCC TGC CAC TTA GTC GAA ATC CCG -3’    
 
Rat PRK Δ940 
 
DWS 234 (sense) 
5’- C CGG GAT TTC TAA TTT GTG GCA GGA G -3’ 
 
DWS 235 (antisense) 
5’- C TCC TGC CAC AAA TTA GAA ATC CCG G -5’     
 
Rat PRK Δ939 
 
DWS 244 (sense) 
5’- CC TTC CGG GAT TGA GAC TTT GTG GCA G -3’ 
                                         
DWS 245 (antisense) 
5’- C TGC CAC AAA GTC TCA ATC CCG GAA GG -3’ 
 
Rat PRK Δ938 
 
DWS 232 (sense) 
5’- G GCC TTC CGG TAA TTC GAC TTT GTG -3’ 
 
DWS 233 (antisense) 
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Rat PRK Δ924 
 
DWS 431 (sense) 
5’- G AGC CCT CCT CGG TAA GCA CGG CCC -3’ 
 
DWS 432 (antisense) 
5’- GGG CCG TGC TTA CCG AGG AGG GCT C -3’ 
 
Rat PRK Δ923 
 
DWS 429 (sense) 
5’- G AGC CCT CCC TGA GAT GCA CGG -3’ 
 
DWS 430 (antisense) 
5’- CCG TGC ATC TCA GGG AGG GCT C -3’ 
 
Rat PRK Δ921 
 
DWS 479 (sense) 
5’- CC ACA CTG AGC TAG CCC CGG GAT GC -3’ 
 
DWS 480 (antisense) 
5’- GC ATC CCG GGG CTA GCT CAG TGT GG -3’ 
 
Rat PRK Δ920 
 
DWS 367 (sense) 
5’- C CCC ACA CTG TGA CCT CCA CGG GAT G -3’ 
 
DWS 368 (antisense) 
5’- C ATC CCG TGG AGG TCA CAG TGT GGG G -3’ 
 
Rat PRK Δ918 
 
DWS 365 (sense) 
5’-    GCC CCC TAA CTG AGC CCT CCC CGG -3’ 
 
DWS 366 (antisense) 
5’- CCG GGG AGG GCT CAG TTA GGG GGC -3’ 
 
Rat PRK Δ885 
 
DWS 205 (sense) 
5'- G GAC TGG GAT TGA CTG CTG GCC -3' 
 
 DWS 206 (antisense) 
5'- GGC CAG CAG TCA ATC CCA GTC C -3' 
 
Rat PRK Δ882 
 
DWS 207 (sense) 
5’- C AGG ACT CTG TAG TGG GAT GCC C -3’ 
     
DWS 208 (antisense) 
5’- G GGC ATC CCA CTA CAG AGT CCT G -3’ 
 
Rat PRK Δ881 
 
DWS 363 (sense) 
5’- C TTC AGG ACT TAG GAC TGG GAT GCC -3’    
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DWS 363 (antisense) 
5’- GGC ATC CCA GTC CTA AGT CCT GAA G -3’ 
                      
Rat PRK Δ879 
 
DWS 425 (sense) 
5’- G CCT TTC TTC TGA ACT CTG GAC TGG -3’ 
 
DWS 426 (antisense) 
5’- CCA GTC CAG AGT TCA GAA GAA AGG C -3’ 
    
Rat PRK S920A 
 
DWS-78 
5'- CCC ACA CTG GCC CCT CCC -3' 
 
DWS-79 
5'-GGC CTC CCC AGT GAA CTC -3' 
 
Rat PRK D940A 
 
DWS85    
5'- G GAT TTC GCC TTT GTG GC -3'   
 
DWS83 
5'- CG GAA GGC CGC CTG CTC -3' 
 
Rat PRK F939Y 
 
DWS 437 (sense) 
5’- C TTC CGG GAT TAC GAC TTT GTG G -3’ 
 
DWS 438 (Antisense)  
5’- C CAC AAA GTC GTA ATC CCG GAA G -3’ 
 
Rat PRK F941A 
 
DWS 476 (sense) 
5’- CGG GAT TTC GAC GCA GTG GCA GGA GGC -3’ 
                                            
DWS 477 (antisense) 
5’- GCC TCC TGC CAC TGC GTC GAA ATC CCG -3’ 
 
Rat PRK Δ940 F939A 
 
DWS 474 (sense) 
5’-G GCC TTC CGG GAT GCA TAA TTT GTG GC- 3’ 
 
DWS 475 (antisense) 
5’-GC CAC AAA TTA TGC ATC CCG GAA GGC C -3’ 
 
Rat PRK Δ940 F939L 
DWS 447 (sense) 
5’- C TTC CGG GAT TTA TAA TTT GTG GCA GG -3’ 
 
DWS 448 (antisense) 
5’- CC TGC CAC AAA TTA TAA ATC CCG GAA G -3’ 
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Rat PRK Δ940 F939W 
 
DWS 445 (sense) 
5’-C TTC CGG GAT TGG TAA TTT GTG GCA G -3’ 
 
DWS 446 (antisense) 
5’- C TGC CAC AAA TTA CCA ATC CCG GAA G -3’ 
 
Rat PRK Δ940 F939Y 
 
DWS 443 (sense) 
5’- C TTC CGG GAT TAC TAA TTT GTG GCA G -3’                                      
 
DWS 444 (antisense) 




DWS 709 (sense) 
5’-CTG CCT GCT GAT CAC CCC AAG -3’ 
 
DWS 710 (antisense) 




DWS 255 (sense) 
5’- GCG TCC AAC CCC GAA AGA G -3’ 
 
DWS 305 (antisense) 
5’- GCT GAT TGG TGT TAA GTC TAG AGA CAC -3’ 
 
Human PRK2 ∆979 
 
DWS 872 (sense) 
5'- GA GAT TTT GAC TAG ATT GCT GAT TGG TG -3' 
 
DWS 873 (antisense) 
5'- CA CCA ATC AGC AAT CTA GTC AAA ATC TC -3' 
 
Human PRK2 ∆978 
 
DWS 385 (sense) 
5’- C AGA GAT TTT TAG TAC ATT GCT GAT TGG -3’                                     
 
DWS 386 (antisense) 
5’- CCA ATC AGC AAT GTA CTA AAA ATC TCT G -3’ 
 
Human PRK2 ∆977 
 
DWS 516 (sense) 
5’- G TTC AGA GAT TAG GAC TAC ATT GCT GAT TG -3’ 
                                       
DWS 517 (antisense) 
5’- CA ATC AGC AAT GTA GTC CTA ATC TCT GAA C -3’ 
 
Human PRK2 ∆976 
 
DWS 919 (sense) 
5’- G TTC AGA TAG TTT GAC TAC ATT GCT GAT TGG -3’ 
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DWS 920 (antisense) 
5’- CCA ATC AGC AAT GTA GTC AAA CTA TCT GAA C -3’ 
 
Human PRK2 ∆974 
 
DWS 383 (sense) 
5’- GAG GAG CAG GAG ATG TAG AGA GAT TTT G -3’ 
 
DWS 384 (antisense) 
5’- C AAA ATC TCT CTA CAT CTC CTG CTC CTC -3’ 
 
Human PRK2 ∆961 
 
DWS 520 (sense) 
5’- CTG ACT CCA CCA TGA GAA CCA AGG ATA C -3’ 
                                           
DWS 521 (antisense) 
5’- G TAT CCT TGG TTC TCA TGG TGG AGT CAG -3’ 
 
Human PRK2 ∆960 
DWS 522 (sense) 
5’- CT ATT CTG ACT CCA TAG CGA GAA CCA AGG -3’ 
 
DWS 523 (antisense) 
5’- CCT TGG TTC TCG CTA TGG AGT CAG AAT AG -3’ 
 
Human PRK2 ∆958 
 
DWS 381 (sense) 
5’- GCA CCT ATT CTG TAG CCA CCT CGA G -3’ 
 
DWS 382 (antisense) 
5’- C TCG AGG TGG CTA CAG AAT AGG TGC -3’ 
 
Human PRK2 ∆950 
 
DWS 379 (sense) 
5’- GAT GAT GAA TAG ACC TCA GAA GCA C -3’ 
                                   
DWS 380 (antisense) 
5’- G TGC TTC TGA GGT CTA TTC ATC ATC -3’ 
 
Human PRK2 ∆917 
 
DWS 325 (sense) 
5’- G CAC CCA TTT TTC TGA CTA ATT GAT TGG AGT GCT CTG ATG GAC -3’ 
                        
DWS 330 (antisense) 
5’- GTC CAT CAG AGC ACT CCA ATC AAT TAG TCA GAA AAA TGG GTG C -3’ 
 
Human PRK2 T958A 
                                           
DWS 524 (sense) 
5’- CA CCT ATT CTG GCT CCA CCT CGA G -3’ 
                                         
DWS 525 (antisense) 
5’- C TCG AGG TGG AGC CAG AAT AGG TG -3’ 
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Human PRK2 D978A 
 
DWS 526 (sense) 
5’- G TTC AGA GAT TTT GCC TAC ATT GCT G -3’ 
 
DWS 527 (antisense ) 
5’- C AGC AAT GTA GGC AAA ATC TCT GAA C -3’ 
 
Human PRK2 F977A 
 
DWS 528 (sense)  
5’- GAA ATG TTC AGA GAT GCG GAC TAC ATT GCT G- 3’ 
                                                      
DWS 529 (antisense) 
5’- C AGC AAT GTA GTC CGC ATC TCT GAA CAT TTC -3’ 
 
Human PRK2 F977L 
 
DWS 530 (sense) 
5’- G TTC AGA GAT CTT GAC TAC ATT GCT G -3’ 
                                       
DWS 531 (antisense) 
5’- C AGC AAT GTA GTC AAG ATC TCT GAA C -3’ 
 
Human PRK2 F977W 
 
DWS 534 (sense) 
5’- G TTC AGA GAT TGG GAC TAC ATT GCT GAT TG -3’ 
 
DWS 535 (antisense) 
5’- CA ATC AGC AAT GTA GTC CCA ATC TCT GAA C -3’ 
                                                            
Human PRK2 F977Y 
                                                
DWS 532 (sense) 
5’- G TTC AGA GAT TAC GAC TAC ATT GCT GAT TG -3’ 
 
DWS 533 (antisense) 
5’- CA ATC AGC AAT GTA GTC GTA ATC TCT GAA C -3’ 
 
Human PRK2 Y979A 
 
DWS 536 (sense) 
5’- C AGA GAT TTT GAC GCG ATT GCT GAT TGG TG -3’ 
 
DWS 537 (antisense) 
5’- CA CCA ATC AGC AAT CGC GTC AAA ATC TCT G -3’ 
 
Human PRK2 Y979L 
 
DWS 538 (sense) 
5’- C AGA GAT TTT GAC CTC ATT GCT GAT TGG -3’ 
 
DWS 539 (antisense primer) 
5’- CCA ATC AGC AAT GAG GTC AAA ATC TCT G -3’ 
 
Human PRK2 Y979W 
 
DWS 540 (sense)  
5’- C AGA GAT TTT GAC TGG ATT GCT GAT TGG TG -3’ 
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DWS 541 (Antisense ) 
5’- CA CCA ATC AGC AAT CCA GTC AAA ATC TCT G -5’ 
 
Human PRK2 Y979F 
 
DWS 542 (sense) 
5’- GA GAT TTT GAC TTC ATT GCT GAT TGG TG -3’ 
 
DWS 543 (antisense) 
5’- CA CCA ATC AGC AAT GAA GTC AAA ATC TC -3’                              
 
Human PRK2 ∆978 F977A 
 
DWS 1215 (sense) 
5’- G TTC AGA GAT GCG TAG TAC ATT GCT GAT TG -3’ 
 
DWS 1216 (antisense) 
5’- CA ATC AGC AAT GTA CTA CGC ATC TCT GAA C -3’ 
 
Human PRK2 ∆978 F977L 
 
DWS 1217 (sense) 
5’- G TTC AGA GAT TTA TAG TAC ATT GCT G -3’ 
 
DWS 1218 (antisense) 
5’- C AGC AAT GTA CTA TAA ATC TCT GAA C -3’ 
 
Human PRK2 ∆978 F977W 
 
DWS 1219 (sense) 
5’- G TTC AGA GAT TGG TAG TAC ATT GCT G -3’ 
                                       
DWS 1220 (Antisense) 
5’- C AGC AAT GTA CTA CCA ATC TCT GAA C -3’ 
 
Human PRK2 ∆978 F977Y 
 
DWS 1221 (sense) 
5’- G TTC AGA GAT TAC TAG TAC ATT GCT G -3’ 
 
DWS 1222 (antisense) 
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Appendix C: Sequecing primers  
 
DWS 43 (sense) 
5'- CGAAATTAATACGACTCACT -3' 
 
DWS 68 (antisense) 
5'- GGGGAGGGGCAAACAACAGATG -3' 
 
DWS 249 (sense) 
5’- GCTGTTAAGAAGAAATCCTG -3’ 
 
     
  89 
 
                            
 
Chapter 3: 
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3.1.1 Generation of PRK1 Deletion and Point Mutants 
This goal of this study was to determine the importance of individual residues and the 
collective contribution of the region within V5 to the catalytic activity of PRK1. A 
full-length rat PRK1 cDNA was cloned into mammalian expression vector pcDNA3.  
As the study involved serial deletion of C-terminal residues, the DNA sequence 
encoding a Myc-tag (EQKLISEEDL) was incorporated at the N-terminal before the 
second amino acid residue of PRK1 to facilitate the identification and purification of 
the recombinant PRK1. Point mutation and serial deletion of the C terminus was 
performed. PKA terminates at Phe350, corresponding to Phe939 in rat PRK1. To this 
end, residues after the Phe939 of PRK1 (which contains 946 residues) were deleted to 
determine the role of these seven residues in conferring catalytic competence of 
PRK1. Highly conserved residues at the turn motif, hydrophobic motif and residues 
flanking these motifs were also deleted or mutated to elucidate their importance in 
catalytic activity and regulation of PRK1. The schematic diagram of the PRK1 
domain structure and all the PRK1 constructs used in this study is shown in Fig. 3.1. 
 
All mutants containing deletions, point mutations and the combination thereof were 
generated using a polymerase chain reaction (PCR)-based mutagenesis protocol with 
a circular plasmid as a template as described in Materials and Methods. The deletion 
mutants were generated by introducing an in-frame stop codon at the designated 
positions, e.g. the PRK1-∆946 mutant carried a stop codon at position 946, yielding 
PRK1-(1-945). All mutants were verified by gene sequencing and the results are 
listed in Appendix D. 
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Fig. 3.1.  Domain structure of PRK1 and PRK1 constructs used in this study.  (A) Wild-
type PRK1 (WT) consists of a regulatory domain (blue) and a catalytic domain (yellow), and 
the full length protein and mutants thereof were N-terminally tagged with a Myc epitope.  
The hinge region (V3), which links these two domains and the C-terminal segment (V5) are 
shown. Also shown are the turn motif (Ser-920) and the hydrophobic motif (Asp-940). (B) 
Enlarged view of the V5 domain showing the turn motif (Ser-920) and the hydrophobic motif 
(Asp-940). (C). Various PRK1 deletions were generated. The number at each C-terminus 
indicates the position of the stop codon, with the last expressed residue being the one just 
prior to the number. (D) Various point mutations generated in full length and deleted PRK1, 
where S920A indicate the mutation of serine to alanine at position 920. The whole PRK1 
molecule and the enlarged V5 domain illustrated are not drawn to scale.  
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3.1.2 The Hydrophobic Motif is Not Required for the Solubility of PRK1 
PKA terminates at Phe350, corresponding to Phe939 in rat PRK1. The phosphor-
acceptor at the hydrophobic motif in rat PRK1 is a phosphomimetic which 
corresponds to the residue Asp940. In PKCα [95] and PKCβII [96], mutation of the 
phosphorylatable residue of the activation loop to a neutral, nonphosphorylatable 
residue resulted in the expression of a dephosphorylated protein that accumulates in 
the detergent-insoluble fraction. It has been proposed that PKC mutants lacking the C-
terminal segment might be insoluble [45], thus it was important to analyse the 
solubility of the C-terminal deletion mutants of PRK1. The requirement of the 
hydrophobic phosphorylation motif in the solubility of PRK1 was explored by 
generating a PRK1 deletion mutant (PRK1-∆940) that lacks the segment spanning the 
phosphorylation mimetic Asp940 and the C-terminal residue.  
 
COS cells were used to ensure proper folding and post-translational modifications of 
the recombinant PRK.  Furthermore, COS cells have a SV40 T antigen which will 
bind to the SV40 origin of replication sequence in the pcDNA3 vector, that will cause 
the amplification of the vector so that one obtains higher yield than other cell lines 
that do not have SV40 T antigen.  
 
When introduced into COS-1 cells by transient transfection, there was little 
appreciable change in the distribution of ectopically expressed PRK1-∆940 in the 
supernatant and pellet fractions upon cell lysis by Triton X-100 compared to that of 
the wild-type PRK1 (Fig. 3.2). Furthermore, other mutants in this region, PRK1-
∆940+F939Y, PRK1-F939Y, PRK1-D940A and PRK1-F941A, also displayed no 
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significant change in the solubility of the mutant PRK1 as shown in Fig. 3.2. In 
addition, mutants in which the phosphor-acceptor and the negative charge at the turn 
motif and hydrophobic motif (PRK1-S920A+D940A) were eliminated also showed 
no discernible changes in the solubility of the mutant PRK1. Surprisingly PRK1-∆939 
exhibited significantly reduced solubility compared to PRK1-∆940 mutant (Fig. 3.2).  
Deletion at the turn motif phosphorylation site (Ser920) resulted in a further decrease 
in the solubility of the mutant PRK1 (PRK1-∆920 and PRK1-∆918). Removal of the 
entire V5 domain (PRK1-∆879) resulted in a mostly insoluble protein (Fig. 3.2). 
Thus, the negative charge at the hydrophobic motif and the phosphorylation of the 
turn motif did not contribute significantly to the solubility of PRK1. Rather, the 
physical presence of Phe939, which is absolutely conserved in AGC kinases, and the 
integrity of the N-terminal portion of the V5 domain (residues 878 to 920) played 
critical roles in conferring detergent solubility and subcellular localization to PRK1. 
 
 
Fig. 3.2. Determinants of detergent solubility of PRK1 in the C-terminus of the 
catalytic domain.  Expression constructs for Myc-tagged wild-type PRK1 and PRK1 
point mutants and/or deletion mutants were transiently transfected into COS-1 cells.  
Twenty hours post-transfection, cells were lysed with ice-cold buffer A containing 1% 
Triton X-100 and the detergent-soluble supernatant and detergent–insoluble particulate 
fractions were obtained after centrifugation. Approximately 18% of the supernatant and 
all of the particulate fractions were subjected to SDS-PAGE and Western blotting using 
anti-Myc (9E10). The construct 4A is a Myc-PRK1 mutant with all the four potential 
phosphor-acceptor serine/threonine residues in the activation loop changed to alanine. 
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The percentage of PRK1 in detergent-soluble (Soluble) and detergent-insoluble 
(Particulate) fractions in each sample is shown. Data presented as means ± s.e.m.; n=4.   
 
3.1.3 The Highly Conserved Phe939 but Not the Phosphorylation Mimetic Asp940 
Is Absolutely Required for the Catalytic Competence of PRK1 
Previous structural studies linked phosphorylation of the hydrophobic motif to the 
stabilization of the kinase core, where mutation of the conserved serine or threonine 
residue at the hydrophobic motif to an alanine residue in PKC revealed that 
phosphorylation of the hydrophobic motif was not required for PKC function; rather, 
it stabilized the enzyme [129, 130, 330, 331]. However, it is noteworthy that in those 
studies, the contribution of the hydrophobic motif to kinase activity was determined in 
isolation via point mutation at a single residue. Point mutation studies are useful to 
elucidate the importance of single residues; however, such studies do not probe the 
combined interactions of adjacent residues. Thus, my study adopted a more 
comprehensive approach to determine the role of the C-terminus in kinase activity. 
Point mutations were generated to determine the importance of each residue; 
concurrently, C-terminal residues were serially deleted to assess the collective 
contributions of the C-terminal residues to PRK1 catalytic activity. 
Autophosphorylation assay was chosen to assess PRK1 kinase activity because such 
analysis examines the ability of a kinase to phosphorylate its true physiological 
substrate and therefore is a better indication of the intrinsic catalytic activity. As a 
control, the kinase-inactive quadruple mutant of PRK1 (i.e. T776A, T777A, T778A 
and T782A), termed 4A was generated in which all phosphorylatable threonine 
residues in the activation loop in PRK1 (T778) were mutated to alanine in order to 
prevent compensating phosphorylation.  
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Fig. 3.3A and 3.3B show that the removal of the C-terminal tail up to Phe941 in PRK1, 
or even inclusive of the phosphomimetic Asp940 (i.e. PRK1-Δ942, PRK1-Δ941 and 
PRK1-Δ940) had little impact on catalytic competence. However, the catalytic 
activity diminished by 95% once Phe939 was deleted (i.e. PRK1-Δ939). To assess 
whether the loss of kinase activity was due to absence of residues 940-946 or the 
absence of Phe939, phenylalanine at position 939 was replaced with various other 
residues in the background of PRK1-∆940 mutant, in which the last amino acid 
residue is Phe939 and hence a mimetic of the C-terminus of PKA. Notably, catalytic 
activity was lost with either conservative substitution of Phe939 (tyrosine or 
tryptophan) or substitution with non-polar residues with similar hydropathy index 
(alanine or leucine) (Fig. 3.3C, 3.3D). Identical results were obtained in 
transphosphorylation assays employing a peptide derived from ribosomal protein S6 
peptide as a substrate for all the PRK1 mutants shown in Fig. 3.3. Therefore, it 
appears that the C-terminal extension residues 940-946 of PRK1 in the V5 domain, 
which are absent in PKA, are dispensable for the catalytic competence of PRK1. Once 
the C-terminal extension is removed, the side chain of Phe939 is absolutely necessary 
for activity, most likely by keeping the rest of the catalytic domain of PRK1 in an 
active conformation. Apparently, the structural function performed by the phenyl ring 
of Phe939 in PRK1-∆940 mutant cannot be mimicked by the phenyl ring of tyrosine or 
tryptophan, consistent with the fact that phenylalanine is an invariant residue at this 
position all AGC [112]. 
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Fig. 3.3.  Phe939 but not the C-terminal extension in the V5 domain of PRK1 is 
required for the catalytic competence of the kinase.  Myc-tagged PRK1 expression 
constructs were transiently transfected into COS-1 cells. At 20 h post-transfection, 
cells were lysed and the exogenous wild-type or mutant PRK1 were 
immunoprecipitated with anti-Myc antibodies.  The catalytic activity of PRK1 was 
determined in an autophosphorylation assay and is expressed as percentage of the 
activity of wild-type PRK1.  All reactions proceeded linearly with time.  3A, 3C, the 
autophosphorylation activities of PRK1 mutants are compared with that of wild-type 
kinase (means ± s.e.m.; n=3). 3B, 3D, representative autoradiographs and 
corresponding Western blots used to determine the apparent molecular mass of the 
mutant protein encoded by each construct and to derive the specific activity of PRK1. 
The protein 4A, a Myc-PRK1 mutant in which all four potential phosphor-acceptor 
serine/threonine residues in the activation loop were changed to alanine.
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3.1.4 A Network of Intramolecular Interactions in the V5 Domain Contributes 
to the Catalytic Competence of PRK1 
To compare the relative importance of Phe939 and the last seven amino acids in the V5 
domain to catalytic competence in PRK1, Phe939 was mutated in the full length PRK1 
construct. In the full-length PRK1, two phenylalanines, Phe939 and Phe941, surround 
the phosphorylation mimetic Asp940. The Phe939 is highly conserved among the PKC 
members, whereas Phe941 is less conserved and may be replaced with a tyrosine 
residue in PRK2 and PKCα. To determine the relative importance between the two 
conserved hydrophobic residues for catalytic competence, Phe941 was mutated to 
aromatic residues (tyrosine or tryptophan) or non-polar residues with similar 
hydropathy index (alanine or leucine) in a full length PRK1 and compared with 
similarly mutated Phe939 mutants. The effect of these mutations in the conserved 
residues in the V5 domain of PRK1 on the catalytic activity of full-length PRK1 was 
analysed in a kinase assay.  
 
Mutations at Phe939 were not tolerated whereas mutations at Phe941 had much less 
deleterious impact on the catalytic competence of the mutant enzyme (Fig. 3.4A, B). 
Intriguingly, the kinase activities of these Phe939 point mutants are in sharp contrast 
with the Phe939 deletion mutant in which resides 940 to 946 were removed, resulting 
in a deleted PRK1 that was almost as active as the wild-type enzyme (Fig. 3.3A). The 
activity of Phe939 mutants varied from 50% (F939W) to less than 10% (F939A, F939L 
and F939Y). On the other hand, the activity of the Phe941 mutants F941W, F941L and 
F941Y was >50%, although the mutant F941A had greatly reduced activity (25%). 
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The phosphor-acceptor or phosphomimetic residues in the turn motif and hydrophobic 
motif (Ser920 and Asp940) were mutated to alanine to determine the importance of 
these conserved residues. In line with previous studies where mutation of the 
phosphor-acceptor impaired catalysis significantly [103, 104], the mutant PRK1-
S920A had negligible catalytic activity (Fig. 3.4A). However, the finding that PRK1-
D940A was also catalytically inactive (Fig. 3.4A) was unexpected because the PRK1-
∆940 deletion mutant, lacking Asp940 was fully active (Fig. 3.3A).  Moreover, 
mutation of Phe939 to tryptophan in PRK1-∆940 deletion (PRK1-∆940+F939W, Fig. 
3.3C) resulted in an inactive kinase, but the same mutation introduced to the full-
length PRK1 (PRK1-F939W) yielded at least 55% of the catalytic activity compared 
with that of the wild-type PRK1 (Fig. 3.4A).   
 
These seemingly contradictory and unexpected results suggest that residues within the 
V5 domain interact with each other and with those in the catalytic core. The overall 
impact on the establishment of a catalytically competent conformation of the catalytic 
core must be governed by the outcome of a network of intramolecular interactions 
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Fig. 3.4. Contributions of several key amino acid residues in turn motif and 
hydrophobic motif to the catalytic competence of PRK1.  Plasmids encoding Myc-
tagged wild-type and mutant PRK1 were introduced into COS-1 cells.  Twenty hours 
post-transfection, cells were lysed and ectopically expressed PRK1 was 
immunoprecipitated with anti-Myc antibodies. The specific activity for 
autophosphorylation of PRK1 was analyzed in an immune-complex kinase assay in 
vitro.   The means ± s.e.m of autophosphorylation (percentage of that of wild-type 
PRK1) of three independent experiments are shown (4A), along with a typical 
autoradiograph and a Western blot used to derive the specific activity (4B). 4A, a 
Myc-PRK1 mutant with all the four potential phosphor-acceptor serine/threonine 
residues in the activation loop changed to alanine.  
 
3.1.5 The C-terminal Tail Of PRK1 Is Critical in Conveying Stability to the 
Kinase in vivo 
Despite a single residue difference, there exists distinct divergence in catalytic activity 
between PRK1-Δ940 and PRK1-Δ939. A relevant question at this juncture would be 
whether the deletion of the C-terminal residues results in PRK1 adopting a structural 
conformation that is more susceptible to degradation. Consequently, PRK1-Δ939 had 
reduced activity because of decreased structural stability. Thus, the stability of PRK1 
V5 domain deletion mutants was assessed by determination of the heat stability 
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replicating in vitro kinase assay conditions. While in vitro kinase assay was 
performed at 30 °C for 10 min, the in vitro heat stability was carried out at 30 °C for 
an extended period of 30 min to study the effect of heat on PRK1 stability. Deletion 
that removes the C-terminal tail that is absent in PKA had no gross negative effect on 
the in vitro heat stability of the PRK1-∆940 mutant as it exhibited similar activity 
before and after heat treatment (Fig. 3.5A). From Fig. 3.5B, it is apparent that there 
was little degradation of PRK1 deletion mutants after incubation at 30 °C for 30 min 
in vitro. Thus, the negligible kinase activity of PRK1-Δ939 observed (Fig. 3.3A) was 
most likely a result of impaired catalysis rather than the degradation of the mutant.  
 
The heat stability assay was indicative of the stability of the deletion mutants under in 
vitro conditions. To reflect the physiological stability, the half-lives of PRK1 mutants 
ectopically expressed in COS-1 cells were determined under in vivo condition. 
Cycloheximide is a glutarimide antibiotic that inhibits protein synthesis in systems 
that utilize ribosomes of the 80S type [332]. Cycloheximide exerts its effect by 
interfering with peptidyl transferase activity of the 60S ribosome, thus blocking 
translational elongation. COS-1 cells transiently transfected with PRK1 expression 
constructs were incubated with 200 μg/ml cycloheximide for several hours as this 
treatment had been shown to effectively inhibit protein synthesis in this cell line [333, 
334]. The transfected cells were incubated with cycloheximide for 4 h to ensure 
complete inhibition of protein synthesis before the first lysis which was designated as 
time zero, with subsequent cell lysis performed every 2 h. Thirty percent of the total 
cell lysate from the different time points was loaded in SDS-PAGE and analysed with 
anti-Myc antibody in Western blotting to determine the relative ectopically expressed 
PRK1. The amount of actin for each lane was determined with actin specific antibody 
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to normalize differences in the amount of total cellular proteins in each lane. During 
the experiments, cycloheximide was replenished every 8 h to ensure near-complete 
inhibition of protein synthesis of COS-1 cells. 
 
The half-lives of total cellular PRK1 and soluble PRK1 were measured separately, as 
the former represents the half-life of both detergent-soluble and detergent-insoluble 
pools of PRK1 while the latter represents the half-life of the detergent-soluble (mainly 
cytosolic) pool of PRK1. Data presented in Table 3.1 indicate that for WT-PRK1, the 
turnover of the detergent-insoluble fraction of PRK1 was faster than that of the 
detergent-soluble fraction.  Removal of the segment of Phe941-Tyr946 resulted in an 
approximately nine-fold reduction in the stability of the mutant PRK1 in both the total 
cellular pool and the detergent-soluble (cytosolic) pool in vivo.  Further deletion of the 
V5 domain of PRK1, including the removal of the entire V5 segment (the PRK1-∆879 
mutant) did not shorten the half life of PRK1 any further.  Thus, the C-terminal 
segment (residues 941-946) of the V5 domain of PRK1 that does not exist in PKA 
conferred the stability to the kinase against degradation by intracellular protein 
destruction machineries.  




Fig. 3.5. Effect of the removal of the C-terminal extension of V5 domain in PRK1 
has little impact on heat stability of the kinase.  Myc-tagged PRK1 expression 
constructs were introduced into COS-1 cells.  Twenty hours post-transfection, 
exogenously expressly PRK1 was immunoprecipitated.  After three stringent washes, 
the immune-complexes were incubated at 30 °C for 30 min before proceeding to a 
peptide phosphorylation assay.  The specific activity of each PRK1 after heat 
treatment is expressed as percentage of the activity of the untreated control sample 
and is shown as means ± s.e.m of three independent experiments (Fig. 3.5A).  A 
representative Western blot showing the mass of the proteins before and after heat 
treatment is shown in Fig. 2.5B. 
 
TABLE 3.1 
Apparent half-life of exogenous PRK1 in COS-1 cells 
PRK1 WT PRK1 Δ879 Δ939 Δ940 Δ941 Δ942 Δ943 
Soluble (h) 64 ± 5 6 ± 0.3 6 ± 0.1 6 ± 0.1 6 ± 0.4 6 ± 0.4 6 ± 0.1 
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3.1.6 The Full-Length Hydrophobic Motif Is Dispensable for the 
Phosphorylation of the Activation Loop of PRK1 by PDK-1 
It has been proposed that the hydrophobic motif of PKC isozymes is the anchor for 
docking with PDK-1 [270]. The phosphorylation of a conserved threonine residue at 
the activation loop in isozymes of the PKC superfamily by PDK-1 is the first and rate-
limiting step in the maturation process of this group of serine/threonine kinases [45].   
 
Fig. 3.3A shows that in the absence of the hydrophobic motif (Asp940) and its C-
terminal residues, PRK1-Δ940 mutant displayed kinase activity as high as that of the 
wild-type PRK1. Yet, PRK1 Phe939 point mutants with complete hydrophobic motif 
and C-terminal residues had significantly decreased kinase activity. While the extent 
of activation loop phosphorylation is not proportional to kinase activity, it may serve 
as an indicator of the catalytic competence of the kinase. Thus the phosphorylation 
status of the activation loop of the PRK1 Phe939 point mutants and PRK1 deletion 
mutants was investigated to determine the relationship between activation loop 
phosphorylation and catalytic competence and the requirement for the C-terminal 
residues for activation loop phosphorylation.  
 
To determine if Asp940 which corresponds to the phosphorylation mimetic residue of 
the hydrophobic motif is required for activation loop phosphorylation, PRK1-Δ940 
was expressed in COS cells and deleted proteins were immunoprecipitated followed 
by Western blot analysis using the P500 antibody that specifically recognizes the 
phosphorylated activation loop of PKCs [97, 335].  As has been demonstrated 
previously by others [97, 335], the P500 antibody is highly specific for 
phosphorylated activation loop as it did not react with the PRK1-4A mutant in which 
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all the four possible phosphor-acceptor serine/threonine residues in the activation loop 
are replaced with alanine residues (Fig. 3.6 top panel). PRK1-Δ938, PRK1-Δ939 and 
PRK1-Δ941 were also examined for the phosphorylation of the activation loop to test 
for correlation with earlier data (Fig. 3.3B). In contrast to what has been reported for 
PRK2 [270], the deletion of either the segment of Phe941-Tyr946 (PRK1-Δ941) or that 
of Asp940-Tyr946 (PRK1-Δ940) had no significant effect on the extent of the 
phosphorylation of the activation loop of PRK1 (Fig. 3.6, top panel). Deletion of the 
segment of Phe939-Tyr946 (PRK1-Δ939) or that of Asp938-Tyr946 (PRK1-Δ938) of 
PRK1 abolished the phosphorylation at the activation loop. Thus, it appears that 
phosphorylation mimetic residue of Asp940 and the succeeding hydrophobic residue of 
Phe941 are not required for activation loop phosphorylation, since the absence of both 
(as evident in PRK1-Δ940) still resulted in an activation loop phosphorylated PRK1. 
This finding corresponds to the kinase activity of the respective PRK1 deletion 
mutants: PRK1-Δ941 and PRK1-Δ940 were phosphorylated at the activation loop and 
had kinase activity as high as that of the wild-type PRK1 while PRK1-Δ939 and 
PRK1-Δ938 lacked activation loop phosphorylation and were catalytically inactive 
(Fig. 3.3A).  
 
To study further whether phenylalanine is absolutely required at position 939 for the 
phosphorylation of the activation loop, a series of different point mutations at position 
939 in the full-length protein was introduced. As shown in Fig. 3.6, the PRK1-F939Y 
mutant had a slightly reduced phosphorylation at its activation loop. In contrast, the 
PRK1-F939W mutant had a similar, if not higher, extent of phosphorylation at its 
activation loop. The idea that phenylalanine at position 939 is not absolutely required 
for the phosphorylation at the activation loop was further strengthened by the finding 
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that PRK1-F939L or even F939A mutants had reduced but still readily detectable 
phosphorylation at the activation loop (Fig. 3.6). The phosphorylation status of these 
PRK1 point mutants paralleled the kinase activity where PRK1-F939A exhibited low 
activation loop phosphorylation and low kinase activity, and PRK1-F939W had a 
higher level of activation loop phosphorylation and a corresponding higher level of 
kinase activity. It should be noted that while there is a relation between activation 
loop phosphorylation and kinase activity, the two parameters are not directly 
proportional, i.e. a higher level of activation loop phosphorylation does not 
necessarily equate to a higher level of kinase activity.  
 
Thus, the phosphorylation mimetic residue of Asp940 and the hydrophobic residue of 
Phe941 are not required for activation loop phosphorylation, as demonstrated by 
PRK1-Δ940; the absence of both residues still resulted in an activation loop 
phosphorylated PRK1. However, the absence of another hydrophobic residue at 
position 939 (PRK1-Δ939) resulted in a PRK1 mutant that was not phosphorylated at 
the activation loop. Taken together, these results provide evidence that the full length 
hydrophobic motif in PRK1 is not necessary for the activation loop phosphorylation 
by PDK-1. 
    
Fig. 3.6. Phosphorylation of consensus PDK-1 phosphorylation motif in the 
activation loop of PRK1 deletion mutants.  Twenty hours post-transfection, myc-
tagged PRK1 mutants were immunoprecipitated from COS-1 cells and subjected to 
Western blot analysis using P500 antibody followed by stripping and reprobing with 
anti-PRK1 regulatory domain antibody (Ab49). Data shown are typical of 6 
independent experiments.  4A, a Myc-PRK1 mutant with all the four potential 
phosphor-acceptor serine/threonine residues in the activation loop changed to alanine.  
IP: immunoprecipitation  
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3.1.7 Interaction of PDK-1 with PRK1 and the Productive Phosphorylation of 
the Activation Loop Are Separate Biochemical Events 
The docking of PDK-1 to the hydrophobic motif of PKC was proposed to be central 
to the regulation of PKC activity. The current working model of PDK-1 interaction 
with the AGC family of serine/threonine protein kinases states that PDK-1 binds with 
the hydrophobic motif of its substrate kinases (such as PKCs) and subsequently 
phosphorylates its substrate’s activation loop [270]. In PRK2, mutation of the 
conserved aromatic residues in the hydrophobic motif was reported to result in the 
inhibition of the interaction of PRK2 with PDK-1 [108]. Data presented in Fig. 3.6 
indicate that in PRK1, the mutation of conserved phenylalanine residues at the 
hydrophobic motif (PRK1-F939A, PRK1-F939L, PRK1-F939W and PRK1-F939Y) 
does not prevent PDK-1 interaction. In this section, the question of whether the 
hydrophobic motif, the entire V5 domain or even the activation loop itself of PRK1 is 
required for the physical interaction between PDK-1 and PRK1 in vivo is addressed.  
 
The in vivo binding of PDK-1 to PRK1 was analysed in a co-transfection and co-
immunoprecipitation assay in which PRK1 deletion mutants and PDK-1 were 
coexpressed in COS cells. After cell lysis, PRK1 mutants were immunoprecipitated 
and the immunoprecipitates were washed twice sequentially with 1% NP-40 and 300 
mM NaCl to remove non-specific binding. The purified immunoprecipitate was 
subsequently analysed in SDS-PAGE and Western blot with antibody against PDK-1 
to detect PDK-1 interaction with PRK1 (Fig. 3.7A, top panel). As PDK-1 and PRK1 
deletion mutants have similar molecular mass, the blot was stripped off PDK-1-
specific antibody and reprobed with antibody against PRK1 to determine the amount 
of PRK immunoprecipitated (Fig. 7B, 2nd panel). To determine the expression level of 
   
 107
PDK-1, 20% of cell lysate was loaded in a separate SDS-PAGE and analysed (Fig. 
3.7A, 3rd panel). The amount of beads used for each immunoprecipitation was 
analysed by bands corresponding to IgG heavy chain bands (Fig. 7A, last panel). The 
specificity of the co-immunoprecipitation was confirmed in control experiments in 
which a Myc-tagged PRK1 regulatory domain-only construct failed to 
immunoprecipitate the co-transfected Myc-PDK-1 (Fig. 3.7C, middle panel).  
 
As shown in Fig. 3.7, the PRK1-∆918 mutant in which the C-terminal segment 
containing turn motif was removed could still bind with PDK-1, indicating that the 
hydrophobic motif of PRK1 is dispensable for the physical interaction with PDK-1.  
Surprisingly, PRK1 mutants with further deletions into the catalytic domain all 
retained the capacity of interaction with PDK-1 (Fig. 3.7A).  These mutants include 
the PRK1-∆860 mutant in which the entire V5 segment was removed, the PRK1-∆830 
and PRK1-∆800 mutants in which part of the catalytic core was removed and even the 
PRK1-∆770 mutant in which the activation loop was deleted. The binding of PDK-1 
to the above PRK1 mutants was confirmed in the reciprocal immunoprecipitation 
(Fig. 3.7B). The data in Fig. 3.7A-C also suggest that PDK-1 could interact with 
PRK1 in the segment between the hinge (V3) region and NH2 terminus of the 
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Fig. 3.7. Co-immunoprecipitation of PDK-1 with various PRK1 deletion mutants.  
COS-1 cells were transiently co-transfected with Myc-PDK-1 and one of the Myc-
PRK1 plasmids as indicated.  Twenty hours post-transfection, cells were lysed.  A, 
PRK1 were immunoprecipitated using an anti-PRK1 regulatory domain antibody 
(Ab49), and co-immunoprecipitation of PDK-1 was evaluated by Western blot 
analysis with an anti-PDK-1 antibody.  The blot was stripped and re-probed with anti-
Myc.  Approximate 20% of the total input PDK-1 was evaluated with Western blot 
analysis.  B, Co-immunoprecipitation of PRK1 with PDK-1 was evaluated by Western 
blot analysis with anti-PRK1 antibody (Ab49). Twenty percent of input PRK1 was 
evaluated in Western blot using Ab49. C, Myc-PDK-1 was co-transfected with Myc-
PRK1 regulatory domain-only construct. The possible interaction between PDK-1 and 
PRK1 regulatory domain was evaluated by immunoprecipitation with anti-PRK1 




3.1.8 The C-terminal Portion of the V5 Domain of PRK1 Is Critical for Full 
Lipid Responsiveness 
PRK1 is activated by a variety of lipids, among which arachidonic acid is one of the 
best characterized lipid activators [53]. The arachidonic acid binding site in PRK1 has 
been mapped to the C-terminal portion of the regulatory domain of PRK1 (residues 
455-511) [267]. It is noteworthy that Ono and colleagues [267] mapped the 
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arachidonic acid binding site in PRK1 by systematically truncating the N-terminal 
half of PRK1. While PRK1 N-terminal deletion mutant 455-946 was found to have 
low basal activity similar to the wild type PRK1, and was highly dependent on 
arachidonic acid, the PRK1 N-terminal deletion mutant 511-946 had higher basal 
activity with only a slight dependence on arachidonic acid. Thus a region N-terminal 
to the hinge region (residues 455-511) was mapped as the region that binds 
arachidonic acid. However, the precise mechanism by which this region regulates the 
catalytic domain of PRK1 has not been elucidated.  
 
The present study demonstrated that the V5 domain is critical for catalytic function 
because the removal of seven residues resulted in an inactive kinase (Fig. 3.3A). A 
possibility for the lack of activity in PRK1-Δ939 is that the last seven residues are 
necessary for maintaining the catalytic domain in an optimal conformation for 
catalysis, absence of which results in PRK1 inability to phosphorylate its substrate. To 
address this possibility, PRK1 C-terminal residues were deleted sequentially and 
tested for catalytic activity with and without lipid activator. To this end, PRK1 
deletion mutants were over-expressed in COS cells and immunoprecipitated. 
Immunoprecipitated PRK1 mutants were equally divided into two tubes to ensure that 
similar amount of proteins were used. Subsequently, PRK1 deletion mutants were 
tested for their control of lipid responsiveness by analysing the ability to 
transphosphorylate a S6 peptide substrate in the presence or absence of arachidonic 
acid.  
 
As shown in Fig. 3.5A and Fig. 3.8, the deletion of amino acid residues between 940 
to 946 did not have any gross detrimental effect on the basal catalytic activity of 
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PRK1. However, removal of the last three amino acid residues from the C-terminus of 
PRK1 (the PRK1-∆944 mutant) resulted in reduced activation by arachidonic acid 
(Fig. 3.8). Intriguingly, further deletion of the C-terminal portion of the V5 domain of 
PRK1 (PRK1-∆942, ∆941 and ∆940 mutants) almost abolished the lipid 
responsiveness of PRK1 to arachidonic acid (with only 0.2-0.25-fold activation). 
Deletion at Phe939 resulted in a PRK1-∆939 mutant that not only lost its basal catalytic 
activity but also could not be revived/activated by arachidonic acid, indicating that the 
last seven amino acids in the V5 domain are necessary for maintaining an optimal 
conformation of the catalytic domain. Thus, a novel element that controls the lipid 
responsiveness of PRK1 at the extreme C-terminus of the V5 domain was 
serendipitously identified.  
 
 
Fig. 3.8.  In vitro arachidonic acid responsiveness of wild-type PRK1 and PRK1 
deletion mutants.  Myc-tagged PRK1 expression constructs were transiently 
transfected into COS-1 cells.  Twenty hours post-transfection, PRK1 was 
immunoprecipitated with anti-Myc (9E10) antibody.  The catalytic activity of various 
PRK1 constructs towards an S6 peptide was analyzed in an immune-complex kinase 
assay with or without 40 μM arachidonic acid solublised in 20mM Tris, pH 7.5.  Data 
are expressed as percentage of activity of wild-type PRK1 and are means ± s.e.m. of 
three independent experiments. A representative Western blot used to derive the 
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specific activity of PRK1 is shown at the bottom.  AA, arachidonic acid. *, p<0.01 
using single-factor ANOVA. 
 
 
3.1.9 Computer Modeling of Three-Dimensional Structure of the Catalytic 
Domain of PRK1 
Sequence alignment is a central technique in homology modeling used to establish the 
correspondence of each amino acid between the reference protein(s) and those of the 
unknown proteins, providing a basis for transferring coordinates from the reference to 
the model protein.  The overall folding topology and patterns of all mammalian AGC 
family of serine/threonine kinases are very similar [85, 107].  Therefore, homology 
modeling based on protein sequence alignment may be useful in predicting the three-
dimensional structure of the catalytic domain of PRK1.  The alignment of the amino 
acid sequence of the catalytic domain of rat PRK1 with that of human PKBβ and the 
catalytic subunit of mouse PKA guided by the crystal structures of the latter kinases 
[85, 336] is shown in Fig. 3.9A. Rat PRK1 has 39% and 43% sequence identity with 
mouse PKA (1APM) and human PKBβ (1O6L), respectively. Notably, the amino acid 
sequence of PKA terminates at Phe350 (corresponding to Phe939 in rat PRK1), while 
PKBβ [337]   terminates at Glu481 (Arg480 in human PKBβ corresponds to Tyr946 in rat 
PRK1). To gain further insights into the conformation and properties of the catalytic 
domain of PRK1, in particular the role of the V5 segment in the establishment of the 
catalytic competence of the kinase, a three-dimensional structure model of the 
catalytic domain of PRK1 was built (Fig 3.9 B-D) based on the X-ray structures of 
PKA and PKB that contain the structures of the respective V5 domain [85, 336].    
 
The three-dimensional model of the catalytic domain of rat PRK1 (residues 612 to 
946, including the C-terminus of the kinase) consists of an N-lobe and a C-lobe linked 
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by the V5 segment (Fig. 3.9A, B), consistent with conserved packing as shown for 
PKA and PKB. The absolutely conserved ATP-binding motif (Asp-Phe-Gly) is 
located in a deep cleft between the two lobes; while the activation loop (in which the 
Thr778 residue is labelled) is situated near the entrance to the active site of the kinase.  
The V5 domain assumes an extended loop structure and transverses the surface of the 
two lobes.  As shown in Fig. 3.9A, B, the extreme C-terminus of the V5 domain 
containing the hydrophobic phosphorylation motif makes a turn at the apex of the 
kinase core and embeds in the conserved hydrophobic patch that is located at the back 
of the kinase core, as in the case of other AGC kinases [85, 338]. 
 
To define the possible roles of the V5 domain of PRK1 in maintaining the active 
conformation(s), I focused on the carboxyl terminal residues 911-946. This stretch of 
sequence shows low sequence homology among the V5 domains of various AGC 
kinases and assumes variable conformations in different protein kinases.  In the 
absence of a crystal structure, I used molecular dynamics (MD) to refine my 
homology to provide an estimate of its stability. The root mean square deviation 
(RMSD) from the initial protein model was analysed, focusing on intramolecular 
distance between residues Gln690 in the β4-sheet in N-lobe and Phe936 within the 
hydrophobic motif in the V5 domain. The δ-carboxyl group of Gln690 was found to 
form a hydrogen bond with the carbonyl group of Phe936 in my analysis. The 
intramolecular distance between Gln690 and Phe936 is shown in Fig. 3.10A.  In a stable 
protein, the intramolecular distances fluctuate around an equilibrium, but in a non-
equilibrated conformation there will be a continuous drift in the intramolecular 
distances as the MD protocol samples the conformational space for its global minima. 
The RMSD of the intramolecular distance between Gln690 and Phe936 was found to 
   
 113
drift towards a stable value of about 8.5 Å after 500 ps, suggesting that the atomic 
model of rPRK1 built using homology modeling (Fig. 3.9 B-D) is energetically stable. 
Most of the protein motions were found to be confined to the carboxyl terminus and 
the unstructured loops (Fig. 3.10B). The conformation of the protein model remained 
relatively stable after the initial 500 ps and the coordinates of rPRK1612-946 at the end 
of the 5 ns simulation were used as a basis for predicting the potential interactions 
between residues in the hydrophobic motif in the V5 domain and those in the N-lobe 
(Fig. 3.9D). The model from my simulation shows that Asp940 potentially forms salt 
bridges with Lys668, whereas the δ-carboxyl group of Gln690 and the ε-amino group of 
Lys668 independently formed a hydrogen bond with the carbonyl group of Phe936.  
Phe939, Phe936, Phe689, and Val695 potentially form a hydrophobic cluster (encircled 
with light blue dotted line in Fig. 2.9D) that would help to stabilize the N-lobe. Val942, 
Phe941 and Met665 may form hydrophobic contacts (encircled with pink dotted line in 
Fig. 3.9D). 





Fig. 3.9.  Homology model of PRK1 catalytic domain.  A, alignment of the catalytic 
domains of rat PRK1 (rPRK1) with mouse PKA (mPKA, Protein Data Bank code 
1APM) and human PKBβ (h PKBβ, Protein Data Bank code 1O6L). The number on 
top of the alignment refers to sequence of rat PRK1 with the numbering of mouse 
PKA and human PKBβ labelled above the respective sequences.  Identical residues 
are shown by white letters on a red background, while similar residues are denoted by 
red letters in blue boxes.  The secondary structure is shown as black arrows for β 
strands and as loops for α helices. Note, in the engineered human PKBβ (1O6L), the 
last 15 amino acid residues were replaced by a PIFtide from PRK2 (21).  B, a ribbon 
model of residues 612-946 of rPRK1.  α-helices are shown in red, extended β strands 
are colored yellow and unstructured loops are shown in blue. The V5 domain is 
denoted in green.  Asp-940 in the conserved hydrophobic motif, the DFG ATP-
binding motif and the conserved PDK-1 phosphorylation residue Thr-778 of the 
activation segment are shown as sticks. Figures were drawn using POVScript+ 
(http://www.stanford.edu/~fenn/povscript/).   C, a 90° rotation of B.  D, a close up 
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view of the hydrophobic motif and the residues interacting with the N-lobe. The V5 
domain is shown in green.  Backbones are shown in grey.  Residues shown as sticks 
are colored as follows: hydrophobic residues in brown; acidic residues in red; basic 
residues in blue and polar residues in yellow.  Asp-940 potentially forms salt bridges 
with Lys-668 and Phe-936 potentially forms a salt bridge with Gln-690 (indicated as 
brown dotted lines). The δ-carboxyl group of Gln-690 and the ε-amino group of Lys-
668 independently formed a hydrogen bond with the carbonyl group of Phe-936 
(brown dotted lines). Phe-939, Phe-936, Phe-689, and Val-695 form a hydrophobic 
cluster (encircled with light blue dotted line) that helps to stabilize the N-lobe. Val-





Fig. 3.10.  Molecular dynamics simulation of catalytic domain of PRK1.  A,  
Cα RMSD of the intramolecular distance between Q690 and F936 was analyzed as a 
function of time over the entire trajectory of a 5 ns molecular dynanmics simulation 
for rPRK1612-946.  B,  the main chain (N, Cα, C and O) RMSD for each residue as a 
function of time during the same molecular dynanmics. α-helical sections of the 
structure are highlighted in red whereas extended strands are highlighted in yellow.  
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3.2 DISCUSSION 
One of the key questions in PKC research is how the exquisite PKC isozyme 
specificity is achieved in vivo, given that members of the PKC superfamily are 
seemingly catalytically promiscuous when studied in vitro.  Structurally, all known 
members of the PKC superfamily, except for the recently reported PKCζII [339], are 
composed of a highly conserved catalytic core (C3-V4-C4 domains) flanked by an 
less conserved  NH2-terminal regulatory segment (V1-C1-V2-C2-V3 domains) and a 
C-terminal V5 tail.  The catalytic core of PKC seems less likely to contain 
determinants for in vivo isozyme specificity.  Although the NH2-terminal regulatory 
domain of the PKC superfamily kinases certainly plays major roles in allosteric 
regulation, how this domain contributes to the known isozyme-specific functions 
within subgroups of PKC superfamily remains to be explored.  The V5 domain is a 
segment of approximately 50-70 amino acid residues located C-terminal to the 
catalytic core of PKC. Despite the fact that it contains several highly conserved 
residues, it apparently has the lowest overall amino acid sequence identity in PKC 
[340].  Such low conservation of sequence homology led some investigators to 
propose that the C-terminal portion of PKC has little importance in PKC function 
[341].  However, more recent studies show that the V5 domain is not only important 
in the maturation of PKC [45] but also governs some of the PKC’s isozyme-specific 
functions [120, 342]. 
 
Based on the results of expression of C-terminal deletion mutants of bovine PKCα in 
the yeast [341], one might predict that the removal of the V5 domain of PKC could 
generate a mutant kinase that is insoluble [45].  However, at least in the case of 
PRK1, removal of up to 94% of the V5 domain (PRK1-∆882) still resulted in a 
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mutant kinase with substantial solubility (~40% of that of the wild-type enzyme).  
Further deletion of the V5 domain of PRK1 (PRK1-∆881) resulted in diminished 
solubility of the mutant kinase.  Intriguingly, additional deletion into the catalytic core 
of PRK1 (PRK1-∆860) generated a mutant kinase with enhanced solubility (Fig. 3.2).  
My data indicate that both the NH2-terminal portion of the V5 domain and the C-
terminal portion of the catalytic core are important for the proper folding of PRK1.   
  
Although the C-terminal extension segment in the V5 domain of PRK1 (Asp940-
Tyr946) is dispensable for the solubility of the kinase, this segment is important for the 
stability of PRK1.  Removal of this carboxyl tail in the V5 domain resulted in a 
~ninefold decrease of the half-lives of the PRK1-∆941/940 mutants when introduced 
into COS-1 cells (Fig. 3.5 and Table 3), suggesting that this segment may guard 
PRK1 against premature degradation by cellular proteolysis machineries such as the 
proteasome system [343].  In terms of the contribution to the catalytic competence of 
the kinase, my results show that the removal of this segment has little, if any, 
appreciable effect on the catalytic activity of the mutant PRK1-∆940 under my 
experimental conditions (Fig. 3.3A).  However, once a stop codon was placed at the 
position of Phe939, which corresponds to the C-terminus of PKA, the catalytic activity 
of the resultant PRK1-∆939 was completely lost. The sharp demarcation of the 
catalytic activity between PRK1-∆940 and PRK1-∆939 mutants is surprising: instead 
of a quantitative change in the catalytic activity, an all-or-none effect was observed 
with deletion of just one additional amino acid residue. 
  
One of the key recent advances in the study of the regulation of the PKC superfamily 
of serine/threonine kinases is the elucidation of the importance of turn motif and 
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hydrophobic motif in the maturation, signaling and down-regulation of PKCs [45, 
112, 198].  Although the role of phosphorylation at these two motifs in the regulation 
of PKC has been well defined with selected PKC isozymes, the contribution by the 
phosphorylation at these two motifs to PKC isozyme specificity is less well 
understood.  An emerging theme regarding the presence of these two motifs in all 
PKC isozymes is their unique contribution to the biochemical properties of each 
isozyme.  For turn motif, the mutation of the phosphor-acceptor residue to alanine in 
closely related classic PKC (cPKC) isozymes reveals strikingly different contribution 
of the phosphothreonine to the catalytic activity of individual cPKC:  the PKCβ1-
T642A mutant has completely lost its catalytic activity [344], while PKCα-T638A 
mutant has retained ~80% of the catalytic activity of the wild-type counterpart [103]. 
As for novel PKC (nPKC), the serine-to-alanine mutant in turn motif of PKCδ 
(PKCδ-S643A) retains ~53% of the specific activity of the wild-type enzyme [104].  
In contrast, it is demonstrated in this study that the PRK1-S920A mutant had low 
catalytic activity (Fig. 3.4). It remains to be established whether the observed different 
effects of turn motif threonine/serine-to-alanine mutation on the specific activity of 
PKC isozymes are due to different degrees of compensating phosphorylation of 
surrounding serine/threonine residues [130], selective interaction with other cellular 
proteins such as heat shock proteins [212] or different types of host cell lines used for 
the production of PKC mutants. In terms of the hydrophobic motif at the V5 domain, 
the effect of serine-to-alanine mutant on PKC’s specific activity is drastically 
different for closely related cPKC isozymes: PKCβ2-S660A has greatly reduced 
catalytic activity [130] but PKCα-S657A mutant has very similar catalytic activity to 
the wild-type protein [129].  In atypical PKC (aPKC) and PRK subgroups, the 
phosphor-acceptor Ser/Thr residue in hydrophobic motif is replaced by an acidic 
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residue, aspartic acid or glutamic acid. Nonetheless, isozyme-specific effects of 
Glu/Asp-to-alanine mutation persist. A PKCζ-E579A mutant retains 55% specific 
activity compared with the wild-type enzyme, PRK2-D978A-∆NT (generated on a 
version of PRK2 that lacks the auto-inhibitory N-terminal domain) is only 20% active 
compared with the wild-type enzyme [345]. In contrast, I show here that the PRK1-
D940A mutant is completely inactive under my assay conditions (Fig. 3.4).  The data 
presented here reinforce the notion that each member of the PKC superfamily must be 
studied individually to reveal isozyme-specific variation of the common theme of 
regulation and to understand the mechanistic basis for isozyme-specific function of 
PKC in vivo [112, 346]. 
  
Using a strategy combining serial deletion and site-directed point mutation, I made 
several intriguing observations on the role of V5 domain in maintaining a catalytic 
competent conformation of PRK1. First, deleting the C-terminal extension (940-946) 
of the V5 domain in PRK1 had no apparent negative effect on the in vitro catalytic 
competence of the PRK1-∆940 and PRK1-∆941 mutants.  In contrast, replacing the 
Phe941 with alanine in the full-length PRK1 resulted in ~80% reduction of the 
catalytic activity of the PRK1-F941A mutant (Fig. 3.3A). Second, mutation of the last 
amino acid residue (Phe939) in PRK1-∆940 (including PRK1-∆940-F939W) resulted 
in an inactive kinase (Fig. 3.3C); while the same Phe939-to-Trp mutation introduced 
into the full-length protein had only a moderate effect on the catalytic activity of 
PRK1-F939W mutant (~55% of the wild-type protein) (Fig. 3.4A).  Third, the PRK1-
D940A mutant was catalytically inactive (Fig. 2.4A); while deleting the Asp940 and 
the rest of the C-terminal residues had little effect on the catalytic activity of the 
resultant PRK1-∆940 mutant (Fig. 3.3A).  Similar intriguing observations have been 
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made for PKA: while a PKA mutant with a Phe350-to-Ala mutation is devoid of 
measurable enzymatic activity (51), the PKA deletion mutant lacking C-terminal 16 
amino acid residues retains 40% activity [347]. It is possible that the C-terminal 
extension of the V5 domain in PRK1 (residues 940-946) interacts with other elements 
in PRK1.  Such interactions may be important for regulatory functions but might not 
be required for the catalytic competence of the kinase per se.  In fact, the net outcome 
of such interactions might put unfavourable structural constrains on active 
conformations of the kinase and therefore necessitate the presence of a negatively 
charged residue in position 940 (Asp940) to override the unfavourable constrains in the 
wild type enzyme.  It is the collective intramolecular interactions between residues in 
the C-terminus and those in the rest of the protein that define an active conformation 
of PRK1 and ensure isozyme-specific regulatory flexibility. This hypothesis is 
supported by my model of the three-dimensional structure of the catalytic domain of 
PRK1 based on homology modelling and molecular dynamics simulation.  In my 
homology model of PRK1 (Fig. 3.9), Phe941 and Val942 potentially form hydrophobic 
interaction with Met665 located at αC helix; while Asp940 potentially forms a salt 
bridge with Lys668 (corresponding to Lys92 in PKA) at αC helix.  The αC helix in 
PKA and PKB has been shown to be instrumental in organizing an active kinase 
structure by maintaining the nucleotide-binding site and activation segment in a 
catalytically competent state and integrates inputs from other segments in the catalytic 
core [85, 107, 111].  Importantly, the extent of the twist of αC helix has been shown 
to determine the functional mode of protein kinases [338, 348] and the precise 
position of αC helix can be determined by the phosphorylation state of the protein or 
the binding of nucleotide [85, 111]. The result from the homology modeling suggests 
an explanation on the paradoxical result where D940A mutant was catalytically 
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inactive but PRK1-Δ940 has high activity. Replacing aspartate with a non-polar 
residue of Ala may play an inhibitory role, such that alanine at position 941 interferes 
with the hydrophobic interaction between the aromatic residues of Phe939 and Met665.  
At the same time, the findings that mutation of PRK1-F949Y has less effect than 
deleting the residue together with the rest of the C-terminal residues suggest that 
tryptophan in place of phenylalanine, together with phenylalanine at 941 largely 
maintains the configuration required for kinase activity. Thus, it is possible that in the 
full-length PRK1, the side chains of the last 6 amino acid residues at the C-terminus 
interact with the αC helix in such a way that elements in the catalytic core are not 
optimally aligned.  The additional contribution from the side chain of Asp940 might 
help to orient αC helix properly to allow the final configuration of an active 
conformation of PRK1 through its interaction with Lys668 and other residues in the αC 
helix. Such a critical coordinating function of Asp940 would become redundant for the 
catalytic competence in the absence of the last 6 amino acid resides as in the case of 
the PRK1-∆940 mutant.   
 
Recently, a hydrophobic pocket located at the back of the N-lobe of AGC kinases has 
been identified [85, 270, 349].  This pocket is formed by the hydrophobic residues 
from αB and αC helices with the β4 and β5 strands of the central β-sheet.  The 
interaction of the hydrophobic residues at the C-terminus of AGC kinases with this 
pocket stabilizes the ordered αB and αC helices and thus is essential for catalysis.  In 
my model of PRK1, the Phe936 and Phe939, (corresponding to Phe347/Phe350 in PKA or 
Phe470/Phe473 in PKB) potentially forms hydrophobic contact with Phe689 (in β4 
strand) and Val695 (in β5 strand).  Tempering Phe939 with an alanine substitution or 
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deletion will therefore inevitably compromise the conformation required for a 
catalytically active kinase.   
   
A major leap in the understanding of how PKC is regulated in vivo was the discovery 
of PDK-1 as the upstream kinase that phosphorylates the activation loop of PKC in 
1998 [97, 98, 100].  Most members in the PKC superfamily of serine/threonine 
kinases, except for PKCδ, are synthesized as an inactive precursor in cells [45]. The 
phosphorylation of a threonine residue within the context of a conserved Thr-Phe-
Cys-Gly-Thr motif in the activation loop located in the kinase subdomain VIII of 
PKCs constitutes the initial priming step that triggers a maturation process that is 
mandatory for most of the PKCs to become a functional kinase [45, 198, 350].  
Studies of the role of hydrophobic motifs in the regulation of PKCζ and PRK2 by 
PDK-1 via mutagenesis analysis show that mutation of glutamic acid or aspartic acid 
or any of the conserved hydrophobic residues in the hydrophobic motif (Phe-Xaa-
Xaa-Phe-Ser/Thr/Asp/Glu-Phe/Tyr) either abolished or greatly reduced the ability of 
PDK-1 to interact with PKCζ and PRK2 and to phosphorylate the activation loop 
[345]. Such observations led to a generalized proposal advocating that the 
hydrophobic motif of AGC kinases functions as a substrate-docking site to enable 
PDK-1 to bind and then phosphorylate its substrates [270].  However, findings from 
this study suggest that careful dissection of the contributions from individual residues 
in the hydrophobic motif and those from other domains of the kinase in question is 
necessary for a complete and comprehensive picture of how PDK-1 interacts with 
individual isozymes in the PKC superfamily.  First, my study has shown that a PRK1-
∆940 deletion mutant lacking the last two residues in the hydrophobic motif is 
catalytically active and with the activation loop well phosphorylated (Fig. 2.5, Fig. 
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2.6). Hence, at least in the cases of PRK1, the last two residues in the hydrophobic 
motif are dispensable for interaction with PDK-1. In fact, hydrophobic motif 
originated as a hydrophobic phosphorylation motif (FSF/Y) where serine is flanked 
by two hydrophobic residues. In the case of aPKC and PRK, the phosphor-acceptor is 
replaced by an negatively charged Glu/Asp residue) [45].  Therefore, if one deletes 
the phosphor-acceptor residue and its C-terminal hydrophobic residue, the 
hydrophobic phosphorylation motif would no longer exist.  In this sense, the 
hydrophobic motif in both PRK1 is not required for the docking and phosphorylation 
of the activation loop by PDK-1.  Second, my serial deletion experiments showed that 
PDK-1 could still physically interact with PRK1-∆770 even after the removal of a 
segment encompassing the activation loop and the C-terminus of PRK1 (Fig. 3.7).  
Third, domains in PKC other than the catalytic core can influence the interaction of 
PDK-1 with PKC.  For example, when expressed in HEK293 cells, the catalytic 
domain-only construct of PKCζ is not phosphorylated at Thr410 in the activation 
looop.  However, the full-length PKCζ-F578A mutant is partially phosphorylated at 
Thr410 and has reduced but significant catalytic activity [351].  Furthermore, when 
introduced into tsA201 cells, the glutathione S-transferase (GST)-fusion full-length 
PKCβII associates well with the co-expressed PDK-1.  However, the GST-fusion 
construct of the catalytic domain of PKCβII interacts with PDK-1 poorly in the same 
cells [110].  Thus, at least in the case of PKCβII and PKCζ, the regulatory domain of 
PKC may play a role in PDK-1 interaction. Fourth, in embryonic stem cells lacking 
PDK-1 (the PDK-1 gene knockout cells), there is a remarkable isozyme-specific 
difference in the detectable protein levels of members of the PKC superfamily: the 
expression of PKCζ and PRK2 is similar to that in control cells; while the expressions 
of many other PKC isozymes are reduced with virtually undetectable protein levels 
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for PKCε and PRK1 [352].  The amount of mRNA for PRK1 in PDK-1 null cells is 
the same as that in the control cells.  The absence of PRK1 protein in PDK-1-null 
cells is unlikely to be due to the lack of phosphorylation of the activation loop of 
PRK1 by PDK-1, as in my hands the protein for a PRK1 mutant in which all the four 
possible phosphor-acceptor serine/threonine residues in the activation loop are 
replaced by alanine (PRK1-4A) is readily detectable when transfected into different 
types of mammalian cells (Fig.3.6 and data not shown).  Rather, this indicates that 
PDK-1 may directly or indirectly regulate the biosynthesis and/or in vivo stability of 
some of its PKC substrates at a site other than the activation loop. 
  
PKCs are lipid activated kinases [8].  With the exception of diacylglycerol and 
phorbol ester, there is limited knowledge about how other lipids, such as fatty acids, 
ceramide, phosphatidic acid and lysophospholipids, activate PKCs.  For PRK1, the 
structural and biochemical basis for its activation by Rho proteins has been 
extensively characterized [56, 266, 353].  However, the mechanisms of PRK1 
activation by other fatty acid and phospholipids [44, 53, 54] remain elusive.  Ono and 
colleagues identified an essential autoinhibitory domain (residues 455-511) near the 
N-terminal of the V3 (hinge) domain of PRK1 [267].  It is proposed that arachidonic 
acid directly interferes with the interaction between this autoinhibitory domain and 
the catalytic domain, thus relieving the autoinhibition on PRK1 [267].  My data 
indicate that the last 5 amino acid residues at the C-terminus of PRK1 are essential for 
full lipid responsiveness. The activation of the PRK1-∆942 mutant in response to the 
stimulation of 40 μM arachidonic acid was almost abolished (Fig. 3.8). To my 
knowledge, this is the first report on the identification of a modulating element of 
lipid responsiveness at the C-terminus of a member of the PKC superfamily of 
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serine/threonine kinases.  The C-terminus of the V5 domain of PKC is a segment that 
displays great variability (in terms of amino acid sequence and length) among 
isozymes in the family.  This small segment is ideally poised for conferring isozyme-
specific regulation of each member in the PKC superfamily.  For example, it has been 
shown that the last four amino acid residues at the C-terminus of PKCα are essential 
for the binding of PICK1 and consequently the mitochondrial targeting of PKCα in 
NIH3T3 cells upon serum stimulation [125, 354].  In Drosophila eye PKC, the last 
three amino acid residues at C-terminus have been shown to be critical in the binding 
of INAD and thus proper visual transduction in the fly [355, 356].  It has been well 
established that in mammalian cells, most arachidonic acid is esterified as a fatty acyl 
chain of glycerophospholipids in cell membranes, in particular the plasma membrane 
[357].  Free arachidonic acid is released in cells in response to a variety of cellular 
stimulations that result in the activation of phospholipases (phospholipase A2, 
diacylglycerol and monoacylglycerol lipases) [358]. Our laboratory has recently 
identified an integral plasma membrane pool of PRK1 that transduces signals from 
activated RhoA [359]. It is therefore tempting to speculate that PRK1 could be 
activated by cellular stimuli that result in the release of free arachidonic acid from the 
plasma membrane to mediate physiological and pathological processes in which 
arachidonic acid has been shown to be involved, such as insulin secretion [360], 
neurotransmitter release [361], mood disorders/schizophrenia [362, 363], colorectal 
carcinogenesis [364] and cell death [365].  
  
In conclusion, this study has shown that in PRK1, the seven amino acid residues at the 
C-terminal segment (which is absent in PKA) are an important element in conferring 
in vivo stability in PRK1. The full-length hydrophobic motif in PRK1 is dispensable 
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for catalytic activity and the interaction with PDK-1.  PDK-1 can physically interact 
with PRK1 at the catalytic core in the absence of the V5 domain that harbours the 
hydrophobic motif.  The last five amino acid residues at the C-terminus of PRK1 
control the full lipid response of the kinase to arachidonic acid.  Elucidation of the 
function of the C-terminal segment in members of the PKC superfamily of 
serine/threonine kinases will not only advance understanding of the biochemical 
mechanisms underlying the known in vivo isozyme specificity but also might pave the 
way for the development of highly selective pharmacological agents that are able to 
modulate the activity of each isozyme of PKC in human diseases. 
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Appendix D: 
Sequencing Results of PRK1 mutants 
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Chapter 4:  
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4.1 RESULTS 
4.1.1 Generation and Characterization of Deletion Mutants of PRK1 
Previously, a novel element within the extreme C-terminus that controlled the lipid 
responsiveness of PRK1 to arachidonic acid was identified [366]. To determine if the 
element within the V5 is specifically responsive to only arachidonic acid, PRK1 C-
terminal deletion mutants were studied for the response to another PRK1 activator: 
RhoA. A full-length rat PRK1 cDNA was cloned into the mammalian expression 
vector pcDNA3. As the study involved serial deletion of C-terminal residues of 
PRK1, the DNA sequence coding for Myc-tag (EQKLISEEDL) was incorporated at 
the N-terminal before the second amino acid residue of PRK1 to facilitate the 
identification and purification of the recombinant PRK1.  
 
Previous work has revealed that GST fusion HR1a or HR1b can bind RhoA but GST-
HR1c does not interact with RhoA [55, 56]. It has also been shown that HR1abc binds 
RhoA more tightly than HR1a or HR1b alone [56, 353]. The focus of those studies 
was on the interaction of PRK1 and RhoA. Therefore, the authors removed the kinase 
domain and used only the N-terminal regulatory domain in their studies [55, 353]. In 
contrast, the present study aims to determine the contribution of the C-terminus of 
PRK1 to the response of PRK1 to RhoA stimulation. Serial deletion mutants were 
generated by introducing an in-frame stop codon at designated positions at the C-
terminus of wild-type N-terminally Myc tagged rat PRK1 (Fig. 4.1A). For example, 
as illustrated in Fig. 4.1B, the PRK1-∆941 mutant carried a stop codon at residue 941 
with the last expressed residue being residue 940.  
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The HR1 region in the regulatory domain has been proposed to be the sole 
determinant for the interaction between PRK1 and RhoA, thus a negative control 
which does not respond to RhoA stimulation was generated by deleting the HR1 
domain of PRK1. This was accomplished by deleting residues 30 to 280 from an N-
terminally Myc-tagged rat PRK1 (Fig. 4.1C). Breifely, HR domain deletion mutants 
were generated with a pair of non-complimentary phosphorylated primrs that flank 
upstream of residue 30 and downstream of residue 280. The PCR product was ligated 
to repair the nick before transforming into E. coli and subsequent steps are as listed in 
Materials and Methods. This HR1 deletion mutant was named PRK1-ΔHR1 (Fig. 
4.1C). To provide evidence that PRK1 C-terminal deletion is RhoA specific, serial 
deletion mutants were generated by introducing an in-frame stop codon at designated 
positions at the C-terminus of the HR1 deletion mutant.  As illustrated in Fig. 4.1B, 
for example, the ΔHR1-∆941 mutant carried a stop codon at amino acid residue 941 
with the C-terminus of the mutant being amino acid residue 940 on a background of 
HR1 deletion (Fig. 4.1C). Since I reported previously that the C-terminal deletion 
mutants (PRK1-Δ941 and PRK1-Δ943) have an apparent half-life of approximately 6 
h compared to that of 64 h for the wild-type PRK1 [366], the half-life of the HR1 
deletion mutants in cells was measured. As shown in Table 4.1, the deletion of the 
HR1 region, either alone or in combination with C-terminal deletion, led to a further 
decrease of the apparent half-life of the PRK1-ΔHR1 mutants, presumably due to the 
accelerated rate of turnover of the mutant PRK1 proteins. However, such decreased 
half-life did not translate into significantly altered steady-state protein levels of the 
PRK1 deletion or deletion mutants in COS cells (Fig. 4.2). This means the amount of 
intact proteins that can be immunoprecipitated from each of the different deletion 
   
 135
constructs would be similar, thus I proceeded with the analysis of the activation of 
PRK1 mutants by RhoA.  
 
 
Fig. 4.1.  Domain structure of PRK1 and PRK1 constructs used in this study. A, 
Wild-type PRK1 (WT) is comprised of a regulatory domain (blue) and a catalytic 
domain (red) linked by a hinge region and was N-terminally tagged with a Myc 
epitope. The HR1abc region in the regulatory domain and the V5 domain is shown. 
The number at each C-terminus indicates the position of the stop codon, with the last 
expressed residue being the one just prior to the number. B, The PRK1 C-terminal 





 WT-PRK1 ΔHR1 ΔHR1-Δ946 ΔHR1-Δ944 
Half-life (h) 64 ± 5 2.1 ± 0.1 2.6 ± 0.15 2.25 ± 0.25 
Apparent half-life of PRK1 and  HR1-deletion mutants in COS cells 
Values given as mean ± S.E. (n=4).  COS-1 cells transfected with plasmids encoding 
wild-type (WT) or various deletion/deletion mutants of PRK1 were treated with 200 
μg/ml cycloheximide and lysed hourly up to the 10 h time point.  The amount of 
PRK1 in the total cell lysate at each time point was determined by Western blot 
analysis after normalizing the signals for β-actin. The apparent half-life was 
determined from plotting the amount of protein remaining against time on a semi-
logarithmic graph as described under “Materials and Methods.”  
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Fig. 4.2. Similar steady state of protein levels between wild type and deletion 
mutants. Myc-tagged wild type PRK1 and deletion mutants were transiently 
transfected into COS-1 cells. Twenty and thirty hours post transfection, cells were 
lysed and exogenous wild type or mutant PRK1 were immunoprecipitated with anti-
Myc antibodies. The amount of protein immunoprecipitated was determined by 
Western blotting.   
 
4.1.2 Effect of Deletion of HR1 on the Interaction between PRK1 and RhoA 
Although previous studies have reached the conclusion that the HR1 region in PRK1 
is the RhoA binding site, it is noteworthy that the studies were carried out using PRK1 
constructs without the catalytic domain. In this study, the aim was to determine the 
contribution of the C-terminus to catalytic activity by RhoA activation in a more 
physiological setting, thus I choose to include both the regulatory and catalytic 
domains in my studies. The contribution of HR1 to the binding of a full length PRK1 
to RhoA in vitro was first assessed. GST-fusion RhoA was produced using an E. coli 
expression system. The solubility and the amount of protein expressed were verified 
by Coomassie staining (Fig. 4.3A). It has been shown that PRK1 interacts with GTP-
RhoA but not with GDP-RhoA in cells [57, 58], thus after affinity purification (Fig. 
4.3B), the GST-RhoA was loaded with GTPγS, a GTP analogue that is not 
hydrolysable by GTPase to produce GTP-bound RhoA. Transfection of plasmids 
encoding the wild-type PRK1, the HR1 deleted PRK1, the C-terminal deletion or 
combined N- and C-terminual deletion mutants of PRK1 was carried out in COS-1 
cells. The Myc epitope-tagged PRK1 was immunoprecipitated and stringently washed 
with 0.5M LiCl to remove non-specifically bound proteins. The purified Myc-tagged 
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PRK1 and GST-GTPγS-RhoA were incubated together for one hour to allow binding 
in vitro. Unbound RhoA was removed by three washes consisting of 1% NP-40 and 
150 mM NaCl. The immunoprecipitated Myc-PRK1 was then subjected to SDS-
PAGE and the interaction of GST-RhoA with Myc-PRK1 was determined by Western 
blot analysis to detect the co-immunoprecipitated GST-RhoA. The specificity of the 
binding assay was verified in the separate negative control experiments. First, Myc-
PDK1 failed to co-precipitate GST-RhoA (Fig. 4.4A, last lane), demonstrating that 
GST-RhoA could not be co-precipitated by an over-expressed Myc-tagged protein in 
the experimental setting. Second, GST-Tau1 could not co-precipitate Myc-PRK1 or 
Myc-PRK1-ΔHR1 (Fig. 4.4C); demonstrating that a large amount of irrelevant GST-
tagged protein was unable to co-precipitate Myc-PRK1.  
 
As shown in Fig. 4.4A and 4.4B, the deletion of one to six residues from the C-
terminus had only marginal adverse effects on the binding of PRK1 to RhoA. On the 
other hand, the deletion of the HR1 significantly reduced the amount of GST-RhoA 
co-immunoprecipitated with PRK1. Interestingly, the removal of the HR1 region from 
PRK1 did not completely abolish the interaction between PRK1 and GST-RhoA, as 
there was approximately 20% GST-RhoA co-immunoprecipitated with PRK1-ΔHR1 
compared with that of the wild-type PRK1 (Fig. 4.4B). The deletion of the C-terminal 
residues from the PRK1-ΔHR1 mutant had no apparent additional effect on RhoA 
binding in the C-terminal deletion mutants of PRK1-ΔHR1 (Fig. 4.4A and B). Taken 
together, the results suggest that RhoA may interact with PRK1 directly at regions 
other than HR1. 
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Fig. 4.3. Coomassie blue staining of bacterially expressed GST-RhoA. (A) 
Bacterial lysate before purification. (B). Affinity purified bacterial lysate showing 
single GST-RhoA band without other protein contamination.  
 
 
Fig. 4.4.  In vitro binding of GST-GTPγS-RhoA to PRK1 and its deletion-deletion 
mutants.  A, PRK1 immunoprecipitation.  Myc-tagged PRK1 constructs were 
expressed in COS-1 cells and immunoprecipitated followed by three stringent 
washings. Bacterially expressed GST-RhoA was loaded with GTPγS and then added 
to the immobilized PRK1. After incubation for 1 h, PRK1 was immunoprecipitated 
followed by two washings with 150 mM NaCl and 1% Triton X-100 as described 
under “Materials and Methods”. The RhoA bound to immunoprecipitated PRK1 was 
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determined in Western blot analysis using an anti-GST antibody (top panel). The 
amounts of immunoprecipitated Myc-tagged PRK1 were determined using an anti-
Myc antibody (middle panel).  Equal amounts of input GST-GTPγS-RhoA protein 
were used (bottom panel) for PRK1 pull-down. B, quantification of GST-GTPγS-
RhoA bound to immunoprecipitated PRK1 in vitro as shown in A.  Results shown are 
mean ± S.E. of at least five independent experiments and are represented as 
percentage of the GST-GTPγS-RhoA bound to the wild-type PRK1.  C, GST-Tau-1 
was used to demonstrate that the interaction between GST-RhoA and PRK1 is 
specific in PRK1 pull-down.  Bacterially expressed GST-Tau-1 or GST-GTPγS-RhoA 
was used for PRK1 immunoprecipitation.  The GST-protein co-immunoprecipitated 
(top panel) and the immunoprecipitated PRK1 (middle panel) were determined in 
Western blot analysis using anti-GST and anti-Myc antibodies, respectively. Amounts 
of input GTP-fusion protein in each sample are shown in the bottom panel.  Data 
shown are representative of at least five (Fig. 4.4A) or two (Fig. 4.4C) independent 
experiments. 
  
4.1.3 Contribution of Regions other than HR1 to the Activation of PRK1 by 
RhoA in vitro 
Having demonstrated that HR1 is not the sole region responsible for RhoA binding 
with PRK1 in vitro, a question arose as to whether this putative new Rho binding site 
is functional in activating PRK1. In other words, is HR1 the only element on PRK1 
that is required for the activation of this kinase by RhoA? To assess the direct 
interaction and activation of PRK1-ΔHR1 by RhoA, in vitro kinase assay was 
performed to examine changes in the kinase activity of PRK1-ΔHR1 in the presence 
of RhoA. To this end, PRK1 deletion mutants were over-expressed in COS cells and 
immunoprecipitated. Immunoprecipitated PRK1 mutants were equally divided into 
two tubes to ensure similar amount of proteins were used. Subsequently, PRK1 
deletion mutants were tested for their response to GTPγS-RhoA in an in vitro 
immune-complex kinase assay employing an S6 peptide as a substrate in the presence 
or absence of the activator GTPγS-RhoA. Ideally, the negative control for this RhoA 
activation experiment would be a PRK1 protein which does not interact with RhoA. 
However, as shown in Fig. 4.4A, HR1 deleted PRK1 is still capable of binding RhoA 
in vitro. Thus, a surrogate negative control of PRK1 with activation loop mutation 
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(4A) is used instead as this mutant is kinase inactive and would not respond to 
activation.   
 
Consistent with previous reports on the activation of PRK1 by RhoA in vitro [57, 58], 
in the in vitro system of this study, the addition of GST-GTPγS-RhoA to the immuno-
purified wild-type PRK1 resulted in an approximately 4-fold activation of PRK1 as 
determined by its capacity to phosphorylate an exogenous S6 peptide (Fig. 4.5A and 
B).  Surprisingly, the removal of only one amino acid residue from the C-terminus of 
PRK1 resulted in an approximately 40% reduction of the activation (Fig. 4.5A). 
Further deletion of two to six residues from the C-terminus resulted in progressive 
reduction of the magnitude of RhoA activation in the PRK1 C-terminal deletion 
mutants, culminating at the PRK1-Δ941 mutant that was hardly activated by RhoA 
(Fig. 4.5A) despite the fact that it could physically interact with GST-RhoA (Fig. 4.4A 
and B). Even more surprising was the finding that the deletion of the HR1 region 
resulted in a PRK1-ΔHR1 mutant that could still be activated by GTP-RhoA for about 
2-fold (Fig. 4.5B). The deletion of one or more C-terminal residues from the PRK1-
ΔHR1 mutant completely abrogated the activation of the mutant PRK1 by RhoA (Fig. 
4.5B). These findings indicate that the HR1 region is only partially responsible for the 
direct activation of PRK1 by RhoA in vitro. It is the very C-terminus of PRK1 that 
critically controls the direct activation of this kinase by RhoA, at least in vitro. 
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Fig. 4.5.  In vitro activation of PRK1 by GST-GTPγS-RhoA.  The catalytic activity of 
wild-type PRK1 and that of PRK1 C-terminal deletion mutants (A) or HR1-deletion and 
HR1-deletion plus C-terminal deletion mutants (B) was determined in the presence or 
absence of GST-GTPγS-RhoA. A S6 peptide was used as a substrate in the 
transphosphorylation assay as described under “Materials and Methods”. The amount of 
PRK1 or PRK1 mutant protein captured on beads during kinase assay in each sample was 
determined in a Western blot analysis using an anti-Myc antibody to derive specific 
activity of PRK1.  Data shown are mean ± S.E. of at least three to five independent 
experiments and are represented as percentage of the activity of the corresponding PRK1 
or PRK1 mutant that was not treated with GST-GTPγS-RhoA. A representative Western 
blot used to derive the specific activity for each pair of samples is shown below each bar 
chart. 
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4.1.4 Critical Role of the C-terminus of PRK1 in its Activation by RhoA in 
Cells 
It was previously shown that the addition of lysophosphatidic acid (LPA) to the cell 
culture medium resulted in the activation of PRK1 via RhoA [57, 58, 359].  As LPA 
binds to cell surface receptors (LPA1 and LPA2) and activates RhoA via the G12/13 
protein coupled to its receptors [367], there is a need to determine which element(s) in 
PRK1 are necessary and sufficient for controlling PRK1’s response to RhoA that is 
activated endogenously in cells by its physiological agonist. To do this, various Myc-
tagged PRK1 constructs were transiently transfected into COS-1 cells. After treating 
cells with physiological concentration of LPA for 30 min, cells were lysed and Myc-
PRK1 was immunoprecipitated. The catalytic activity of each PRK1 construct in cells 
before and after LPA treatment was analyzed in an immune-complex kinase assay. 
Consistent with previous findings [57, 58, 359], the treatment with LPA to activate 
endogenous RhoA resulted in an approximately 3-fold activation of the wild-type 
PRK1 in COS cells, as determined in a trans-phosphorylation assay using an S6 
peptide (Fig. 4.6A).  The deletion of one to five amino acid residues from the C-
terminus resulted in a progressive reduction in the activation of the PRK1-Δ946 to 
PRK1-Δ942 mutants by LPA. Removal of the six C-terminal amino acid residues 
resulted in a PRK1-Δ941 mutant that lost its capacity to be activated by RhoA (Fig. 
4.6A), although this mutant has been shown to have a basal catalytic activity 
comparable to that of the wild-type PRK1 [366] and could bind GST-GTPγS-RhoA in 
vitro (Fig. 4.4). Notably, deletion of the HR1 region resulted in a significant reduction 
in the activation of the PRK1-ΔHR1 mutant by LPA (Fig. 4.6B).  However, the 
removal of HR1 did not completely abrogate the activation of PRK1-ΔHR1 by LPA, 
as this mutant had a 50% increase in its catalytic activity upon treatment of LPA. 
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Deletion of one or three C-terminal residues from the PRK1-ΔHR1 mutant completely 
abolished the ability of the resultant PRK1-ΔHR1-Δ946 or PRK1-ΔHR1-Δ944 to be 
activated by LPA (Fig. 4.6B). These data suggest that the HR1 region is not the sole 
determinant for the activation of PRK1 by RhoA in cells. Rather, the last six amino 
acid residues in PRK1 play critical roles in conferring the full responsiveness of 
PRK1 to RhoA.  




Fig. 4.6.  Activation of PRK1 by LPA in cells.  COS-1 cells were transfected with 
wild-type PRK1 or PRK1 deletion or deletion mutants as indicated.  After serum 
starvation for 24 h, cells were treated with 5 μM LPA or vehicle for 5 min and lysed 
by 1% Triton X-100. The specific activity of PRK1 or its mutants was determined in 
an immune-complex kinase assay using an S6 peptide as a substrate.  The activation 
of wild-type PRK1 and that of PRK1 C-terminal deletion mutants (A) or HR1-deletion 
and HR1-deletion plus C-terminal deletion mutants (B) was quantified after 
normalizing the amount of protein in each sample.  Data shown are mean ± SEM of 
four independent experiments and are represented as percentage of phosphorylation 
by LPA-treated PRK1/mutant compared with that of the corresponding vehicle-
treated sample.  A representative Western blot used to derive the specific activity for 
each pair of samples is shown below the bar chart. 
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4.1.5 Functional Importance of the Very C-terminus of PRK1 in Medicating 
LPA-elicited Actin/myosin II Contractility 
To evaluate the functional importance of the very C-terminus of PRK1 in transducing 
signals downstream of RhoA in cells, a cellular model of neurite retraction was 
adopted. Previous work from our lab has shown that PRK1 participates in mediating 
LPA-elicited neurite retraction in mouse neuronal cells N1E-115 [359]. It was 
established that PRK1, when transiently transfected into N1E-115 cells, signals 
downstream of RhoA, as co-transfection of either a dominant-negative RhoA (T19N) 
or a potent RhoA inhibitor botulinum ADP-ribosyltransferase C3 abolishes PRK1’s 
ability to modulate neurite retraction upon LPA treatment [359].  In order to test 
which element is critical for PRK1 to mediate LPA-elicited neurite retraction, 
expression plasmids encoding the wild-type PRK1 or various PRK1 mutants were 
transiently transfected into N1E-115 cells. Once differentiated by becoming flattened 
and developing neurites, these neuronal cells will undergo RhoA-mediated neurite 
retraction and rounding within 2-3 minutes of stimulation by physiological 
concentration of LPA [368, 369].  As shown in Fig. 4.7A, the wild-type PRK1 and the 
PRK1-Δ942 mutant could augment LPA-stimulated neurite remodeling (P<0.001 
compared to the vector-only control).  However, the deletion of the six C-terminal 
residues resulted in the failure of the PRK1-Δ941 mutant in augmenting LPA-
stimulated neurite remodeling, as in the cases of the HR1 deletion mutants (P>0.05, 
compared to the empty vector control).  Therefore, it is demonstrated that the very C-
terminus of PRK1 is not only important for the full activation of PRK1 by RhoA in 
cells, but is also critical for PRK1 to mediate actin/myosin II contractility downstream 
of RhoA in neuronal cells.  
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Fig. 4.7.  Analysis of the capacity of PRK1 and its mutants in mediating LPA-
elicited neurite retraction in neuronal cells.  A, N1E-115 cells were transiently 
transfected with wild-type PRK1 or PRK1 mutants as indicated.  After serum-
starvation for 30 h to allow the outgrowth of neurites, cells were treated with 3 μM 
LPA or vehicle for 3 min and immediately photographed for morphological analysis. 
Data are expressed as mean ± SEM of five to six independent experiments.  B, cells 
after photography were lysed using 1 x SDS-PAGE loading buffer and the total cell 
lysate was subjected to immunoblotting using an anti-Myc antibody to control the 
expression of each PRK1/mutant protein used in neurite retraction assay.  A 
representative immunoblot showing the expression of Myc-PRK1/mutant (top panel) 
along with an immunoblot showing the content for β-actin in the cell lysate to control 
for the loading (bottom panel) are shown.  Asterisk, P < 0.001 compared with empty 
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4.2 DISCUSSION 
In this study, it is shown that a segment distant from the RhoA binding sites in a Rho 
effector serine/threonine protein kinase critically controls the activation of the kinase 
after the binding of RhoA and the subsequent regulation of cytoskeleton dynamics in 
cells is demonstrated. 
 
Given the importance of the Rho family of small GTPases in the control of a diverse 
array of cellular functions, intense studies have been carried out to elucidate the 
molecular mechanisms of the interaction between RhoA and PRK1.  The interaction 
between RhoA and HR1 region in the regulatory domain of PRK1 has been 
characterized using yeast two-hybrid system, in vitro binding assays either on solid 
support or in solution and using filter overlay assay [55-58, 268, 353, 370].  It is now 
established that RhoA binds with high affinity to the HR1a region of PRK1 in a GTP-
dependent manner. It also interacts with the HR1b region with relatively low affinity 
and less dependence on the status of the nucleotide [55, 56, 353, 371]. Detailed 
structural analysis via X-ray crystallography and NMR suggests that both HR1a and 
HR1b interact with RhoA via a platform formed by an ACC fold from these two 
elements [266, 353].  The HR1a of PRK1 makes two possible contacts with RhoA 
(designated Contact I and II), while HR1b probably interacts with RhoA at one site. 
Although such elegant studies have provided insights into the molecular basis of 
RhoA-PRK1 interaction, the use of isolated domain to study protein-protein 
interaction is not without its limitations. For example, it was reported that 
recombinant protein of HR1 repeats produced in E. coli behaves as a dimer on gel 
filtration [56]. In addition, GST fusion might affect the binding of the fusion protein 
to RhoA due to steric hindrance as exemplified by the 16-fold reduction in affinity 
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between GST-Rhotekin and RhoA [371].  A more critical question that has not been 
addressed is whether the HR1 domain in PRK1 is sufficient for the activation of this 
kinase upon activation by RhoA in cells. This study attempted to answer this question 
by generating RhoA binding site deletion mutants followed by analyses of the RhoA 
binding and activation. Although it has been shown that RhoA interacts with the 
isolated HR1a and HR1b but not HR1c, independent studies using different 
methodologies have firmly established that HR1abc does bind RhoA with higher 
affinity in a GTP-dependent manner than either HR1a or HR1b alone [56, 371].  
Therefore, an HR1 domain deletion mutant of PRK1 was generated and found to 
result in a substantial reduction in the amount of PRK1-ΔHR1 mutant bound to 
GSTγS-RhoA compared with that of wild-type PRK1 in an in vitro binding assay 
(Fig. 4.4).  However, the removal of HR1 from the regulatory domain does not 
completely abrogate the interaction between PRK1 and RhoA, as there is still 
approximately 18% of GSTγS-RhoA bound to PRK1-ΔHR1.  This suggests that 
RhoA may directly interact with PRK1 in site(s) other than the known HR1 domain.  
It also implies that the interaction between RhoA and its effectors is more complex 
than originally thought and this might involve multiple contact sites from distinct 
regions on the effector molecule with RhoA via a higher-order structure.  Since RhoB 
and Rac1 are also found to bind HR1 domain of PRK1 [56, 268], the findings in this 
study are consistent with the recent concept that the utilization of multiple contact 
regions in both Rho GTPases and their effectors is one of the mechanisms underlying 
signal transduction of Rho in distinct cellular pathways [370].  
 
Most of the studies regarding the role of PRK1 in medicating RhoA signaling have 
focused on the understanding of the nature of the physical interaction between RhoA 
   
 149
and PRK1.  Since the pseudosubstrate segment (residues 39-53) of PRK1 that keeps 
matured PRK1 in an inactivated state overlaps with the HR1a ACC finger, the 
prevailing consensus is that the binding of RhoA to HR1a and HR1b region elicits a 
conformational change that dislodges the pseudosubstrate segment from the active site 
of PRK1 and thus activates the kinase.  The structural requirement and biochemical 
mechanisms underlying the activation of PRK1 after the binding of RhoA are, 
however, poorly understood. 
 
Earlier, it was shown that despite the fact that deletion of last seven amino acid 
residues from the C-terminus of PRK1 does not have a discernible adverse effect on 
the basal catalytic activity of this kinase, deletion of the five C-terminal residues from 
PRK1 completely abrogates the activation of PRK1 by arachidonic acid (see chapter 
2) [366].  In the past, the C-terminal segment (the V5 domain) of PKC/PRK is 
thought to be too short to be considered a protein domain [340] and functionally 
unimportant [341].  The newly discovered critical role of the very C-terminus of 
PRK1 in lipid responsiveness prompted the hypothesis that the very C-terminus of 
PRK1 may also play a role in the activation of this kinase by RhoA.  To address the 
critical question of whether HR1 region is necessary and sufficient for the activation 
of PRK1 upon binding of RhoA, the effect of deletion of HR1 or the very C-terminus 
on the activation of PRK1 by RhoA was studied. In an in vitro activation assay, it 
appears that GSTγS-RhoA can still activate PRK1-ΔHR1 by least 2-fold, while 
deletion of three to five C-terminal residues further reduces the activation of PRK1 by 
RhoA (Fig. 4.5). Importantly, removal of the last 6 residues from the C-terminus of 
PRK1 or deletion of HR1 combined with deletion of a single C-terminal residue 
PRK1 completely abrogates the direct activation of the mutant PRK1-ΔHR1-Δ946 by 
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GSTγS-RhoA. The findings of the importance of the very C-terminus of PRK1 in the 
activation of the kinase by RhoA in vitro is further supported by the data on the 
activation of PRK1 by RhoA in cells (Fig. 4.6). In this assay, RhoA is activated 
through a well established signaling pathway: from the binding of a physiological 
agonist of RhoA (LPA) to its G protein-coupled receptor followed by the activation of 
Rho guanine nucleotide exchange factors [367, 372].  In mammalian cells, the 
removal of HR1 does not completely abolish the activation of PRK1-ΔHR1 by LPA; 
however, the deletion of the last six amino acid residues at the C-terminus of PRK1 or 
the deletion of one C-terminal residue in PRK1-ΔHR1 completely abolishes the 
capacity of PRK1-Δ941 or PRK1-ΔHR1- Δ946 to be activated by LPA (Fig. 4.6). The 
physiological relevance of the very C-terminus of PRK1 in signal transduction of 
RhoA-medicated cytoskeletal dynamics is underscored by the functional analysis of 
PRK1 in the regulation of neurite retraction in which the PRK1-Δ941 mutant fails to 
augment LPA-elicited neurite retraction (Fig. 4.7). 
 
For the other five known Rho effector serine/threonine protein kinases (p21-activated 
kinases, mixed-lineage kinases, Rho-kinases, citron kinase and myotonin-related 
Cdc42-binding kinases), the binding of GTPase causes dimerization or 
multimerization of the effector kinase and leads to changes to the autoinhibitory 
regions as well as elevated catalytic activity.  The subsequent trans-
autophosphorylation is thought to be responsible for releasing the autoinhibition and 
lead to the eventual activation of these Rho effector kinases [370]. However, such a 
mechanism is unlikely to be operational for PRK1, as there is no evidence for 
dimerization of this kinase [56].  In co-transfection systems using certain cell lines, 
the interaction of Rho with PRK1 seems to facilitate the phosphorylation of the 
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activation loop of PRK1 by PDK-1 [268, 269]. Nevertheless, the extent of 
phosphorylation of the activation loop of PRK1 is probably not responsible for the 
inability of PRK1-Δ941 to be activated by RhoA in cells, as it was previously shown 
that the extent of phosphorylation of the activation loop and the basal catalytic 
activity of this mutant are essentially the same as that of the wild-type counterpart 
[366]. 
 
These findings suggest that, although the very C-terminus of PRK1 is not the major 
site of interaction with RhoA, it critically controls the magnitude of activation after 
the binding of RhoA. Homology modeling and molecular dynamics simulation was 
employed to study the contribution of the C-terminus of PRK1 in the activation of this 
kinase [366]. Phe-941 and Val-942 were shown to potentially form hydrophobic 
interactions with Met-665 which is located in αC helix [366].  The αC helix in PKA, 
PKB and PKCθ and PKCι has been shown to be essential in maintaining an active 
kinase structure and integrates inputs from other segments in the catalytic core [85, 
87, 88, 107, 111].  In addition, the extent of the twist of αC helix is known to 
determine the functional mode of protein kinases [338, 348].  Therefore, it is tempting 
to speculate that the binding of RhoA to HR1 in PRK1 elicits a series of 
conformational changes to displace the pseudosubstrate segment from its substrate 
binding site and to reposition or realign the αC helix and other elements in the 
catalytic domain. Such conformational changes are critical for the full activation of 
PRK1 and activation could not proceed in the absence of the very C-terminus, as it 
might hold and position the αC helix in a delicately controlled three-dimensional 
space required for optimal catalysis. Whether the control of the activation of PRK1 by 
RhoA via C-terminus residues involves an inter-molecular mechanism(s), such as 
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reported for Gem and Rad in the inhibition of Rho-kinases [373], awaits further 
experimental exploration.  
  
Rho GTPases have been shown to be involved in the pathogenesis of cancer [372, 
374].  Recently, work from this laboratory and others has implicated PRK1 in the 
progression of prostate cancer [359, 375]. Therefore, the development of 
pharmacological agents to inhibit signaling pathways downstream of specific Rho 
GTPases, such as RhoA, may be valuable for cancer therapy.  The HR1-like domains 
are found in other Rho effectors, such as rhophilin [58], Rhotekin [79], Rho-kinase, 
citron and kinectin [371].  Targeting the HR1 region on Rho effectors may have 
problem in the specificity of inhibition, as there is a high sequence homology in the 
α2 helix of the ACC finger in HR1 where most residues in the effector involving the 
interaction of Rho GTPase are located.  On the other hand, the very C-terminus (V5 
domain) of PRK/PKC is least conserved, both in length and in amino acid sequence, 
among members of the PKC superfamily [340], and it is obviously not found in other 
Rho effectors. Thus, monoclonal antibodies, peptides or small molecules that are able 
to bind to the very C-terminus of PRK1 and suppress its activation by RhoA could 
constitute a new generation of drugs for treating diseases in which the activation of 
PRK1 by RhoA is implicated. 
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Chapter 5:  
Role of the PRK2 V5 domain in kinase function 
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5.1 OVERVIEW 
The structure of members of the PKC superfamily is highly conserved, with an N-
terminal regulatory domain linked to a C-terminal catalytic domain via a linker 
segment (the hinge region). The catalytic core of all PKC/PRK superfamily members 
has 40-50% sequence identitity. The V5 domain, located at the extreme C-terminal 
tail is present in all PKC/PRKs, ranging from yeast to humans, but with a much lower 
sequence homology compared with that of the catalytic core [340]. In fact, PRK1 and 
PRK2 have 87% amino acid sequence identity at the kinase domain but only 46% 
amino acid sequence identitity at the V5 domain. In chapter 3, it was found that PDK-
1 can physically interact with PRK1 at the catalytic core in the absence of the V5 
domain that harbours the hydrophobic motif. In addition, the last five amino acid 
residues at the C-terminus of PRK1 were found to control the full lipid response of 
the kinase to arachidonic acid. Hence, it begs the question of whether the V5 domain 
plays a similar role in the regulation of PRK2.  
 
Thus, this study aims to determine the importance of individual residues and the 
collective contribution of the region within the V5 domain to the catalytic activity of 
PRK2. At the same time, this study hoped to provide direct comparison of the 
mechanisms of regulation between PRK1 and PRK2, giving valuable insights to 
similarity and differences between these two closely related kinases 
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5.2 RESULTS 
5.2.1 Generation and Characterization of PRK2 Mutants 
A full-length human PRK2 cDNA with a Flag-epitope 
(GACTACAAGGACGACGATGAAAG) tag fused before the second amino acid 
residue was cloned into a mammalian expression vector pcDNA3 to enable 
identification and purification of the protein of interest. This was subsequently used as 
a template for the generation of point mutation and C-terminal deletion mutants. As 
subsequent study involved serial C-terminal deletion, the Flag tag was purposely 
inserted at the N-terminal. The conserved residues of the turn motif, hydrophobic 
motif and conserved hydrophobic residues flanking the hydrophobic motif were 
mutated and PRK2 was serially deleted from the C-terminal, to determine their 
contribution to PRK2 catalytic activity. In addition, results from PRK1 deletion and 
point mutants (see chapter 3) provided a working model for the generation of the 
deletion and point mutants which enable direct comparison of the mechanisms of 
regulation between PRK1 and PRK2. A schematic diagram of the PRK2 domain 
structure and all the PRK2 constructs used in this study is shown in Fig. 5.1. 
 
All mutants containing deletions, point mutations and the combination thereof were 
generated using a polymerase chain reaction (PCR)-based mutagenesis protocol with 
a circular plasmid as a template as described in Materials and Methods. The deletion 
mutants were generated by introducing an in-frame stop codon at the designated 
positions, e.g. the PRK2-∆979 mutant carried a stop codon at position 979, yielding 
PRK1-(1-976). The mutants were verified by gene sequencing and the results are 
listed in Appendix E. 
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Fig. 5.1. Schematic diagram of PRK2 domain structure and PRK2 constructs used in this 
study. (A) Wild-type PRK2 (WT) consists of a regulatory domain (blue) and a catalytic domain 
(yellow) and the full length protein and mutants thereof were N-terminally tagged with a Flag 
epitope.  The hinge region (V3) that links the two domains and the C-terminal segment (V5) are 
shown. Also shown are the turn motif (Thr-958) and the hydrophobic motif (Asp-978), depicted 
by black boxes. (B) Enlarged view of the V5 domain showing the turn motif and the 
hydrophobic motif. (C) Various PRK1 deletions generated. The numbers indicate the position of 
the stop codon, with the last expressed residue being the one just prior to the number. (D) 
Various point mutations (indicated in red) generated in full length and C-terminus deleted PRK2, 
e.g. T958A indicates the mutation of Thr to Alanine at position 958. The whole PRK2 molecule 
and the enlarged V5 domain illustrated are not drawn to scale. Nomenclatures of the constructs 
used are stated on the right panel.  
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5.2.2 The Last Eight Amino Acid Residues and the Highly Conserved Phe977 
are Critical for the Catalytic Competence of PRK2 
Although the crystal structures of the kinase domain of two PKC members were 
recently elucidated (PKCθ and PKCι), the extreme C-terminal of the kinase domain 
was too disordered to enable its structure to be assigned [87, 88]. Thus, how the V5 
residues interact with the kinase domain and contribute to kinase function is 
unknown. To delineate the role of the V5 residues in catalytic activity, C-terminal 
residues were systematically deleted and the catalytic activity of these mutants was 
assessed by in vitro kinase assay. Furthermore, in PRK1, removal of the last eight 
amino acids resulted in a catalytically inactive kinase (Fig. 3.3A). In this section, the 
question of whether the corresponding segment at the C-terminus in PRK2 is also 
critical for catalytic function was addressed.  
 
C-terminal residues within the V5 domain of PRK2 were deleted and the catalytic 
activity of these mutants was assessed in in vitro kinase assay. After transient 
transfection, the FLAG-tagged PRK2 was immunoprecipitated from COS cells lysate 
and was washed extensively with 0.5M lithium chloride. Lithium chloride is able to 
disrupt strong ionic interactions and thus was used to ensure that the purified PRK2 is 
free from contaminating proteins that non-specifically interact with PRK2. This 
purified PRK2 was subsequently subjected to an in vitro immune-complex kinase 
assay. Protamine sulfate was used as a substrate, as this arginine-rich protein binds 
PKC superfamily kinases and releases the pseudosubstrate and thus serves as an 
excellent cofactor-independent substrate of PKC/PRK [60, 200, 376].  
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Fig. 5.2A shows that deletion of up to seven residues from the V5 region did not 
significantly impair the deletion mutants PRK2-Δ979 and PRK2-Δ978. However, a 
significant decrease from full activity to almost null activity was observed when eight 
or more residues were removed from the C-terminal (PRK2-Δ977 to PRK-Δ917) (Fig. 
5.2A). The full length sequence of PRK2 contains 984 residues, with the hydrophobic 
motif at position 978 (Asp978). In full length PRK2, there are two hydrophobic 
residues surrounding the phosphorylation mimetic Asp978: Phe977 and Tyr979. The 
hydrophobic phenylalanine residue preceding the hydrophobic motif is highly 
conserved among the PKC members, while the succeeding hydrophobic residue is less 
conserved where tyrosine is replaced by phenylalanine in PRK1. The data presented 
thus far suggest that either the segment of eight amino acids in V5 in PRK2 was 
important for the catalytic activities (the removal of which results in a catalytically 
inactive PRK2) and/or the highly conserved hydrophobic residue preceding the 
hydrophobic motif Asp978 is critical for the catalytic competence of this kinase 
(absence of which results in a catalytically inactive kinase).  
 
In PRK2-Δ978, the last residue expressed corresponded to Phe977. In order to establish 
if the removal of Phe977 was responsible for this sharp decrease in catalytic activity in 
PRK2-Δ977 mutant, Phe977 was mutated in the background of PRK2-Δ978. The 
phenylalanine at position 977 was mutated to residues with similar aromatic side 
chain (tyrosine or tryptophan) or nonpolar amino acid residues with similar 
hydropathy index (alanine or leucine) to determine whether an amino acid with 
similar biochemical properties could substitute Phe977. PRK2-Δ978 mutants with 
Phe977 point mutations (PRK2-Δ978+F977A, PRK2-Δ978+F977L, PRK2-
Δ978+F977W, PRK2-Δ978+F977Y) were virtually inactive (Fig. 5.2B). Neither 
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substitution of phenylalanine by residues of similar hydropathicity or hydrophobicity 
was tolerated, indicating that the phenylalanine residue at position 977 in PRK2 is 
necessary for the kinase activity.  
 
As the foregoing study was performed with deletion mutants without the extreme C-
terminal, the study of point mutation of Phe977 in the presence of the last eight 
residues is necessary to examine the importance of Phe977 within the context of a full 
length PRK2. Therefore Phe977 was mutated to tyrosine, tryptophan, alanine or leucine 
in the wild-type PRK2. In the full length PRK2, mutation of the aromatic residue 
greatly reduced the kinase activity (PRK2-F977A, PRK2-F977L, PRK2-F977W, 
PRK2-F977Y) (Fig 5.2C). Mutation of Phe977 to residues with similar aromatic side 
chains (PRK2-F977W, PRK2-F977Y) resulted in kinase activities of approximately 
60% and 45% respectively, while mutation to residues with similar hydrophobicity 
(PRK2-F977A, PRK2-F977L) resulted in 10% and 30% activity. Thus, Phe977 plays a 
critical role in catalytic function of PRK2.  
 
However, the segment of residues at the extreme C-terminus is not functionally 
redundant. A comparison of the catalytic activity of PRK2 point mutation at Phe977 
(Fig. 5.2C) and PRK2 point mutation at Phe977 in a background of PRK2-Δ978 (Fig. 
5.2B) revealed that in the absence of the last eight amino acids, the catalytic activities 
of PRK2-F977A, PRK2-F977L, PRK2-F977W and PRK2-F977Y were all abolished. 
Therefore, the data suggest that while Phe977 is important for kinase activity, the 
segment of residues at the C-terminal is also critical to kinase function.  
As mentioned earlier, there are two hydrophobic residues surrounding the 
phosphorylation mimetic Asp978: Phe977 and Tyr979. To determine if the conserved 
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hydrophobic residue Tyr979 succeeding the phosphorylation mimetic Asp978 is 
absolutely required and equally important as Phe939 for kinase activity, a Tyr979 point 
mutation was generated (PRK2-Y979A, PRK2-Y979L, PRK2-Y979W and PRK2-
Y979F).  Mutation of Tyr979 did not affect the kinase activity as much as mutation at 
Phe977 (Fig. 5.2D). Comparatively, Tyr979 appears to be less critical for kinase 
function than its upstream counterpart.  
 
The phosphor-acceptor in the activation loop, turn and hydrophobic motif (Thr816, 
Thr958 and Asp978) was mutated to alanine to determine the importance of these 
conserved residues. The mutation of the critical activation loop residue (T816) to a 
non-phosphorylatable residue inhibited the activity (Fig. 5.2E), in accordance with 
previous studies in PKC βII, PKA and PKB [60, 93-95]. Mutation of the turn motif 
(T958) to alanine also resulted in a catalytically inactive PRK2 (Fig. 5.2E), in contrast 
to PKCα, which was reported to tolerate mutation at the turn motif [103]. The finding 
that PRK2-D978A has high activity (Fig. 5.2E) was expected as PRK2-Δ978 which 
lacked Asp978 also demonstrated high activity. Taken together, in PRK2, the activation 
loop and the turn motif were found to be more critical than the hydrophobic motif for 
catalytic activity.   
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Fig. 5.2. Phe977 and the C-terminal of V5 domain are required for the catalytic 
competence of PRK2. Expression constructs encoding the wild-type or various 
deletion and/or point mutation mutants of PRK2 were transiently transfected into 
COS-1 cells. Twenty hour after transfection, the FLAG-tagged recombinant PRK2 
was immunoprecipitated after lysing cells with 1% Triton X-100. A, the specific 
activity of PRK2 and deletion mutants was determined in an in vitro immune-complex 
kinase assay using 0.67 mg/ml protamine sulfate as a substrate after normalization of 
protein levels as described under “Materials and Methods”. Results are mean ± S.E. of 
at least 3 independent experiments and are represented as percentage of the activity of 
the wild-type PRK2. B, the specific activity of PRK2 Phe977 point mutants on Δ978 
background. C, the specific activity of PRK2 Phe977 point mutants. D, the specific 
activity of PRK2 Tyr979 point mutants. E, the specific activity of PRK2 activation 
loop, turn motif, hydrophobic motif and turn motif + hydrophobic motif mutations.  
 
5.2.3 The C-terminal Tail of PRK2 Does Not Significantly Affect the Stability 
of the Kinase in vitro 
There is a marked difference in catalytic activity between PRK2-Δ978 and PRK2-
Δ977 despite the fact that they differ in only one residue (Fig. 5.2). To determine if 
the absence of the C-terminal residues contributed to aberrant folding of PRK2-Δ977 
that rendered the mutant kinases more susceptible to degradation, the in vitro thermal 
stability of PRK2 deletion mutants was assessed. The thermal stability was studied in 
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conditions that closely resemble the in vitro kinase assay condition of 30oC, except 
that the duration of the kinase assay was extended from 10 min to 30 min to study the 
effect of heat on the structural stability.    
 
Wild-type Flag-PRK2 and Flag-PRK2 deletion mutants were transfected into COS 
cells. The ectopically expressed PRK2 were immunoprecipitated by anti-Flag 
antibody and washed with buffer containing 0.5M LiCl to remove non-specifically 
bound proteins before being equally divided into two aliquots, with one incubated at 
30oC and the other at 4oC for 30 min. Both samples were subsequently subjected to an 
in vitro immune-complex assay with protamine sulfate as a substrate. After SDS-
PAGE, the amount of intact PRK2 immunoprecipitated was determined using 
Western Blot (Fig. 5.3) 
 
The Western blot analysis in Fig. 5.3 shows similar amounts of intact PRK2 mutants 
before and after heat treatment for wild-type PRK2, PRK2-Δ978 and PRK2-Δ977. To 
further verify that the in vitro stability was not compromised in PRK2 point mutants, 
the in vitro heat stability of PRK2-F977A was assessed. Mutation of Phe977 had no 
significant effect on the kinase stability in vitro as no significant degradation was 
observed (Fig. 5.3).  
 
Thus, PRK2-Δ977 and PRK2-F977A are inherently catalytically inactive and the 
observed null kinase activity of PRK2-Δ977 and PRK2-F977A in Fig. 5.2 was not 
duo to accelerated degradation. This indicates that, at least in vitro, the C-terminal tail 
of PRK2 does not significantly affect the stability of the kinase.  
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Fig. 5.3. The V5 domain of PRK2 is not required for thermal stability in vitro. 
Flag-tagged PRK2 expression constructs were introduced into COS-1 cells. Twenty 
hours post-transfection, exogenously expressed PRK2 were incubated at 30oC for 30 
min before proceeding to a peptide phosphorylation assay. The amount of intact 
PRK2 construct after heat treatment is expressed as a percentage of the amount of the 
intact untreated sample and is shown as means ± s.e.m of three independent 
experiments. A representative Western Blot showing the amount of proteins before 
and after heat treatment is shown.  
 
5.2.4 The Turn Motif But Not the Hydrophobic Motif in PRK2 is Necessary for 
Activation Loop Phosphorylation.  
The first and rate limiting step in the processing of members of the PKC superfamily 
is the phosphorylation of the activation loop by PDK-1; isozymes that are 
phosphorylated at the activation loop become catalytically competent [45]. A series of 
studies by Alessi and co-workers provided the first evidence that PDK-1 interacts 
with high affinity with sequences corresponding to the hydrophobic motif by 
identifying the C-terminal of PRK2 in a yeast two-hybrid screen for PDK-1 binding 
partners [108]. This region of PRK2 was termed ‘PDK-1 Interacting Fragment’ (PIF), 
which corresponds to the 77 residues at the extreme C-terminal of PRK2.  
 
To dissect the regions within these C-terminal residues which are required for 
activation loop phosphorylation, the extent of phosphorylation at the activation loop 
of PRK2 C-terminal deletion mutants was determined. To this end, Flag-PRK2 C-
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terminal deletion mutants were expressed in COS cells. The cells were lysed and the 
deleted protein was immunoprecipitated with anti-Flag antibody. Following stringent  
washings with 1% NP-40 and 0.5M LiCl to remove non-specific interacting proteins, 
the immunoprecipates were separated on SDS-PAGE and analysed using Western blot 
with phosphor-specific antibody (P500) that only reacts with a PKC/PRK with its 
conserved threonine at its activation loop phosphorylated [97, 335]. The specificity of 
the activation loop phosphorylation under the experimental conditions employed was 
confirmed with the PRK2-Δ917 mutant (which had the entire V5 domain deleted and 
thus was unable to interact with PDK-1) whose activation loop was not 
phosphorylated.  
 
Fig. 5.4 shows that PRK2-Δ978 which lacked the phosphorylation mimetic Asp978 
and PRK2-Δ977 which lacked the conserved hydrophobic Phe977 were phosphorylated 
at the activation loop. As Phe977 and Asp978 are the main constituents of the 
hydrophobic motif, these results show that in PRK2; the hydrophobic motif is 
dispensable for activation loop phosphorylation. Indeed, this was consistent with the 
analysis of deletion mutants (PRK2-Δ974, PRK2-Δ961 and PRK2-Δ960) which 
lacked the hydrophobic motif but were phosphorylated at the activation loop (Fig. 
5.4). However, PRK2 mutants without the turn motif (Thr958), PRK2-Δ958, PRK2-
Δ950 and PRK2-Δ917 (Fig. 5.4) were deficient in activation loop phosphorylation. 
Thus, the turn motif but not the hydrophobic motif is necessary for the productive 
phosphorylation at the activation loop of PRK2.   
 
Fig. 5.2A shows that PRK2 lacking eight or more residues from the C-terminal were 
catalytically inactive. It is interesting to examine whether the extent of 
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phosphorylation at the activation loop is proportional to the catalytic competence of 
the kinase. The catalytically inactive mutants (PRK2-Δ977 to PRK2-Δ960) were 
phosphorylated at the activation loop (Fig. 5.2A). Therefore, there is no correlation 
between the extent of phosphorylation at the activation loop and the catalytic 
competence.  
 
A possible explanation for the discrepancy is that C-terminal residues are important 
for maintaining the structure of the catalytic domain optimal for catalytic function. 
Although the absence of the C-terminal residues in PRK2-Δ977, PRK2-Δ974, PRK2-
Δ961, and PRK2-Δ960 deletion mutants permitted phosphorylation at the activation 
loop, the presence of the C-terminal residues is critical for proper folding of the 
kinase domain to a conformation necessary for PRK2’s catalytic activities.   
 
 
Fig. 5.4. Phosphorylation of consensus PDK-1 phosphorylation motif in the 
activation loop of PRK2 deletion mutants. FLAG-tagged PRK2 deletion mutants 
were transiently tranfected into COS-1 cells. Twenty hours post transfection, cells 
were lysed and FLAG-tagged PRK2 mutants were immunoprecipitated with 
Dynabeads coated with FLAG antibody. The immunoprecipitates were subjected to 
Western blot analysis using P500 anti-loop antibody specific to phosphorylated 
activation loop, followed by stripping and reprobing with anti-FLAG antibody. Data 
shown are typical of at least three independent experiments.   
 
5.2.5 The Turn Motif and Hydrophobic Motif are Dispensable for PRK2 
Interaction with PDK-1  
The current dogma of PDK-1 interaction with AGC family of serine/threonine protein 
kinases states that PDK-1 binds with the hydrophobic motif of PKC superfamily and 
subsequently phosphorylates its substrate’s activation loop [270]. However, Fig. 5.4 
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demonstrates that the turn motif but not the hydrophobic motif in PRK2 is necessary 
for activation loop phosphorylation as PRK2-Δ978, PRK2-Δ977, PRK2-Δ974, PRK2-
Δ961 and PRK2-Δ960 were phosphorylated at the activation loop, but PRK2-Δ958, 
PRK2-Δ950 and PRK2-Δ917 were not phosphorylated at the activation loop (Fig. 
5.4). To determine whether the failure of phosphorylation at the activation loop in 
PRK2-Δ958 was due to the inability of PDK-1 to interact with PRK2, the physical 
interaction between PRK2 deletion mutants and PDK-1 within the cell was examined.  
 
The in vivo binding of PDK-1 to PRK2 was analysed in a co-transfection and co-
immunoprecipitation assay in which Flag-PRK2 deletion mutants and Myc-PDK-1 
were co-expressed in COS cells. After cell lysis, PRK2 mutants were 
immunoprecipitated via the N-terminal using an anti-Flag antibody. The 
immunoprecipitates were washed twice sequentially with 1% NP-40 and 300mM 
NaCl to remove non-specific binding. The washed immunoprecipitate was 
subsequently analysed in SDS-PAGE and Western blot with anti-Myc antibody to 
detect PDK-1 that is co-immunoprecipitated with PRK2 (Fig. 5.5, top panel). As 
PDK-1 and PRK2 deletion mutants have similar molecular mass, the blot was stripped 
of anti-Myc antibody and re-probed with Flag antibody to determine the amount of 
PRK2 co-immunoprecipitated (Fig. 5.5, middle panel). The similar level of expression 
of Myc-PDK-1 among various samples was verified by loading 20% of cell lysate in a 
separate SDS-PAGE followed by Western blot analysis (Fig. 5.5, last panel). The 
specificity of the co-immunoprecipitation was confirmed with PRK2-Δ917 deletion 
mutant which had its entire V5 domain removed and was thus unable to interact with 
PDK-1.  
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PRK2 was able to form stable interactions with PDK-1 without the hydrophobic 
motif, evident in the association of PDK-1 with PRK2-Δ978, PRK2-Δ977, PRK2-
Δ976, and PRK2-Δ974 (Fig. 5.5). Contrary to the current thinking, it appears that the 
hydrophobic motif in PRK2 is dispensable for PDK-1 interaction, at least under the 
experimental conditions used in this study. This is confirmed by the fact that PRK2-
Δ958 deletion mutant, in the absence of both hydrophobic and turn motif, was able to 
interact with PDK-1 (Fig. 5.5). The data also indicate that the failure of PRK2-Δ958 
to be phosphorylated at the activation loop was not due to PDK-1’s inability to 
interact with PRK2-Δ958. In PKCα, it was proposed that phosphorylation at the 
activation loop and the turn motif contributed to maintain the contact between the C-
terminal (V5) domain and the catalytic core (C3/C4), thereby keeping the kinase 
domain in an active, phosphatase-resistant and closed conformation [103, 129]. It 
seems that in the partially phosphorylated state (no turn motif phosphorylation), the 
solitary phosphate at the activation loop was unable to maintain a closed 
conformation. Thus, a possible explanation for PRK2-Δ958 to exhibit PDK-1 binding 
but not phosphorylation at the activation loop was that the absence of a 
phosphorylated turn motif in PRK2-Δ958 resulted in PRK2-Δ958 deletion mutant 
adopting an open conformation susceptible to phosphatase action such that the 
phosphorylated activation loop was dephosphorylated.   
A potential limitation of co-immunoprecipitation is the forced interaction of two 
proteins from gross over-expression of the two proteins. A feature of forced 
interaction of two proteins is proportionate association of the interacting protein to the 
amount of immunoprecipitated protein. While the amount of wild-type PRK2, PRK2-
Δ958 and PRK2-Δ917 immunoprecipitated were similar (Fig. 5.5, middle panel), the 
amount of PDK-1 associated with wild-type PRK2 and each PRK2 deletion mutant 
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was different despite the equal expression of co-transfected PDK-1 among the wild-
type PRK2 and PRK2 trunction mutants (Fig. 5.5, bottom panel). A higher level of 
PDK-1 interaction with wild-type PRK2 than PRK2-Δ958 was observed; while no 
PDK-1 interaction with PRK2-Δ917 was detected, indicating differential binding 
affinity. Thus, the positive co-immunoprecipitations observed are not artifacts due to 
over-expression of PDK-1.  
 
To confirm the physical interaction between PRK2 deletion mutants and PDK-1, 
reciprocal detection of PRK2 association with PDK-1 immunoprecipitation is 
necessary. Unfortunately, reciprocal association of PRK2 with PDK-1 
immunoprecipitation was not readily detected. The likely cause for this failure was 
the low expression level of PRK2. Without immunoprecipitation, PRK2 bands were 
not clearly visible in Western blots, suggesting lower expression efficiency. For 
unknown reasons, PRK2 expression efficiency was much lower than that for PRK1. 
Although using the same expression conditions were used for both PRK1 and PRK2, 
there was a substantial difference in expression between the two.  
 
It is firmly established that PDK-1 functions as a master upstream kinase controlling 
the activation of numerous AGC kinase members [270]. Therefore, another possible 
reason for the failure in reciprocal binding is that PRK2 was unable to compete with 
other PDK-1-binding proteins in the protein-protein interactions between PDK-1 and 
its numerous substrates.  
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Fig. 5.5. Interaction of PRK2 and PDK in intact cells. FLAG-tagged PRK2 and 
Myc-tagged PDK-1 were contransfected into COS-1 cells. 24 h post transfection, cells 
were lysed by homogenization and immunoprecipitated with anti-FLAG coated 
Dynabeads. The immunoprecipitates were washed three times with buffer D 
consisting of 300 mM NaCl for 10 min each before being resolved by SDS-PAGE and 
transferred onto nitrocellulose membranes and examined by immunoblotting. The 
upper panel shows the amount of bound PDK-1 to the various PRK2 deletion mutants. 
The middle panel shows the amount of PRK2 immunoprecipitated. The bottom panel 
shows the amount of input of Myc-PDK-1. Data shown are representative of three 
independent experiments.  
 
 
5.2.6 Last Seven Residues in V5 Domain of PRK2 is Required for Optimal 
RhoA Activation in vivo 
The involvement of small G proteins in the control of PRK1/2  was first defined when 
PRK1 was found to be a target for Rho [57, 81]. The interaction of RhoA with the N-
terminal HR1 domain of PRK disrupted an autoinhibitory pseudosubstrate 
intramolecular interaction [78], such that the incubation of PRK2 with Rho GTPase 
resulted in a significant increase in the kinase activity [57, 58, 82]. To determine the 
involvement of the C-terminal of PRK2 in the Rho GTPase regulation of PRK2 
kinase activity, PRK2 C-terminal deletion mutants were tested for their kinase activity 
with and without RhoA. 
 
To this end, wild-type Flag-PRK2 and Flag-PRK2 deletion mutants were transfected 
into COS cells. These ectopically expressed PRK2 were immunoprecipitated with 
anti-Flag antibody and washed with 0.5M LiCl to remove non-specific interacting 
proteins. To ensure that similar amount of immunoprecipitated proteins were used in 
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subsequent kinase assays, the immunoprecipitated PRK2 were equally divided into 
two aliquots. The catalytic activity of PRK2 was assayed in the presence or absence 
of purified GST-RhoA fusion protein in solution.  
 
In this study, the wild-type PRK2 could not be activated by GST-RhoA (data not 
shown). A likely reason for the lack of activation is that the activation of PRK2 
requires the GTP-bound form of RhoA. To test this hypothesis of GTP-dependency, 
GST-RhoA was loaded with GTP-γ-S, a GTP analogue that is not hydrolysable by 
GTPase. Kinase assay of the wild-type PRK2 incubated with GTP-γ-S GST-RhoA 
demonstrated approximately 1.8-fold increase in activity compared with that of the 
wild-type PRK2 without GTP-γ-S GST-RhoA (Fig. 5.6). Consistent with the results 
with wild-type PRK2, PRK2-Δ978 was also activated approximately 1.8-fold in the 
presence of GTP-γ-S GST-RhoA. The catalytically inactive deletion mutants of 
PRK2-Δ977, PRK2-Δ976 and PRK2-Δ958 remained catalytically inactive in the 
presence of GTP-γ-S GST-RhoA (Fig. 5.6). Thus, contrary to a previous report that 
the interaction of PRK2 with RhoA in vitro is nucleotide-independent [82], the 
activation of PRK2 by RhoA was nucleotide-dependent under the experimental 
conditions employed in this study.  
  
A drawback of in vitro assays is that in vitro experimental conditions are not 
reflective of physiological conditions. To ensure specificity of interaction between 
two proteins of interest, stringent washes to remove all interacting proteins which 
would otherwise be interacting with either protein of interest within the cells have to 
be performed. Since some proteins require complexes with multiple protein-protein 
interactions to be functional, a study of the activation of PRK2 by RhoA in a cellular 
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context is necessary. This is particularly important for PRK2 since it has been found 
that in the presence of RhoA, there was enhanced interaction between PDK-1 and 
PRK2 [268].  
 
The in vivo activation of PRK2 by PDK-1 was studied in a co-transfection and co-
immunoprecipitation assay in which wild-type Flag-PRK2 or Flag-PRK2 deletion 
mutants and RhoA were coexpressed in COS cells. Two different forms of RhoA 
were employed in this study, a Myc-RhoA-Q61L (a constitutively active mutant 
which prevents intrinsic and GAP-induced GTP hydrolysis) and a RhoA-T19N (a 
dominant negative mutant defective in GDP exchange). RhoA-Q61L and RhoA-T19N 
were used as mimetics for GTP- and GDP-bound form of RhoA, respectively. After 
cell lysis, PRK2 mutants were immunoprecipitated using anti-Flag antibody before 
washing twice sequentially with 1% NP-40 and 300 mM NaCl to remove non-specific 
binding. It should be noted that washing with 300 mM NaCl used in the in vivo assay 
was milder than the 0.5 M LiCl used in in vitro assay and 300 mM NaCl had been 
demonstrated to allow PDK-1 binding (Section 5.1.4 and Fig. 5.5). The washed 
immunoprecipitate was subsequently subjected to kinase assay to determine the 
catalytic activity. 
 
The wild-type PRK2 demonstrated approximately 4-fold increase in kinase activity in 
the presence of constitutively active RhoA-Q61L. In contrast, the same wild-type 
PRK2 co-transfected with dominant negative RhoA-T19N had kinase activity 
comparable to wild-type PRK2 without co-expression of RhoA (Fig. 5.6), suggesting 
that specificity of activation of PRK2 by RhoA is GTP-dependent. Furthermore, co-
transfection of C3 with wild-type PRK2 or PRK2-Δ978 with RhoA-Q61L abolished 
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the activation of kinase activity of wild-type PRK2 or PRK2-Δ978 with RhoA-Q61L 
only (Fig. 5.7), thus confirming that only GTP-RhoA, but not GDP-RhoA is able to 




Fig. 5.6. In vitro activation of PRK2 by GST-GTP-γS RhoA. Expression constructs 
encoding the wild-type or the various deletion mutants of PRK2 as indicated were 
transiently transfected into COS-1 cells. Cells were lysed after 24 h and the Flag-
tagged PRK2 was immunoprecipitated. The catalytic activity of wild-type PRK2 and 
that of the C-terminal deletion mutants was determined in the presence and absence of 
purified bacterially expressed GSTP-GTP-γS RhoA using an immune-complex kinase 
assay with protamine sulfate as substrate. Data shown are mean ± S.E. of at least three 
independent experiments.  
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Fig. 5.7. PRK2 in vivo activation by RhoA. Wild-type FLAG-tagged PRK2 or 
PRK2 deletion mutants were co-transfected with either constitiutively active mutant 
RhoA (Myc-tagged Q61L) or dominant negative mutant (untagged T19N) or with 
potent RhoA inhibitor Botulinum ADP-ribosyltransferase C3. Twenty-four hours post 
tranfection, cells were lysed and the activity of the immunoprecipitated PRK2 was 
assayed as described in “Materials and Methods”. Data are mean ± SD of at least 
three independent experiments.   
 
5.2.7 The Extreme C-terminus Residues of PRK2 Negatively Regulates the 
Activation of the Kinase by Cardiolipin  
In this study, the last seven residues in PRK2 were shown to be necessary for optimal 
activation by RhoA. To determine if the requirement of these last seven residues for 
activation of PRK2 is specific to RhoA, PRK2 deletion mutants were tested for their 
lipid responsiveness by analyzing autophosphorylation of PRK2 in the 
presence/absence of phospholipids. PRK2 were reported to show propensity for acidic 
phospholipids in lipid activatability. The most potent acidic phospholipid activator of 
PRK2, cardiolipin, has been shown to stimulate the autophosphorylation of  PRK2 
appreciably [264], therefore lipid responsiveness of PRK2-Δ978 to cardiolipin was 
examined. 
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The wild-type Flag-PRK2 and Flag-PRK2-Δ978 were transiently transfected in COS 
cells. The exogenous PRK2 were immunoprecipitated with anti-Flag antibody and 
washed extensively with 0.5M LiCl before being subjected to an in vitro kinase assay 
in the presence of cardiolipin. After separation of the reaction mixture using SDS-
PAGE, autophosphorylation was quantified by phosphoimaging (Fig. 5.8B top panel). 
The protein masses of immunoprecipitated PRK2 samples present in each lipid 
activation assay were determined using Western Blot and were used to derive the 
specific activity of PRK2 (Fig. 5.8B bottom panel). Surprisingly, although wild-type 
PRK2 was activated by 1.5-fold, PRK2-Δ978 was activated by 3-fold by cardiolipin 
(Fig. 5.8A).  
 
The seven extreme C-terminal residues were shown to be required for optimal 
activation of PRK2 by RhoA (Fig. 5.7). The same residues appeared to play an 
opposing role in cardiolipin regulation where the presence of these residues reduced 
activation of the kinase by cardiolipin. Thus, a novel element within the C-terminus 
that plays a dual role in regulation of kinase activity has been identified.   




Fig. 5.8. In vitro responsiveness of wild-type PRK2 and PRK2-Δ978.  N-terminal 
FLAG-tagged PRK2 were transiently transfected in COS-1 cells. Twenty-four hours 
post transfection, cells were lysed and exogenous PRK2 or mutant PRK2 were 
immunoprecipitated with anti-FLAG antibodies. The kinetic activity of PRK2 was 
determined in an immune-complex kinase assay with or without the activator 
cardiolipin (50 ug/ml final concentration). (A) The degree of autophosphorylation was 
determined by phosphoimaging and is expressed as a percentage to the wild-type 
unactivated. (B) The amount of protein immunoprecipitated was analysed by Western 
Blotting with anti-FLAG antibody. Data shown are representative of at least 3 
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Sequencing Result for PRK2 
 






























































































































































>Human PRK2 ∆917_sequencing primer DWS 249 
NTTTCCNANNGGGATGTAAAAAAGCACCCATTTTTCTGACTAATTGATTGGAGTGCTCTGATGGACAAA
AAAGTAAAGCCACCATTTATACCTACCATAAGAGGACGAGAAGATGTTAGTAATTTTGATGATGAATTT









































































































































































The number of PKC/PRK isotypes in existence represents a great challenge to the 
elucidation of their function. PKC/PRKs are involved in a plethora of biological 
functions and interact with an assortment of proteins. Thus the difficulty of 
determining the individual regulation and contributions of each of the PKC isotype is 
immense. The V5 region was initially assigned based upon the deterioration in 
sequence conservation towards the end of the kinases domain [34]. This segment of 
50-70 residues has been shown to play important role in PKC maturation [45] and 
isozyme specific functions [120, 342].  
 
In PRK1, removal of up to 94% of the V5 domain (PRK1-Δ882, Fig. 3.2) resulted in a 
mutant kinase with reduced solubility (approximately 40% that of the wild-type 
PRK1). It was not possible to determine the contribution of the V5 domain to PRK2 
solubility. Although the same expression conditions were used for both PRK1 and 
PRK2, for unknown reason, there was a substantial difference in expression between 
the two kinases. PRK2 expression efficiency was much lower than that for PRK1. A 
study by Palmer and Parker failed to detect PRK2 mRNA in liver tissues [43]. In the 
same study, the detection of relatively high levels of PRK2 in PCR analyses of 
myeloma compared with liver RNA suggested a higher mRNA abundance linked to 
the cancerous state of myelomas [43]. Thus, a possible reason for the lower 
expression observed in this study may be due to the high level of turnover of mRNA 
and/or secondary structure interference, which prevents efficient translation of PRK2 
leading to a low PRK2 protein level in cells.  
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There is a remarkable similarity in terms of the kinase activity of C-terminus deletion 
mutants between PRK1 and PRK2. PRK1-Δ940 and PRK2-Δ978 both have catalytic 
activity as high as their respective wild-type kinases (Fig. 3.3A and Fig. 5.2A). 
However, further deletion of V5 residues resulted in PRK1-Δ939 and PRK2-Δ977 to 
be catalytically inactive (Fig. 3.3A and Fig. 5.2A). The sequence of PKA terminates 
at Phe350 which corresponds to the conserved phenylalanine residue Phe977 in PRK2 
and Phe939 in PRK1. These results imply that, at least in the context of PRK1 and 
PRK2, either the extreme C-terminus residues are important for catalytic function 
and/or the presence of the conserved hydrophobic residue preceding the phosphor-
acceptor is critical for kinase activity. To delineate if PRK2-Δ977 is catalytically 
inactive due to the absence of the conserved phenylalanine at position 977, Phe977 in 
the hydrophobic motif was mutated. The absolute requirement for phenylalanine was 
demonstrated in PRK2-F977A, PRK2-F977L, PRK2-F977W and PRK2-F977Y 
mutants. Substitution with residues similar in aromatic side chains or similar 
hydropathy property proved to be poor surrogates; these point mutants exhibited 
significantly lower activity compared to the wild-type PRK2 (Fig. 5.2C). The 
importance of Phe977 was further illustrated in a PRK2-Δ978 deletion mutant with 
Phe977 mutation. PRK2-Δ978 mutants demonstrated activity as high as wild-type 
PRK2, however, in PRK2-Δ978 with Phe977 mutation (PRK2-Δ978+F977A, PRK2-
Δ978+F977L, PRK2-Δ978+F977W and PRK2-Δ978+F977Y) there was a marked 
decrease in kinase activity (Fig. 5.2B). Thus phenylalanine at position 977 plays a 
critical role in the catalytic function of PRK2. 
 
The hydrophobic motif in PRK2 consists of Phe977Asp978 Tyr979, where Asp978 is the 
phosphor-acceptor mimetic. In term of kinase activity in PRK2, the requirement for a 
   
 187
hydrophobic residue succeeding the phosphor-acceptor mimetic (Asp978) appeared to 
be less strict than a need for a hydrophobic residue preceding the phosphor-acceptor 
mimetic. Mutation of Tyr979 to PRK2-Y979L, PRK2-Y979W, PRK2-Y979F and 
PRK2-Y979A generated kinases with higher activity than kinases with the same 
mutation introduced in Phe977 (Fig. 5.2D). In this regard, PRK2 and PRK1 are highly 
similar where in PRK1, mutation at Phe939 (corresponding to PRK2 Phe977) resulted in 
kinases with substantial reduction in kinase activity (Fig. 3.4A,B) while mutation at 
Phe941 (corresponding to PRK2 Tyr978) had much less deleterious impact on the 
catalytic competence of the mutant enzyme (Fig. 3.4A, B). The results presented here 
and in chapter 2 define the importance of the hydrophobic residues flanking the 
phosphor-acceptor site in PRK1 and PRK2. In PKCα, the hydrophobic motif was 
found to interact with the catalytic core to maintain an active, phosphatase-resistant, 
closed conformation of the kinase domain [129]. The recent elucidation of the crystal 
structures of PKCθ and PKCι further demonstrated that the hydrophobic motif plays a 
key role in stabilizing the active conformation of the kinase [87, 88].  
 
The basis of the changes observed for PRK2 Phe977 and Tyr979 may be related to the 
disruption of the closed conformation consequent to the V5-C3/4 domain interactions. 
A working model from this study suggests that in wild type PRK2, the Phe977 residue 
appears to play a role alongside Tyr979 in forming an active and closed conformation 
of the kinase domain. Both hydrophobic residues contribute to maintain contact with 
the catalytic core, albeit Phe977 appears to play a more dominant role than Tyr979. Thus 
in terms of kinase activity, the importance of hydrophobicity of the hydrophobic motif 
is defined by the phenylalanine at position 977. 
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The segment of residues at the extreme C-terminus of the V5 domain in PRK2 is not 
functionally redundant. Comparison of the catalytic activity of PRK2 Phe977 point 
mutants (Fig. 5.2C) and PRK2 Phe977 point mutants in a background of PRK2-Δ978 
(Fig. 5.2B) demonstrated that in the absence of the last eight amino acids, the catalytic 
activity of PRK2-F977A, PRK2-F977L, PRK2-F977W and PRK2-F977Y were all 
abolished. This is consistent with PRK1 C-terminal deletion mutants where absence 
of the last eight residues of the V5 domain in PRK1 Phe939 point mutants completely 
abolished the kinase activity (Fig. 3.4A). Therefore, the data suggest that while the 
conserved hydrophobic residue in PRK1 and PRK2 are important for kinase activity, 
the segment of residues at the C-terminal of the V5 domain is also critical to kinase 
function.  
 
A major advance in cell signaling was achieved with the purification and cloning of 
PDK-1 [377-380]. Subsequent studies established PDK-1 to be the upstream kinase 
for many key members of the AGC protein kinase superfamily. The PDK1-Interacting 
Fragment (PIF) which corresponds to amino acid residues 908-984 of PRK2 has been 
previously shown to interact directly with a pocket on the small lobe of the kinase 
domain of PDK1 [349]. The interaction of full length PRK2 or PIF itself [345] with 
PDK-1 requires the aspartic acid residue (Asp978) in the hydrophobic motif, at the 
position equivalent to Ser-473 of PKBα. The authors proposed that the hydrophobic 
motifs of PRK2 are likely to be acting as PDK-1 docking sites analogous to those 
present in other kinases that are components of distinct kinase cascades such as 
mitogen-activated protein kinases, CDK2, and c-Jun N-terminal kinase [381]. As in 
the case of PRK1, data from this study demonstrated that the hydrophobic motif and 
even the turn motif in the V5 domain are not required for the interaction between 
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PDK-1 and PRK2 (Fig. 5.5). PRK2-Δ977, which lacks the “FDY” motif in the 
hydrophobic motif, was able to bind PDK-1 (Fig. 5.5) and was phosphorylated at the 
activation loop (Fig. 5.4). However, turn motif deletion mutant (PRK2-Δ958) was 
phosphorylated at the activation loop but was unable to interact with PDK-1 (PRK2-
Δ958 in Fig. 5.4 and 5.5). This raises the possibility that the aromatic and acidic 
residues of the hydrophobic motif in PRK2 may not be the only determinants that 
mediate binding to PDK1. Residues N terminal of the V5 domain (without the 
hydrophobic region) may constitute part of the PDK1 docking site, but the strength of 
binding is not sufficient to support phosphorylation of the activation loop. Another 
possibility is that the C-terminus residues maintain PRK2 in a conformation 
favourable for phosphorylation of the activation loop or that they prevent 
dephosphorylation.  
 
Balendran et al. reported that the mutant PRK2-D978A does not become 
phosphorylated at its activation loop when expressed in cells [345]. In contrast, the 
present study demonstrates that PRK2-D978A has activity as high as that of the wild-
type PRK2 (Fig. 5.2). The two findings are not necessarily mutually exclusive. It is 
known that the AGC kinases require phosphorylation of the activation loop to gain 
catalytic competence, such that the activation loop phosphorylation site functions as a 
switch. Although phosphorylation at the activation loop is required for the maturation 
of the kinases, once this event is completed, phosphate on the activation loop is 
dispensable. Also, mass spectrometric analysis of the mature PKC in an over-
expression system suggests that only one-half of the PKC molecules are 
phosphorylated at the activation loop [89]. In PRK2-D978A mutants, the fact that 
they have similar catalytic activity to wild-type PRK2 suggests that initially, PDK1 
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must bind and phosphorylate the activation loop to prime PRK2-D978A to be 
catalytically competent. The failure to detect a phosphorylated activation loop may be 
attributed to PRK2-D978A folding into a conformation that allows activation loop 
phosphorylation but is susceptible to dephosphorylation by phosphatases.  
 
Furthermore, it was observed that the activity of PRK2 deletion mutants (Fig. 5.2A) 
did not correlate with the phosphorylation of the activation loop (Fig. 5.3). Previous 
studies suggest that phosphorylation of the activation loop in PRK1 and PRK2 [268, 
269] activates these kinases, but finding from this study suggests that  phosphorylated 
activation loop does not equate to catalytic activity. The results here show that even 
with phosphorylated activation loop, the kinase may not be fully active. At first 
glance, this appears contradictory to the findings with the PRK2-D978A mutant 
where there is no detactable phosphorylation at the activation loop but the kinase has 
activity as high as that of the wild-type PRK2.  However these seemingly conflicting 
data can be reconciled based on the new findings of this study that discovered that the 
V5 domain plays two distinct roles in the regulation of PRK2 activity. Not only does 
the V5 domain increases affinity to PDK1 binding, these C-terminal residues also 
help to regulate the catalytic activity by folding the kinase active site in the right 
conformation for catalysis to take place. The basis for this seems to be in part due to 
the interaction of the V5 region with the kinase domain itself, inducing a closed, 
stable conformation. A model for this is provided by the equivalent C-terminal region 
of protein kinase A, which makes extensive contacts, wrapping back around the lower 
and upper lobes of the kinase domain [106]. In the study of phosphorylated and 
unphosphorylated PKB, the C-terminus was too disordered to enable its structure to 
be assigned, but phosphorylation-dependent changes in the core of the kinase 
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suggested a model in which phosphate at the hydrophobic motif orders the C helix, a 
key contact in the upper lobe of the kinase domain, to align residues more favourably 
for catalysis [107]. Thus, even though PDK-1 can interact with the N-terminal portion 
of the V5 domain and phosphorylate the activation loop motif, catalysis cannot take 
place without the critical action of the C-terminus to hold the two lobes of the kinase 
domain in a correct conformation.  
 
PRK1 and PRK2 interact with activated members of the Rho GTPase family, which 
may activate and/or control the cellular location of these enzymes [56, 57, 82, 83, 
265, 268]. Rho complexed to GTP interacts with the N-terminal regulatory region of 
PRK1 and PRK2, and recently the structure of Rho bound to this region of PRK1 has 
been solved [266]. However, controversial results have been reported regarding the 
binding of PRK2 with Rho family GTPase. Quilliam el al. reported that PRK2 
specifically binds to RhoA in a GTP-dependent manner [261], whereas Vincent and 
Settleman reported that the interaction of PRK2 with RhoA in vitro was nucleotide-
independent  [82]. In the present study, GST-RhoA not loaded with GTP-γ-S could 
not activate wild-type PRK2 (data not shown). Instead, in vitro activation of PRK2 by 
RhoA required a GTP-bound form of RhoA (Fig. 5.6). In in vitro assays, GTP-γ-S 
GST-RhoA activated wild-type PRK2 and PRK2-Δ978 approximately 1.7 and 1.8-
fold respectively (Fig. 5.7). When coexpressed with constitutively active RhoA 
(RhoA-Q61L), wild-type PRK2 was activated to about 4-fold; in contrast PRK2-Δ978 
had approximately 2.3-fold increase in activity. Thus, the extreme C-terminus 
residues in the V5 domain of PRK2 may be required for optimal activation by RhoA, 
at least under in vivo conditions.  
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There was a significant difference between in vitro and in vivo results in the extent of 
activation of the wild-type PRK2 by RhoA. While the wild-type PRK2 was activated 
approximately 1.8-fold in vitro, a 4-fold increase in activity was observed in vivo. One 
reason for the observed difference in activation may be due to the presence/absence of 
PDK1. In the in vitro activation, the Flag-tagged PRK2 were immunoprecipitated and 
washed stringently with 0.5 M LiCl to remove contaminants. This stringent wash 
might have stripped PDK1 off from PRK2. In the in vivo system, the 
immunoprecipitated PRK2 were washed with 300 mM NaCl which is much milder 
and would not disrupt the interaction between PDK-1 and PRK2.  Previously, the 
Rho-inactivating Colstridium toxin C3 transferase has been shown to inhibit 
lysophosphatidic acid-induced phosphorylation of PRK in vivo [58]. Subsequent 
studies established subsequently that the formation of PRK·PDK1 complex is Rho-
dependent. Consistent with the requirement for RhoA in the formation of PRK2 and 
PDK-1 binding, the expression of Closridium toxin C3 transferase was found to block 
the PDK1 and PRK2 kinase-kinase interaction [268]. 
 
The difference in the nature of the epitope tag of RhoA employed in vitro and in vivo 
may be relevant to the observed difference in activation between the two studies. The 
GST tag of RhoA used in the in vitro study may have contributed to steric hindrance 
due to its large molecular size of 25 kDa, such that binding of GST-RhoA to PRK2 
was not efficient. In contrast, the use of a ten residue Myc tag to RhoA in the in vivo 
study could circumvent the problem of steric hindrance and permit efficient RhoA 
binding and activation of PRK2.   
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Difference in post-translational modification of RhoA in the different experimental 
systems may also contribute to the different findings reported. Parker et al showed 
that in vitro, the HR1 domains of PRK1 and PRK2 are sufficient for binding to GTP-
loaded bacterially expressed Rho, i.e. non-prenylated Rho·GTP [56]. However, for 
maximal PRK activation, the assembly of the ternary complex of Rho·PRK·PDK1 is 
necessary and the consequent PRK activation loop phosphorylation in vivo requires 
prenylation of Rho [268]. Thus, in the in vitro system, the GST purified RhoA was 
bacterially expressed and did not undergo prenylation, consequently this non-
prenylated RhoA only allowed modest activation by removing the autoinhibitory 
region from the kinase domain. For the in vivo system, the expression of RhoA in a 
mammalian cell allows for post-translational modification, i.e. prenylation. The 
prenyl groups have been found to behave like “greasy handles” that can be grabbed by 
proteins with appropriate hydrophobic binding sites  [382] (in this instance: PRK2), 
such that prenylated RhoA binds with a higher affinity to PRK2, thus producing a 
higher level of activation in the in vivo system.    
 
PKC/PRKs are regulated by lipids [8] and PRK2 was reported to show propensity for 
acidic phospholipids in lipid activatability [264]. The most potent acidic 
phospholipids activator, cardiolipin, has been shown to stimulate the 
autophosphorylation of  PRK2 appreciably [264]. In contrast to a previous study 
where a 7-fold increase in kinase activity was reported [264], this study was only able 
to detect a moderate 1.5-fold elevation in catalytic activity with cardiolipin activation 
(Fig. 5.8A). A possible reason for the difference in activation results between the 
studies is the different experimental conditions. Firstly, this study used recombinant 
Flag-tagged human PRK2 while Wenttenhall et al. used native purified from rat liver 
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PRK2 [264]. The variation in primary sequences between the human and rat PRK2 
may account for, at least partly, differences in catalytic properties observed in the two 
independent studies. Secondly, in this study, PRK2 was immunoprecipitated using 
FLAG-coated beads which bind to the FLAG epitope tag at the N-terminus of PRK2. 
The immunoprecipitation of PRK2 via the N-terminus might have partly dislodged 
the N-terminal pseudosubstrate segment from the substrate binding cavity of PRK2, 
leading to significantly elevated basal catalytic activities and substantially reduced 
auto-inhibition. Therefore, this N-terminally immunoprecipitated PRK2 would have a 
higher basal activity that is unable to be activated by a further 4-fold after treating 
with cardiolipin. Similar observations were made with PRK1. In a similar 
experimental paradigm, the N-terminally immunoprecipitated recombinant PRK1 was 
activated by approximately 3-fold after the treatment with arachidonic acid (Fig. 3.8), 
whereas a 6-fold increase in activity was observed with native PRK1 purified from rat 
liver [267]. Thirdly, in this study the recombinant PRK2 was incubated for 10 min at 
30oC for the analysis of its catalytic activity while previous study used a 45 min 
reaction time [264]. The 10 min reaction time was chosen from a time course study 
which established that phosphorylation of PRK2 proceeded linearly within 12 min. 
Lastly, phosphoimaging was used in this study to determine the amount of 
autophosphorylation. In Wettenhall’s study, the mass of PRK2 was estimated using an 
aliquot of PRK1 preparation by colometric method before loading to SDS-PAGE. The 
gel was excised and subjected to scintillation counting to determine the extent of 
phosphorylation. However, the actual mass of protein in the gel being excised was not 
determined. Thus, all these differences in experimental conditions could collectively 
contribute to the differences in the fold activation of PRK2 by cardiolipin between 
what was observed in this study and that of previously reported [264].  
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Surprisingly, wild-type PRK2 was activated 1.5-fold while PRK2-Δ978 was activated 
3-fold (Fig. 5.8). The fact that wild-type PRK2 and PRK2-Δ978 exhibited differential 
activation by cardiolipin suggests negative regulation by the C-terminal residues. 
Thus, the last seven residues in PRK2 appear to play different roles in different 
signaling pathways. In RhoA signaling, this segment of residues is necessary for 
optimal activation while in cardiolipin signaling, the same residues negatively 
regulate kinase activation. While cardiolipin is unlikely to be a physiological 
regulator, given its exclusive location within the inner mitochondrial membrane [278], 
it could mimic the activation of a more physiological relevant phospholipid 
activator(s). Candidates include phosphatidic acid which has been implicated as a 
second messenger in mammalian signal transduction [278, 279, 383] and has been 
found to directly activate endothelial PKC [384]. The lipid responsiveness of PRK2, 
in vitro, suggests that a lipophilic second messenger may be involved in negative 
regulation of the kinase in cellular system.  
 
The observation of the importance of the extreme C-terminus in PRK2 in controlling 
kinase function and regulating activation is consistent with recent findings in our 
laboratory that the very C-terminus beyond the hydrophobic motif in PKCα is 
essential for conferring the full catalytic competence to the kinase and for transducing 
signals [385]. Thus, the importance of the very C-terminus in conferring the catalytic 
competence in PRK2 may be a common feature among several other PKC isozymes. 
In conclusion, this study has identified the extreme C-terminal of seven amino acids 
in PRK2 is critical for the function and regulation of the kinase. The data suggest that 
this segment of residues in the V5 domain in necessary to maintain critical interaction 
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with the kinase domain to allow proper folding for catalysis. The identification of a 
dual role of regulation of kinase activity by the last seven amino acids suggests that 
the PRK2 V5 domain may be a converging point of multiple signaling pathways.  
  
One of the goals in PKC research is to develop strategies for specific modulation of 
the activity and function of individual PKC isozymes. However, most of the available 
PKC inhibitors lack desired specificity [281, 386]. The findings of this study point to 
a new direction for generating PKC isozyme-specific pharmacological agents. The 
very C-terminus of PKC is not only the least conserved in sequence but is likely to be 
exposed on the surface of folded PKC as judged from the fact that most PKCs can be 
readily immunoprecipitated using isozyme-specific antibodies that are generated 
against the C-terminus. Therefore, monoclonal antibodies, peptides or small 
molecules that are able to interact with the very C-terminus of PKC/PRK and 
suppress its catalytic activity may become an invaluable tool in the study of the 
biology of these kinases. Moreover, such agents could represent a new generation of 
drugs for treating diseases in which the activation of PKC/PRKs is implicated.  
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General Conclusion 
This project aims to investigate the role of the V5 domain in the regulation of PKC 
superfamily. Two members of the PKC family, PKC-Related Kinase 1 (PRK1) and 
PKC-Related Kinase 2 (PRK2) were used in this study to determine the following 
objectives: 
1. the structural elements within the V5 domain of PRK1 and PRK2 that are 
required for the catalytic competence of the kinases;  
2. the necessity of the hydrophobic motif for PDK-1 interaction and activation; 
3. the function of the C-terminal extension of PRK beyond the conserved 
phenylalanine (Phe350 in PKA corresponding to Phe939 in PRK1 and Phe978 in 
PRK2)  in the response of the kinases to lipid activators; 
 
For the first objective, the requirement of residues within the V5 for kinase function 
was studied. C-terminal residues were deleted in both PRK1 and PRK2 and these 
mutants were tested for kinase activity. Both PRK1 and PRK2 tolerated removal of up 
to seven amino acids from the C-terminal (PRK1-Δ940 and PRK2-Δ978). The 
hydrophobic motif is Asp940 in PRK1 and Asp978 in PRK2, thus it appears that the 
hydrophobic motif is dispensable for PRK1 and PRK2 activity. However, with the 
removal of eight residues (PRK1-Δ939 and PRK2-Δ977), both mutant kinases lost 
their catalytic activities. Thus, the last eight amino acids in both PRK1 and PRK2 are 
critical for catalytic function.  
 
For the second objective, the requirement for a hydrophobic motif for PDK-1 binding 
was examined. Co-immunoprecipitation studies indicate that PRK1 mutant PRK1-
Δ800 in which part of the catalytic core was removed and PRK1-Δ770 where the 
activation loop was deleted still retained the capacity of interaction with PDK-1. As in 
the case of PRK1, PRK2 mutant without the hydrophobic motif and turn motif 
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(PRK2-Δ958) is still capable of forming stable interaction with PDK-1. Therefore, it 
appears that in both PRK1 and PRK2, the prevailing dogma that the hydrophobic 
motif functions as a substrate docking site for PDK-1 maybe an over-simplified 
generalization. 
 
The relationship between PDK-1 binding followed by the phosphorylation of the 
activation loop in PRK1 and PRK2 and kinase activities was explored. For PRK1, 
phosphorylation of the activation loop closely correlated kinase activity where PRK1-
Δ940 was phosphorylated at the activation loop and had activity as high as wild type 
kinase. On the other hand, PRK1-Δ939 was not phosphorylated at the loop motif and 
was catalytically inactive. However, both truncation mutants were able to interact 
with PDK-1. In the case of PRK2, there was no discernable pattern between the extent 
of phosphorylation at the activation loop and kinase activity or PDK-1 binding. An 
example is PRK2-Δ958 which could interact with PDK-1 but was not phosphorylated 
at the activation loop and was catalytically inactive. A consensus from these studies is 
that the interaction of PDK-1 with PRK1 and PRK2, and the productive 
phosphorylations of the activation loop are separate biochemical events.  
 
For the third objective, the role of V5 domain in mediating the response to activators 
was analysed. In PRK1, the mode of activation by the well characterized activators 
arachidonic acid and RhoA was employed. The wild type PRK1 was activated three 
fold in the presence of arachidonic acid, however, the mutant PRK1 with its last five 
amino acid residues deleted could no longer be activated under the same conditions. 
Thus, a novel element that controls the lipid responsiveness of PRK1 at the extreme 
C-terminus of the V5 domain is identified. For PRK1 activation by RhoA, both in 
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vitro and in vivo data revealed that the removal of six residues at the C-terminus 
abolished the five-fold activation as seen in the wild type PRK1. Taken together, the 
results point to the importance of the last eight amino acid residues in the V5 domain 
for the full catalytic competence of PRK1. In the case of PRK2, its activation by 
cardiolipin and RhoA were studied. The wild-type PRK2 was activated by cardiolipin 
by 1.5-fold but the deletion of seven residues from the C terminal yielded a mutant 
PRK2 that had a 3-fold activation by cardiolipin. Therefore, it seems that the V5 
domain of PRK2 performs a potential inhibitory role with regards to lipid regulation. 
In terms of activation by RhoA, the wild-type PRK2 could be activated 2-3 fold with 
RhoA, however, the PRK2 mutant lacking the last eight residues remained 
catalytically active.  
 
The failure of two different activators to elevate the kinase activity in both PRK1 and 
PRK2 mutants lacking the last eight residues led to the hypothesis that the missing 
residues must affect the optimal conformation of the kinase domain such that the 
catalytic domain is no longer functional. Taken together, the V5 domain appears to be 
a determinant in isozyme-specific regulation of PRK catalytic activities.  
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Future Studies 
To gain a more thorough understanding of the V5 domain structure-function 
relationship of PRK1 and PRK2, more work needs to be accomplished to examine the 
areas that are yet to be explored in the present study. The future research that could be 
pursued is briefly outlined below: 
 
• Oligonucleotides or antibodies against the last eight amino acids in both PRK1 
and PRK2 should be designed and tested in vitro to determine if inhibition of 
specific kinase can be achieved. In fact, using antibodies directed against the V5 
domain in PKCζ results in low kinase activity (unpublished observation). Thus 
preliminary data suggests that at least in the atypical PKCs and PRKs, isozyme-
specific targeting exploiting the V5 domain appears promising. A relatively new 
technology of protein inhibition is the use of synthetic nucleic acid ligands, 
called aptamers, which bind to protein targets with high specificity, affinity and 
with high inhibitory potential. Furthermore, these ligands are not toxic or 
immunogenic, thus having potential clinical relevance.  
 
• Elucidating the three-dimensional structure is crucial to understanding how a 
protein in question functions. By integrating information about the function and 
3D structure of proteins, more specific ways of interfering with their actions 
can be achieved. Thus, crystallization of PRK1 and PRK2 to determine their 3-
D structure is required to completely characterize the V5 domain and allow the 
use of computational tools to conduct virtual docking experiments with PDK-1 
and ligands targeting the extreme C-terminus.  
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• This study has determined that in both PRK1 and PRK2, the hydrophobic motifs 
are not required for PDK-1 binding. Because PDK-1 is the first and rate-limiting 
step, understanding how PDK-1 interacts with PRK/PKC is critical to 
understand the cellular controls of PKC function. Mapping the region that 
allows for PDK-1 binding will facilitate a deeper understanding of PRK 
activation. This study also found that PDK-1 binding does not correlate with the 
extent of phosphorylation at the activation loop of PRK. One possibility is that 
PDK-1 interacts with PRK in vivo. Thus a kinetic study using surface plasmon 
resonance (SPR) technology can be used to detect and monitor the biomolecular 
interactions. 
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